0000919956-18-000038.txt : 20180802 0000919956-18-000038.hdr.sgml : 20180802 20180802160556 ACCESSION NUMBER: 0000919956-18-000038 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20180630 FILED AS OF DATE: 20180802 DATE AS OF CHANGE: 20180802 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Diversicare Healthcare Services, Inc. CENTRAL INDEX KEY: 0000919956 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SKILLED NURSING CARE FACILITIES [8051] IRS NUMBER: 621559667 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12996 FILM NUMBER: 18988242 BUSINESS ADDRESS: STREET 1: 1621 GALLERIA BLVD. CITY: BRENTWOOD STATE: TN ZIP: 37027 BUSINESS PHONE: 6157717575 MAIL ADDRESS: STREET 1: 1621 GALLERIA BLVD. CITY: BRENTWOOD STATE: TN ZIP: 37027 FORMER COMPANY: FORMER CONFORMED NAME: ADVOCAT INC DATE OF NAME CHANGE: 19940309 10-Q 1 dvcr-20180630x10q.htm 10-Q 2018 Q2 Document


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________ 
FORM 10-Q
________________________________ 
CHECK ONE:
ý
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended: June 30, 2018
OR
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to             .

Commission file No.: 1-12996
________________________________ 
Diversicare Healthcare Services, Inc.
(exact name of registrant as specified in its charter)
 ________________________________
Delaware
 
62-1559667
(State or other jurisdiction of
incorporation or organization)
 
(IRS Employer
Identification No.)
1621 Galleria Boulevard, Brentwood, TN 37027
(Address of principal executive offices) (Zip Code)
(615) 771-7575
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ý    No  ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ý    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer
 
¨
Accelerated filer
 
¨
 
 
 
 
Non-accelerated filer
 
¨(do not check if a smaller reporting company)
Smaller reporting company
 
ý
 
 
 
Emerging growth company
 
¨
       If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 
¨


Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  ý
6,536,158
(Outstanding shares of the issuer’s common stock as of July 30, 2018)
 



Part I. FINANCIAL INFORMATION
ITEM 1 – FINANCIAL STATEMENTS
DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED BALANCE SHEETS
(in thousands)
 
 
June 30,
2018
 
December 31,
2017
 
(Unaudited)
 
 
CURRENT ASSETS:
 
 
 
Cash and cash equivalents
$
3,811

 
$
3,524

Receivables, less allowance for doubtful accounts of $14,235 at December 31, 2017
63,591

 
64,929

Other receivables
1,456

 
375

Prepaid expenses and other current assets
3,672

 
3,248

Income tax refundable
1,298

 
537

Current assets of discontinued operations
20

 
45

Total current assets
73,848

 
72,658

PROPERTY AND EQUIPMENT, at cost
135,485

 
147,549

Less accumulated depreciation and amortization
(81,184
)
 
(78,345
)
Property and equipment, net
54,301

 
69,204

OTHER ASSETS:
 
 
 
Deferred income taxes, net
15,052

 
15,154

Deferred lease and other costs, net
114

 
137

Acquired leasehold interest, net
6,499

 
6,691

Assets held for sale
13,269

 
—

Other noncurrent assets
5,106

 
3,725

Total other assets
40,040

 
25,707

 
$
168,189

 
$
167,569

The accompanying notes are an integral part of these interim consolidated financial statements.

2


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED BALANCE SHEETS
(in thousands, except per share amounts)
(continued)
 
 
June 30,
2018
 
December 31,
2017
 
(Unaudited)
 
 
CURRENT LIABILITIES:
 
 
 
Current portion of long-term debt and capitalized lease obligations
$
12,760

 
$
13,065

Trade accounts payable
14,969

 
14,080

Current liabilities of discontinued operations
461

 
461

Accrued expenses:
 
 
 
Payroll and employee benefits
20,059

 
20,013

Self-insurance reserves, current portion
9,044

 
8,792

Other current liabilities
7,284

 
7,856

Total current liabilities
64,577

 
64,267

NONCURRENT LIABILITIES:
 
 
 
Long-term debt and capitalized lease obligations, less current portion and deferred financing costs, net
74,236

 
74,603

Self-insurance reserves, less current portion
17,393

 
13,458

Other noncurrent liabilities
5,826

 
8,779

Total noncurrent liabilities
97,455

 
96,840

COMMITMENTS AND CONTINGENCIES

 

SHAREHOLDERS’ EQUITY:
 
 
 
Common stock, authorized 20,000 shares, $.01 par value, 6,768 and 6,687 shares issued, and 6,536 and 6,455 shares outstanding, respectively
68

 
67

Treasury stock at cost, 232 shares of common stock
(2,500
)
 
(2,500
)
Paid-in capital
23,249

 
22,720

Accumulated deficit
(15,673
)
 
(14,534
)
Accumulated other comprehensive income
1,013

 
709

Total shareholders’ equity
6,157


6,462

 
$
168,189

 
$
167,569

The accompanying notes are an integral part of these interim consolidated financial statements.

3


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts, unaudited)
 
Three Months Ended June 30,
 
2018
 
2017
PATIENT REVENUES, net
$
141,082

 
$
142,550

EXPENSES:
 
 
 
Operating
111,440

 
113,166

Lease and rent expense
13,725

 
13,763

Professional liability
3,182

 
2,724

General and administrative
9,295

 
8,221

Depreciation and amortization
2,847

 
2,620

Total expenses
140,489

 
140,494

OPERATING INCOME
593

 
2,056

OTHER INCOME (EXPENSE):
 
 
 
Gain on sale of investment in unconsolidated affiliate
308

 
—

Other income
28

 
—

Interest expense, net
(1,661
)
 
(1,541
)
Total other expense
(1,325
)
 
(1,541
)
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
(732
)
 
515

BENEFIT (PROVISION) FOR INCOME TAXES
425

 
(134
)
INCOME (LOSS) FROM CONTINUING OPERATIONS
(307
)
 
381

LOSS FROM DISCONTINUED OPERATIONS:
 
 
 
Operating loss, net of tax expense of $0 and $18, respectively
(4
)
 
(28
)
NET INCOME (LOSS)
$
(311
)
 
$
353

NET INCOME (LOSS) PER COMMON SHARE:
 
 
 
Per common share – basic
 
 
 
Continuing operations
$
(0.05
)
 
$
0.06

Discontinued operations
—

 
—

 
$
(0.05
)
 
$
0.06

Per common share – diluted
 
 
 
Continuing operations
$
(0.05
)
 
$
0.06

Discontinued operations
—

 
—

 
$
(0.05
)
 
$
0.06

COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK
$
0.055

 
$
0.055

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
 
 
 
Basic
6,370

 
6,294

Diluted
6,370

 
6,472

                              
The accompanying notes are an integral part of these interim consolidated financial statements.

4


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(in thousands and unaudited)
 
 
Three Months Ended June 30,
 
2018
 
2017
NET INCOME (LOSS)
$
(311
)
 
$
353

OTHER COMPREHENSIVE INCOME:
 
 
 
Change in fair value of cash flow hedge, net of tax
134

 
146

Less: reclassification adjustment for amounts recognized in net income
(38
)
 
(116
)
Total other comprehensive income
96

 
30

COMPREHENSIVE INCOME (LOSS)
$
(215
)
 
$
383


The accompanying notes are an integral part of these interim consolidated financial statements.

5


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts, unaudited)
 
Six Months Ended June 30,
 
2018
 
2017
PATIENT REVENUES, net
$
282,367

 
$
284,050

EXPENSES:
 
 
 
Operating
223,718

 
223,833

Lease and rent expense
27,438

 
27,506

Professional liability
5,957

 
5,394

General and administrative
17,434

 
17,194

Depreciation and amortization
5,728

 
5,107

Total expenses
280,275

 
279,034

OPERATING INCOME
2,092

 
5,016

OTHER INCOME (EXPENSE):
 
 
 
Gain on sale of investment in unconsolidated affiliate
308

 
733

Other income
79

 
—

Interest expense, net
(3,330
)
 
(3,024
)
Total other expense
(2,943
)
 
(2,291
)
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
(851
)
 
2,725

BENEFIT (PROVISION) FOR INCOME TAXES
463

 
(996
)
INCOME (LOSS) FROM CONTINUING OPERATIONS
(388
)
 
1,729

LOSS FROM DISCONTINUED OPERATIONS:
 
 
 
Operating loss, net of tax expense of $11 and $27, respectively
(26
)
 
(43
)
NET INCOME (LOSS)
$
(414
)
 
$
1,686

NET INCOME (LOSS) PER COMMON SHARE:
 
 
 
Per common share – basic
 
 
 
Continuing operations
$
(0.06
)
 
$
0.28

Discontinued operations
—

 
(0.01
)
 
$
(0.06
)
 
$
0.27

Per common share – diluted
 
 
 
Continuing operations
$
(0.06
)
 
$
0.27

Discontinued operations
—

 
(0.01
)
 
$
(0.06
)
 
$
0.26

COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK
$
0.11

 
$
0.11

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
 
 
 
Basic
6,342

 
6,263

Diluted
6,342

 
6,458

                              
The accompanying notes are an integral part of these interim consolidated financial statements.

6


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(in thousands and unaudited)
 
 
Six Months Ended June 30,
 
2018
 
2017
NET INCOME (LOSS)
$
(414
)
 
$
1,686

OTHER COMPREHENSIVE INCOME:
 
 
 
Change in fair value of cash flow hedge, net of tax
455

 
400

Less: reclassification adjustment for amounts recognized in net income
(151
)
 
(233
)
Total other comprehensive income
304

 
167

COMPREHENSIVE INCOME (LOSS)
$
(110
)
 
$
1,853


The accompanying notes are an integral part of these interim consolidated financial statements.

7


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands and unaudited)
 
 
Six Months Ended June 30,
 
2018
 
2017
CASH FLOWS FROM OPERATING ACTIVITIES:
 
 
 
Net income (loss)
$
(414
)
 
$
1,686

Discontinued operations
(26
)
 
(43
)
Income (loss) from continuing operations
(388
)
 
1,729

Adjustments to reconcile income (loss) from continuing operations to net cash provided by operating activities:
 
 
 
Depreciation and amortization
5,728

 
5,107

Provision for doubtful accounts
—

 
4,187

Deferred income tax provision (benefit)
(34
)
 
403

Provision for self-insured professional liability, net of cash payments
1,722

 
(309
)
Stock-based compensation
765

 
504

Gain on sale of unconsolidated affiliate
(308
)
 
(733
)
Provision for leases in excess of cash payments
(916
)
 
(304
)
Deferred bonus
—

 
600

Other
283

 
247

Changes in assets and liabilities affecting operating activities:
 
 
 
Receivables, net
342

 
(7,313
)
Prepaid expenses and other assets
(2,651
)
 
620

Trade accounts payable and accrued expenses
2,072

 
(2,647
)
Net cash provided by continuing operations
6,615

 
2,091

Discontinued operations
(632
)
 
(329
)
Net cash provided by operating activities
5,983

 
1,762

CASH FLOWS FROM INVESTING ACTIVITIES:
 
 
 
Purchases of property and equipment
(3,896
)
 
(5,121
)
Deposit in escrow
—

 
(8,673
)
Proceeds from sale of unconsolidated affiliate
308

 
1,100

Net cash used in continuing operations
(3,588
)
 
(12,694
)
Discontinued operations
—

 
—

Net cash used in investing activities
(3,588
)
 
(12,694
)
CASH FLOWS FROM FINANCING ACTIVITIES:
 
 
 
Repayment of debt obligations
(9,057
)
 
(14,166
)
Proceeds from issuance of debt
8,203

 
26,074

Financing costs
(137
)
 
(226
)
Issuance and redemption of employee equity awards
(78
)
 
(94
)
Payment of common stock dividends
(702
)
 
(692
)
Payment for preferred stock restructuring
(337
)
 
(327
)
Net cash (used in) provided by financing activities
(2,108
)
 
10,569

Discontinued operations
—

 
—

Net cash (used in) provided by financing activities
$
(2,108
)
 
$
10,569

The accompanying notes are an integral part of these interim consolidated financial statements.

8


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands and unaudited)
(continued)
 
 
Six Months Ended June 30,
 
2018
 
2017
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
$
287

 
$
(363
)
CASH AND CASH EQUIVALENTS, beginning of period
3,524

 
4,263

CASH AND CASH EQUIVALENTS, end of period
$
3,811

 
$
3,900

SUPPLEMENTAL INFORMATION:
 
 
 
Cash payments of interest
$
2,920

 
$
2,563

Cash payments of income taxes
$
321

 
$
625

SUPPLEMENTAL INFORMATION ON NON-CASH INVESTING AND FINANCING TRANSACTIONS:

 
 
 
Acquisition of equipment through capital lease
$
—

 
$
7

The accompanying notes are an integral part of these interim consolidated financial statements.

9


DIVERSICARE HEALTHCARE SERVICES, INC. AND SUBSIDIARIES
NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2018 AND 2017
(Dollars and shares in thousands, except per share data)
(Unaudited)

1.
BUSINESS
Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare” or the “Company”) provides long-term care services to nursing center patients in ten states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Mississippi, Missouri, Ohio, Tennessee, and Texas.
As of June 30, 2018, the Company’s continuing operations consist of 76 nursing centers with 8,456 licensed nursing beds. The Company owns 18 and leases 58 of its nursing centers. Our nursing centers range in size from 48 to 320 licensed nursing beds. The licensed nursing bed count does not include 497 licensed assisted and residential living beds.

2.
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS
The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company had one equity method investee, which was sold during the fourth quarter of 2016. The sale resulted in a $1,366 gain in the fourth quarter of 2016. Subsequently, the Company recognized additional gains of $308 and $733 for the six-month periods ended June 30, 2018 and 2017, respectively, related to the liquidation of remaining assets affiliated with the partnership.
The interim consolidated financial statements for the three and six month periods ended June 30, 2018 and 2017, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at June 30, 2018, and the results of operations for the three and six month periods ended June 30, 2018 and 2017, and cash flows for the six month periods ended June 30, 2018 and 2017. The Company’s balance sheet information at December 31, 2017, was derived from its audited consolidated financial statements as of December 31, 2017.
Effective January 1, 2018, we adopted the requirements of Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606), as discussed in Notes 3 and 4 to the interim consolidated financial statements. All amounts and disclosures set forth in this Form 10-Q have been updated to comply with the new standard.
The results of operations for the periods ended June 30, 2018 and 2017 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017.

3.
RECENT ACCOUNTING GUIDANCE

Recent Accounting Standards Adopted by the Company
In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. Topic 606 is effective for annual and interim reporting periods beginning after December 15, 2017. The Company adopted the requirements of this standard effective January 1, 2018. The Company elected to apply the modified retrospective approach with the cumulative transition effect recognized in beginning retained earnings as of the date of adoption. The impact of the implementation to the consolidated financial statements for periods subsequent to adoption is not material. See Note 4, "Revenue Recognition" for a discussion regarding revenue recognition under the new standard.
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU was issued as part of the FASB Simplification Initiative and involves several aspects of accounting for share-based payment transactions, including the income tax consequences and classification on the statement

10


of cash flows. We adopted this standard as of January 1, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230). The ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The ASU is effective for annual and interim periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018 using a retrospective approach. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires that the Statement of Cash Flows explain the changes during the period of cash and cash equivalents inclusive of amounts categorized as Restricted Cash. As a result, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) - Clarifying the Definition of a Business, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The adoption is effective for annual and interim periods beginning after December 15, 2017. The Company will evaluate future acquisitions under this guidance, which may result in future acquisitions being accounted for as asset acquisitions.
In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The amended standard specifies the modification accounting applicable to any entity which changes the terms or conditions of a share-based payment award. The new guidance is effective for all entities after December 15, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.
Accounting Standards Recently Issued But Not Yet Adopted by the Company
In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. Disclosures will be required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. We anticipate this standard will have a material impact on our consolidated financial position and results of operations. We have organized an implementation group of cross-functional departmental management to ensure the completeness of our lease information, analyze the appropriate classification of current leases under the new standard, and develop new processes to execute, approve and classify leases on an ongoing basis. We have also implemented software tools and processes to maintain lease information critical to applying the new standard. We are continuing to evaluate the extent of this anticipated impact on our consolidated financial position and results of operations and the quantitative and qualitative factors that will impact the Company as part of the adoption.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related notes.
In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which is intended to simplify and amend the application of hedge accounting to more clearly portray the economics of an entity’s risk management strategies in its financial statements. The new guidance will make more financial and nonfinancial hedging strategies eligible for hedge accounting and reduce complexity in fair value hedges of interest rate risk. The new guidance also changes how companies assess effectiveness and amends the presentation and disclosure requirements. The new guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally the entire change in the fair value of a hedging instrument will be required to be presented in the same income statement line as the hedged item. The new guidance also eases certain documentation and assessment requirements and modifies the accounting for components

11


excluded from the assessment of hedge effectiveness. The new guidance is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those years. Early adoption is permitted in any interim period or fiscal year before the effective date. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures.
In February 2018, the FASB issued ASU No. 2018-02, Income Statement- Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows entities the option to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act from accumulated other comprehensive income (OCI) to retained earnings. The new guidance allows the option to apply the guidance retrospectively or in the period of adoption. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures.
In March 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 ("SAB No. 118"), which allowed SEC registrants to record provisional amounts in earnings for the year ended December 31, 2017 due to the complexities involved in accounting for the enactment of the Tax Cuts and Jobs Act. The Company recognized the estimated income tax effects of the Tax Cuts and Jobs Act in its 2017 Consolidated Financial Statements in accordance with SAB No. 118.

4. REVENUE RECOGNITION
On January 1, 2018, the Company adopted ASC 606 using the modified retrospective method for all contracts as of the date of adoption. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC 605, Revenue Recognition (ASC 605), which is also referred to herein as "legacy GAAP". The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of the Company's services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. ASC 606 requires companies to exercise more judgment and recognize revenue in accordance with the standard's core principle by applying the following five steps:
Step 1: Identify the contract with a customer.
Step 2: Identify the performance obligations in the contract.
Step 3: Determine the transaction price.
Step 4: Allocate the transaction price to the performance obligations in the contract.
Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.
Performance obligations are promises made in a contract to transfer a distinct good or service to the customer. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company has concluded that the contracts with patients and residents represent a bundle of distinct services that are substantially the same, with the same pattern of transfer to the customer. Accordingly, the promise to provide quality care is accounted for as a single performance obligation.
The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding state. It was determined that the contracts are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans).
In order to determine the transaction price, the Company estimates the amount of variable consideration at the beginning of the contract using the expected value method. The estimates consider (i) payor type, (ii) historical payment trends, (iii) the maturity of the portfolio, and (iv) geographic payment trends throughout a class of similar payors. The Company typically enters into agreements with third-party payors that provide for payments at amounts different from the established charges. These arrangement terms provide for subsequent settlement and cash flows that may occur well after the service is provided. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. Changes in the Company's expectation of the amount it will receive from the patient or third-party payors will be recorded in revenue unless there is a specific event that suggests the patient or third-party payor no longer has the ability and intent to pay the amount due and, therefore, the changes in its estimate of variable consideration better represent an impairment, or bad debt. These estimates are re-assessed each reporting period, and any amounts allocated to a satisfied performance obligation are recognized as revenue or a reduction of revenue in the period in which the transaction price changes.

12


The Company satisfies its performance obligation by providing quality of care services to its patients and residents on a daily basis until termination of the contract. The performance obligation is recognized on a time elapsed basis, by day, for which the services are provided. For these contracts, the Company has the right to consideration from the customer in an amount that directly corresponds with the value to the customer of the Company's performance to date. Therefore, the Company recognizes revenue based on the amount billable to the customer in accordance with the practical expedient in ASC 606-10-55-18. Additionally, because the Company applied ASC 606 using certain practical expedients, the Company elected not to disclose the aggregate amount of the transaction price for unsatisfied, or partially unsatisfied, performance obligations for all contracts with an original expected length of one year or less.
The Company incurs costs related to patient/resident contracts, such as legal and advertising expenses. The contract costs are expensed as incurred. They are not expected to be recovered and are not chargeable to the patient/resident regardless of whether the contract is executed.

Financial Statement Impact of Adopting ASC 606

The Company adopted ASC 606 using the modified retrospective method. The cumulative effect of applying the new guidance to all contracts with customers as of January 1, 2018 was not material to the interim consolidated financial statements. As a result of applying the modified retrospective method to adopt ASC 606, the following adjustments were made to our operating results:

 
Three Months Ended June 30, 2018
 
As Reported
 
Increase
(Decrease)
 
Balances as if the previous accounting guidance was in effect
Patient Revenues, net
$141,082
 
3,789
(362)
3,427
(a)
(b)
$144,509
Operating Expenses
$111,440
 
3,789
(a)
$115,229
Total Expenses
$140,489
 
3,789
(a)
$144,278

(a) Adjusts for the implicit price concession of bad debt expense.
(b) Adjusts for the implementation of ASC 606.

 
Six Months Ended June 30, 2018
 
As Reported
 
Increase
(Decrease)
 
Balances as if the previous accounting guidance was in effect
Patient Revenues, net
$282,367
 
7,252
(618)
6,634
(a)
(b)
$289,001
Operating Expenses
$223,718
 
7,252
(a)
$230,970
Total Expenses
$280,275
 
7,252
(a)
$287,527

(a) Adjusts for the implicit price concession of bad debt expense.
(b) Adjusts for the implementation of ASC 606.


13


 
As of June 30, 2018
 
As Reported
 
Increase
(Decrease)
 
Balances as if the previous accounting guidance was in effect
Accounts Receivable
$63,591
 
(618)
16,050
15,432
(a)
(b)
$79,023
Accumulated Deficit
$(15,673)
 
618
(198)
420
(a)
(c)

$(15,253)

(a) Adjusts for the implementation of ASC 606.
(b) Adjusts for a direct reduction of accounts receivable that would have been reflected as allowance for doubtful accounts in the consolidated balance sheet prior to the adoption of ASC 606.
(c) Reflects the tax adjustment for the ASC 606 adjustment of $618.

Disaggregation of Revenue
The following table summarizes revenue from contracts with customers by payor source for the periods presented (dollar amounts in thousands):

 
Three Months Ended June 30,
 
2018
 
2018
 
2017(1)
 
As reported
 
As Adjusted to Legacy GAAP
 
As reported
Medicaid
$
65,603

46.5
%
 
$
75,216

52.0
%
 
$
73,510

51.6
%
Medicare
27,863

19.7
%
 
36,079

25.0
%
 
38,900

27.3
%
Managed Care
13,303

9.4
%
 
11,888

8.2
%
 
9,959

7.0
%
Private Pay and other
34,313

24.4
%
 
21,326

14.8
%
 
20,181

14.1
%
Total
$
141,082

100.0
%
 
$
144,509

100.0
%
 
$
142,550

100.0
%
 
Six Months Ended June 30,
 
2018
 
2018
 
2017(1)
 
As reported
 
As Adjusted to Legacy GAAP
 
As reported
Medicaid
$
129,489

45.9
%
 
$
148,431

51.4
%
 
$
146,383

51.5
%
Medicare
57,614

20.4
%
 
74,217

25.7
%
 
76,911

27.1
%
Managed Care
27,515

9.7
%
 
23,980

8.3
%
 
20,764

7.3
%
Private Pay and other
67,749

24.0
%
 
42,373

14.6
%
 
39,992

14.1
%
Total
$
282,367

100.0
%
 
$
289,001

100.0
%
 
$
284,050

100.0
%

(1) As noted above, prior period amounts have not been adjusted under the application of the modified retrospective method.

5.
LONG-TERM DEBT AND INTEREST RATE SWAP
The Company has agreements with a syndicate of banks for a mortgage term loan ("Original Mortgage Loan") and the Company’s revolving credit agreement ("Original Revolver"). On February 26, 2016, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated April 30, 2013. The Credit Agreement increased the Company's borrowing capacity to $100,000 allocated between a $72,500 Mortgage Loan ("Amended Mortgage Loan") and a $27,500 Revolver ("Amended Revolver"). The Amended Mortgage Loan consists of a $60,000 term loan facility and a $12,500 acquisition loan facility. Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of $2,162 and are being amortized over the five-year term of the agreements.
Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original principal balance of $72,500 with a five-year maturity through February 26, 2021, and a $27,500 Amended Revolver through February 26, 2021. The Amended Mortgage Loan has a term of five years, with principal and interest payable monthly based on a 25-year amortization. Interest on the term and acquisition loan facilities is based on LIBOR plus 4.0% and 4.75%, respectively.

14


A portion of the Amended Mortgage Loan is effectively fixed at 5.79% pursuant to an interest rate swap with an initial notional amount of $30,000. The Amended Mortgage Loan balance was $72,630 as of June 30, 2018, consisting of $63,630 on the term loan facility with an interest rate of 6.00% and $9,000 on the acquisition loan facility with an interest rate of 6.8%. The Amended Mortgage Loan is secured by eighteen owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized and cross-defaulted. The Company’s Amended Revolver has an interest rate of LIBOR plus 4.0% and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions.
Effective October 3, 2016, the Company entered into the Second Amendment ("Second Revolver Amendment") to amend the Amended Revolver. The Second Revolver Amendment increased the Amended Revolver capacity from the $27,500 in the Amended Revolver to $52,250; provided that the maximum revolving facility be reduced to $42,250 on August 1, 2017. Subsequently, on June 30, 2017, the Company executed a Fourth Amendment (the "Fourth Revolver Amendment") to amend the Amended Revolver, which modifies the capacity of the revolver to remain at $52,250.
On December 29, 2016, the Company executed a Third Amendment ("Third Revolver Amendment") to amend the Amended Revolver. The Third Amendment modified the terms of the Amended Mortgage Loan Agreement by increasing the Company’s letter of credit sublimit from $10,000 to $15,000.
Effective June 30, 2017, the Company entered into a Second Amendment ("Second Term Amendment") to amend the Amended Mortgage Loan. The Second Term Amendment amended the terms of the Amended Mortgage Loan Agreement by increasing the Company's term loan facility by $7,500.
Effective February 27, 2018, the Company executed a Fifth Amendment to the Amended Revolver and a Third Amendment to the Amended Mortgage Loan. Under the terms of the Amendments, the minimum fixed charge coverage ratio shall not be less than 1.01 to 1.00 as of March 31, 2018 and for each quarter thereafter.
As of June 30, 2018, the Company had $15,000 borrowings outstanding under the Amended Revolver compared to $16,000 outstanding as of December 31, 2017. The outstanding borrowings on the revolver were used primarily to compensate for accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through the change in ownership process with Centers for Medicare & Medicaid Services (“CMS”). Annual fees for letters of credit issued under the Amended Revolver are 3.0% of the amount outstanding. The Company has eleven letters of credit with a total value of $13,714 outstanding as of June 30, 2018. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of $36,891 the balance available for borrowing under the Amended Revolver was $8,177 at June 30, 2018.
The Company’s debt agreements contain various financial covenants, the most restrictive of which relates to debt service coverage ratios. The Company is in compliance with all such covenants at June 30, 2018.
Interest Rate Swap Transaction
As part of the debt agreements entered into in April 2013, the Company entered into an interest rate swap agreement with a member of the bank syndicate as the counterparty. The Company designated its interest rate swap as a cash flow hedge and the earnings component of the hedge, net of taxes, is reflected as a component of other comprehensive income (loss). In conjunction with the February 26, 2016 amendment to the Credit Agreement, the Company amended the terms of its interest rate swap. The interest rate swap agreement has the same effective date and maturity date as the Amended Mortgage Loan, and has an amortizing notional amount that was $28,135 as of June 30, 2018. The interest rate swap agreement requires the Company to make fixed rate payments to the bank calculated on the applicable notional amount at an annual fixed rate of 5.79% while the bank is obligated to make payments to the Company based on LIBOR on the same notional amount.
The Company assesses the effectiveness of its interest rate swap on a quarterly basis, and at June 30, 2018, the Company determined that the interest rate swap was highly effective. The interest rate swap valuation model indicated a net asset of $606 at June 30, 2018. The fair value of the interest rate swap is included in “other noncurrent assets” on the Company’s interim consolidated balance sheet. The asset related to the change in the interest rate swap included in accumulated other comprehensive income at June 30, 2018 is $412 net of the income tax provision of $194. As the Company’s interest rate swap is not traded on a market exchange, the fair value is determined using a valuation based on a discounted cash flow analysis. This analysis reflects the contractual terms of the interest rate swap agreement and uses observable market-based inputs, including estimated future LIBOR interest rates. The interest rate swap valuation is classified in Level 2 of the fair value hierarchy, in accordance with the FASB guidance set forth in ASC 820, Fair Value Measurement.


15


6.    COMMITMENTS AND CONTINGENCIES
Professional Liability and Other Liability Insurance
The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. All of the Company's nursing centers in Florida, and Tennessee are now covered under the captive insurance policies along with many of the nursing centers in Alabama, Kentucky, and Texas. The insurance coverage provided for these centers under the SHC policy provides coverage limits of at least $500 per medical incident with a sublimit per center of $1,000 and total annual aggregate policy limits of $5,000. All other centers within the Company's portfolio are covered through various commercial insurance policies which provide similar coverage limits per medical incident, per location, and on an aggregate basis for covered centers. The deductibles for these policies are covered through the insurance subsidiary.
Reserve for Estimated Self-Insured Professional Liability Claims
Because the Company’s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company’s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of $24,229 as of June 30, 2018. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period.
The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of this reserve. Since May 2012, Merlinos & Associates, Inc. (“Merlinos”) has assisted management in the preparation of the appropriate accrual for incurred but not reported general and professional liability claims based on data furnished as of May 31 and November 30 of each year. Merlinos primarily utilizes historical data regarding the frequency and cost of the Company's past claims over a multi-year period, industry data and information regarding the number of occupied beds to develop its estimates of the Company's ultimate professional liability cost for current periods.
On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company’s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator’s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company’s evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period.
As of June 30, 2018, the Company is engaged in 79 professional liability lawsuits. Eleven lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company’s cash expenditures for self-insured professional liability costs from continuing operations were $2,775 and $4,338 for the six months ended June 30, 2018 and 2017, respectively.
The Company follows the FASB ASU, "Presentation of Insurance Claims and Related Insurance Recoveries," that clarifies that a health care entity should not net insurance recoveries against a related professional liability claim and that the amount of the claim liability should be determined without consideration of insurance recoveries. Accordingly, the estimated insurance recovery receivables are included within "Other Current Assets" and "Other Noncurrent Assets" on the Consolidated Balance Sheet. As of June 30, 2018 there are estimated insurance recovery receivables of $3,080.
Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company’s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company’s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company’s reported earnings and financial position for the period in which the change in accrual is made.
Civil Investigative Demand ("CID")
In July 2013, the Company learned that the United States Attorney for the Middle District of Tennessee ("DOJ") had commenced a civil investigation of potential violations of the False Claims Act ("FCA").

16


In October 2014, the Company learned that the investigation was started by the filing under seal of a false claims action against the two centers that were subject of the original civil investigative demand ("CID"). In connection with this matter, between July 2013 and early February 2016, the Company received three civil investigative demands (a form of subpoena) for documents. The Company has responded to those demands and also provided voluntarily additional information requested by the DOJ. The DOJ has also taken testimony from current and former employees of the Company. In May 2018, the Company learned that a second FCA complaint had been filed in late 2016 relating to the Company’s practices and policies for rehabilitation therapy at some of its facilities. The government’s investigation relates to the Company’s practices and policies for rehabilitation and other services at all of its facilities, for preadmission evaluation forms ("PAEs") required by TennCare and for Pre-Admission Screening and Resident Reviews ("PASRRs") required by the Medicare program.
In June 2016, the Company received an authorized investigative demand (a form of subpoena) for documents in connection with a criminal investigation by the DOJ related to our practices with respect to PAEs and PASRRs, and the Company has provided documents responsive to this subpoena and continues to provide additional information as requested. The Company cannot predict the outcome of these investigations or the related lawsuits, and the outcome could have a materially adverse effect on the Company, including the imposition of treble damages, criminal charges, fines, penalties and/or a corporate integrity agreement. Additionally, the uncertainty regarding the outcome of this investigation makes it more difficult for the Company to pursue strategic possibilities, longer term initiatives or to make significant financial commitments outside of the normal course of its business. The Company is committed to provide caring and professional services to its patients and residents in compliance with applicable laws and regulations.
Other Insurance
With respect to workers’ compensation insurance, substantially all of the Company’s employees became covered under either a prefunded deductible policy or state-sponsored programs. The Company has been and remains a non-subscriber to the Texas workers’ compensation system and is, therefore, completely self-insured for employee injuries with respect to its Texas operations. From June 30, 2003 until June 30, 2007, the Company’s workers’ compensation insurance programs provided coverage for claims incurred with premium adjustments depending on incurred losses. For the period from July 1, 2007 until June 30, 2008, the Company is completely insured for workers' compensation exposure. From the period from July 1, 2008 through June 30, 2018, the Company is covered by a prefunded deductible policy. Under this policy, the Company is self-insured for the first $500 per claim, subject to an aggregate maximum of $3,000. The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers’ compensation claims is $593 at June 30, 2018. The Company has a non-current receivable for workers’ compensation policies covering previous years of $1,030 as of June 30, 2018. The non-current receivable is a function of payments paid to the Company’s insurance carrier in excess of the estimated level of claims expected to be incurred.
As of June 30, 2018, the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to $200 per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims is $1,615 at June 30, 2018. The differences between actual settlements and reserves are included in expense in the period finalized.

7.
STOCK-BASED COMPENSATION

Overview of Plans
In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (“Stock Purchase Plan”). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers. The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (“RSU's”) at 85% of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally two years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period. In June 2016, our shareholders approved an amendment to the Stock Purchase Plan to increase the number of shares of our common stock authorized under the Plan from 150 shares to 350 shares. No grants can be made under the Stock Purchase Plan after April 25, 2028.
In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (“2010 Plan”), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. In June 2017, our shareholders approved an amendment to the Long-Term Incentive Plan to increase the number of shares of our common stock authorized under the Plan from 380 shares to 680 shares. No grants can be made under the 2010 Plan after May 31, 2027.

17


Equity Grants and Valuations
During the six months ended June 30, 2018 and 2017, the Compensation Committee of the Board of Directors approved grants totaling approximately 90 and 88 shares of restricted common stock to certain employees and members of the Board of Directors, respectively. The fair value of restricted shares is determined as the quoted market price of the underlying common shares at the date of the grant. The restricted shares typically vest 33% on the first, second and third anniversaries of the grant date. Generally, unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. Upon vesting, all restrictions are removed.
Prior to 2017, the Compensation Committee of the Board of Directors also approved grants of Stock Only Stock Appreciation Rights (“SOSARs”) and Stock Options at the market price of the Company's common stock on the grant date. The SOSARs and Options vest 33% on the first, second and third anniversaries of the grant date, and expire 10 years from the grant date.
In computing the fair value estimates using the Black-Scholes-Merton valuation method, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.
Summarized activity of the equity compensation plans is presented below:
 
 
 
Weighted
 
Options/
 
Average
 
SOSARs
 
Exercise Price
Outstanding, December 31, 2017
211

 
$
6.64

Granted
30

 
8.14

Exercised
—

 
—

Expired or cancelled
(15
)
 
10.81

Outstanding, June 30, 2018
226

 
$
6.56

 
 
 
 
Exercisable, June 30, 2018
206

 
$
6.41


 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Shares
 
Fair Value
Outstanding, December 31, 2017
164

 
$
9.95

Granted
90

 
8.14

Dividend Equivalents
3

 
7.15

Vested
(79
)
 
10.27

Cancelled
(7
)
 
9.62

Outstanding, June 30, 2018
171

 
$
8.81


18


Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:
 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Share Units
 
Fair Value
Outstanding, December 31, 2017
44

 
$
9.59

Granted
16

 
8.14

Dividend Equivalents
1

 
7.14

Vested
(17
)
 
8.91

Outstanding, June 30, 2018
44

 
$
9.28


The SOSARs and Options were valued and recorded in the same manner, and, other than amounts that may be settled pursuant to employment agreements with certain members of management, will be settled with issuance of new stock for the difference between the market price on the date of exercise and the exercise price. The Company estimated the total recognized and unrecognized compensation related to SOSARs and stock options using the Black-Scholes-Merton equity grant valuation model.

In computing the fair value estimates using the Black-Scholes-Merton valuation model, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.

The following table summarizes information regarding stock options and SOSAR grants outstanding as of June 30, 2018:
 
 
Weighted
 
 
 
 
 
 
 
 
 
 
Average
 
 
 
Intrinsic
 
 
 
Intrinsic
Range of
 
Exercise
 
Grants
 
Value-Grants
 
Grants
 
Value-Grants
Exercise Prices
 
Prices
 
Outstanding
 
Outstanding
 
Exercisable
 
Exercisable
$8.14 to $10.80
 
$
9.32

 
60

 
$
—

 
40

 
$
—

$2.37 to $6.21
 
$
5.56

 
166

 
$
206

 
166

 
$
206

 
 
 
 
226

 
 
 
206

 
 
Stock-based compensation expense is non-cash and is included as a component of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. The Company recorded total stock-based compensation expense of $765 and $504 in the six month periods ended June 30, 2018 and 2017, respectively.


8.
EARNINGS PER COMMON SHARE
Information with respect to basic and diluted net income per common share is presented below in thousands, except per share:
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2018
 
2017
 
2018
 
2017
Net income (loss)
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
(307
)
 
$
381

 
$
(388
)
 
$
1,729

Loss from discontinued operations, net of income taxes
(4
)
 
(28
)
 
(26
)
 
(43
)
Net income (loss)
$
(311
)
 
$
353

 
$
(414
)
 
$
1,686

 

19


 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2018
 
2017
 
2018
 
2017
Net income (loss) per common share:
 
 
 
 
 
 
 
Per common share – basic
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
(0.05
)
 
$
0.06

 
$
(0.06
)
 
$
0.28

Loss from discontinued operations
—

 
—

 
—

 
(0.01
)
Net income (loss) per common share – basic
$
(0.05
)
 
$
0.06

 
$
(0.06
)
 
$
0.27

Per common share – diluted
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
(0.05
)
 
$
0.06

 
$
(0.06
)
 
$
0.27

Loss from discontinued operations
—

 
—

 
—

 
(0.01
)
Net income (loss) per common share – diluted
$
(0.05
)
 
$
0.06

 
$
(0.06
)
 
$
0.26

Weighted Average Common Shares Outstanding:
 
 
 
 
 
 
 
Basic
6,370

 
6,294

 
6,342

 
6,263

Diluted
6,370

 
6,472

 
6,342

 
6,458

The effects of 226 and 46 SOSARs and options outstanding were excluded from the computation of diluted earnings per common share in the six months ended June 30, 2018 and 2017, respectively, because these securities would have been anti-dilutive.

9.
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS
2017 Acquisition
During the year ended December 31, 2017, the Company expanded its operations to acquire a center that complements its current portfolio. On June 8, 2017, the Company entered into an Asset Purchase Agreement (the "Purchase Agreement") with Park Place Nursing and Rehabilitation Center, LLC, Dunn Nursing Home, Inc., Wood Properties of Selma LLC, and Homewood of Selma, LLC to acquire a 103-bed skilled nursing center in Selma, Alabama, for an aggregate purchase price of $8,750. In connection with the funding of the acquisition, on June 30, 2017, the Company amended the terms of its Second Amended and Restated Term Loan Agreement to increase the facility by $7,500, which is described in Note 5 to the interim consolidated financial statements herein. The acquisition transaction closed on July 1, 2017. In accordance with ASC 805, this transaction was accounted for as a business combination, which resulted in the expensing of $140 of acquisition costs and a $925 recorded gain on bargain purchase for the Company for the year ended December 31, 2017. The operating results of the acquired center have been included in the Company's consolidated statement of operations since the acquisition date. Supplemental pro forma information regarding the acquisition is not material to the consolidated financial statements. The allocation of the purchase price to the net assets acquired is as follows:
 
 
Park Place
Purchase Price
 
$
8,750

Gain on bargain purchase
 
925

 
 
$
9,675

 
 
 
Allocation:
 
 
Building
 
$
8,435

Land
 
760

Land Improvements
 
145

Furniture, Fixtures and Equipment
 
335

 
 
$
9,675



20


2018 Assets Held for Sale
During the first quarter of 2018, three of the Company's skilled nursing facilities met the accounting criteria to be classified as held for sale, but did not meet the accounting criteria to be reported as discontinued operations. The Company is selling the property and equipment affiliated with these centers. The recorded values of these centers' assets are $13,269. The centers' assets are classified as held for sale in the accompanying interim consolidated balance sheets.
2017 Lease Termination
On September 30, 2017, the Company entered into an Agreement with Trend Health and Rehab of Carthage, LLC ("Trend Health") to terminate the lease and the Company's right of possession of the center in Carthage, Mississippi. In consideration of the early termination of the lease, Trend Health provided the Company with a $250 cash termination payment which is included in lease termination receipts in the accompanying interim consolidated statements of operations for the year ended December 31, 2017. For accounting purposes, this transaction was not reported as a discontinued operation as this disposal did not represent a strategic shift that has (or will have) a major effect on the Company's operations and financial results.
2016 Sale of Investment in Unconsolidated Affiliate
On October 28, 2016, the Company and its partners entered into an asset purchase agreement to sell the pharmacy joint venture. The sale resulted in a $1,366 gain in the fourth quarter of 2016. Subsequently, the Company recognized additional gains of $308 and $733 for the six-month periods ended June 30, 2018 and 2017, respectively, related to the liquidation of remaining assets affiliated with the partnership.

10.
SUBSEQUENT EVENTS

On July 8, 2018 the Company entered into a membership interest purchase agreement with ALS Ontario Operating, Inc. to sell all of the issued and outstanding membership units of the Ontario Pointe facility. The transaction is expected to become effective in the third quarter of 2018.

On July 9, 2018 the Board of Directors of Diversicare Healthcare Services, Inc. announced the retirement of Kelly Gill as President, Chief Executive Officer and Board member of the Company, effective July 6, 2018. As a result of Mr. Gill's retirement, the Company recorded $1,172 in severance related expenses inclusive of $259 in additional stock based compensation expense in the second quarter of 2018. In accordance with Mr. Gill's employment agreement, the Company determined that the benefits to which Mr. Gill was entitled were probable of being paid. The Company also announced the appointment of James R. McKnight, Jr. as President and Chief Executive Officer of the Company.




21


ITEM 2 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Overview
Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare” or the “Company”) provides long-term care services to nursing center patients in ten states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Mississippi, Missouri, Ohio, Tennessee, and Texas.
As of June 30, 2018, the Company’s continuing operations consist of 76 nursing centers with 8,456 licensed nursing beds. The Company owns 18 and leases 58 of its nursing centers. Our nursing centers range in size from 48 to 320 licensed nursing beds. The licensed nursing bed count does not include 497 licensed assisted living and residential beds.
Key Performance Metrics
Skilled Mix. Skilled mix represents the number of days our Medicare or Managed Care patients are receiving services at the skilled nursing facilities divided by the total number of days (less days from assisted living services) from all payor sources are receiving services as the skilled nursing facilities for any given period.
Average rate per day. Average rate per day is the revenue by primary payor source for a period at the skilled nursing facility divided by actual patient days for the revenue source for a given period.
Average daily skilled nursing census. Average daily skilled nursing census is the average number of patients who are receiving skilled nursing care as a percentage of total number of patient days.
Strategic Operating Initiatives
We identified several key strategic objectives to increase shareholder value through improved operations and business development. These strategic operating initiatives include: improving our facilities' quality metrics, improving skilled mix in our nursing centers, improving our average Medicare rate, implementing and maintaining Electronic Medical Records (“EMR”) to improve Medicaid capture, and completing strategic acquisitions and divestitures. We have experienced success in these initiatives and expect to continue to build on these improvements. In light of challenges facing the industry and the Company specifically, including the unresolved governmental investigation, we believe that now is not the time to attempt to engage in a company-wide strategic transaction.
Improving skilled mix and average Medicare rate:
Our strategic operating initiatives of improving our skilled mix and our average Medicare rate required investing in nursing and clinical care to treat more acute patients along with nursing center-based marketing representatives to attract these patients. These initiatives developed referral and Managed Care relationships that have attracted and are expected to continue to attract payor sources for patients covered by Medicare and Managed Care. The Company's skilled mix for the three months ended June 30, 2018 and 2017 was 14.8% and 15.6%, respectively. The graph below illustrates our success with increasing our average Medicare rate per day:
medicarerateperday.jpg

22


Utilizing Electronic Medical Records to improve Medicaid acuity capture:
As another part of our strategic operating initiatives, we successfully completed a full implementation of EMR to improve Medicaid acuity capture, primarily in our states where the Medicaid payments are acuity based. We completed the implementation on time and under budget, and since implementation, have increased our average Medicaid rate despite rate cuts in certain acuity based states by accurate and timely capture of care delivery. The graph below illustrates our success with increasing our average Medicaid rate per day since implementation:
medicaidrateperday.jpg
Completing strategic acquisitions and dispositions:
Our strategic operating initiatives include a renewed focus on completing strategic acquisitions and dispositions. We continue to pursue and investigate opportunities to acquire, lease or develop new centers, focusing primarily on opportunities within our existing geographic areas of operation. We expect to announce additional development projects in the near future.
Effective July 1, 2017, we acquired a 103-bed skilled nursing center in Selma, Alabama, for an aggregate purchase price of $8,750, pursuant to an Asset Purchase Agreement with Park Place Nursing and Rehabilitation Center, LLC, Dunn Nursing Home, Inc., Wood Properties of Selma LLC, and Homewood of Selma, LLC. This transaction is further discussed in Note 9 "Business Development and Other Significant Transactions" to the interim consolidated financial statements.
During the first quarter of 2018, three of the Company's skilled nursing facilities met the accounting criteria to be classified as held for sale, but did not meet the accounting criteria to be reported as discontinued operations. The Company is selling the property and equipment affiliated with these centers. The recorded values of these centers' assets are $13,269 as of June 30, 2018. The centers' assets are classified as held for sale in the accompanying interim consolidated balance sheet.
As part of our strategic efforts, we have also performed thorough analysis on our existing centers in order to determine whether continuing operations within certain markets or regions was in line with the short-term and long-term strategy of the business. As a result, we ceased operations at our Carthage, Mississippi, facility in September 2017 thus terminating our lease agreements with the lessor. This transaction was not reported as discontinued operations as described in Note 9 to the interim consolidated financial statements.
Basis of Financial Statements
Our patient revenues consist of the fees charged for the care of patients in the nursing centers we own and lease. Our operating expenses include the costs, other than lease, professional liability, depreciation and amortization expenses, incurred in the operation of the nursing centers we own and lease. Our general and administrative expenses consist of the costs of the corporate office and regional support functions. Our interest, depreciation and amortization expenses include all such expenses across the range of our operations.

Critical Accounting Policies and Judgments
A “critical accounting policy” is one which is both important to the understanding of our financial condition and results of operations and requires management’s most difficult, subjective or complex judgments often involving estimates of the effect of matters that are inherently uncertain. Actual results could differ from those estimates and cause our reported net income or loss to vary significantly from period to period. Our critical accounting policies are more fully described in our 2017 Annual Report on Form 10-K.


23


Revenue Sources
We classify our revenues from patients and residents into four major categories: Medicaid, Medicare, Managed Care, and Private Pay and other. Medicaid revenues are composed of the traditional Medicaid program established to provide benefits to those in need of financial assistance in the securing of medical services. Medicare revenues include revenues received under both Part A and Part B of the Medicare program. Managed Care revenues include payments for patients who are insured by a third-party entity, typically called a Health Maintenance Organization, often referred to as an HMO plan, or are Medicare beneficiaries who assign their Medicare benefits to a Managed Care replacement plan often referred to as Medicare replacement products. The Private Pay and other revenues are composed primarily of individuals or parties who directly pay for their services. Included in the Private Pay and other payors are patients who are hospice beneficiaries as well as the recipients of Veterans Administration benefits. Veterans Administration payments are made pursuant to renewable contracts negotiated with these payors.
The following table sets forth net patient and resident revenues related to our continuing operations by primary payor source for the periods presented (dollar amounts in thousands). The difference between 2018 revenue reported below and in the accompanying statements of operations is due to the implementation of ASC 606. Refer to Note 4 "Revenue Recognition" to the interim consolidated financial statements.
 
Three Months Ended June 30,
 
2018
 
2018
 
2017
 
As reported
 
As Adjusted to Legacy GAAP
 
As reported
Medicaid
$
65,603

46.5
%
 
$
75,216

52.0
%
 
$
73,510

51.6
%
Medicare
27,863

19.7
%
 
36,079

25.0
%
 
38,900

27.3
%
Managed Care
13,303

9.4
%
 
11,888

8.2
%
 
9,959

7.0
%
Private Pay and other
34,313

24.4
%
 
21,326

14.8
%
 
20,181

14.1
%
Total
$
141,082

100.0
%
 
$
144,509

100.0
%
 
$
142,550

100.0
%
 
Six Months Ended June 30,
 
2018
 
2018
 
2017
 
As reported
 
As Adjusted to Legacy GAAP
 
As reported
Medicaid
$
129,489

45.9
%
 
$
148,431

51.4
%
 
$
146,383

51.5
%
Medicare
57,614

20.4
%
 
74,217

25.7
%
 
76,911

27.1
%
Managed Care
27,515

9.7
%
 
23,980

8.3
%
 
20,764

7.3
%
Private Pay and other
67,749

24.0
%
 
42,373

14.6
%
 
39,992

14.1
%
Total
$
282,367

100.0
%
 
$
289,001

100.0
%
 
$
284,050

100.0
%

The following table sets forth average daily skilled nursing census by primary payor source for our continuing operations for the periods presented: 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2018
2017
 
2018
2017
Medicaid
4,645

 
68.9
%
 
4,630

 
68.6
%
 
4,617

 
68.4
%
 
4,640

 
68.6
%
Medicare
715

 
10.6

 
810

 
12.0

 
749

 
11.1

 
801

 
11.8

Managed Care
281

 
4.2

 
243

 
3.6

 
292

 
4.3

 
258

 
3.8

Private Pay and other
1,105

 
16.3

 
1,065

 
15.8

 
1,093

 
16.2

 
1,061

 
15.8

Total
6,746

 
100.0
%
 
6,748

 
100.0
%
 
6,751

 
100.0
%
 
6,760

 
100.0
%
Consistent with the nursing home industry in general, changes in the mix of a facility’s patient population among Medicaid, Medicare, Managed Care, and Private Pay and other can significantly affect the profitability of the facility’s operations.

Health Care Industry
The health care industry is subject to regulation by numerous federal, state, and local governments. These laws and regulations include, but are not limited to, matters such as licensure, accreditation, government health care program participation requirements, reimbursement for patient services, quality of patient care and Medicare and Medicaid fraud and abuse. Over the last several years, government activity has increased with respect to investigations and allegations concerning possible violations by health care
providers of a number of statutes and regulations, including those regulating fraud and abuse, false claims, patient privacy and quality of care issues. Violations of these laws and regulations could result in exclusion from government health care programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. Compliance with such laws and regulations is subject to ongoing government review and interpretation, as well as regulatory actions in which government agencies seek to impose fines and penalties. The Company is involved in regulatory actions of this type from time to time.
In recent years, the U.S. Congress and some state legislatures have considered and enacted significant legislation concerning health care and health insurance. The most prominent of these efforts, the Affordable Care Act, affects how health care services are covered, delivered and reimbursed. As currently structured, the Affordable Care Act expands coverage through a combination of public program expansion and private sector reforms, provides for reduced growth in Medicare program spending, and promotes initiatives that tie reimbursement to quality and care coordination. Some of the provisions, such as the requirement that large employers provide health insurance benefits to full-time employees, have increased our operating expenses. The Affordable Care Act expands the role of home-based and community services, which may place downward pressure on our sustaining population of Medicaid patients. Reforms that we believe may have a material impact on the long-term care industry and on our business include, among others, possible modifications to the conditions of qualification for payment, bundling of payments to cover both acute and post-acute care and the imposition of enrollment limitations on new providers. However, there is considerable uncertainty regarding the future of the Affordable Care Act. The Presidential administration and certain members of Congress have expressed their intent to repeal or make significant changes to the law, its implementation or its interpretation. For example, in 2017, Congress eliminated the financial penalty associated with the individual mandate, effective January 1, 2019.
Skilled nursing centers are required to bill Medicare on a consolidated basis for certain items and services that they furnish to patients, regardless of the cost to deliver these services. This consolidated billing requirement essentially makes the skilled nursing center responsible for billing Medicare for all care services delivered to the patient during the length of stay. CMS has instituted a number of test programs designed to extend the reimbursement and financial responsibilities under consolidating billing beyond the traditional discharge date to include a broader set of bundled services. Such examples may include, but are not exclusive to, home health, durable medical equipment, home and community based services, and the cost of re-hospitalizations during a specified bundled period. Currently, these test programs for bundled reimbursement are confined to a small set of clinical conditions, but CMS has indicated that it is developing additional bundled payment models. This bundled form of reimbursement could be extended to a broader range of diagnosis related conditions in the future. The potential impact on skilled nursing center utilization and reimbursement is currently unknown. The process for defining bundled services has not been fully determined by CMS and therefore is subject to change during the rule making process.
On July 31, 2018, CMS issued a final rule outlining Medicare payment rates for skilled nursing facilities that will be effective October 1, 2018. CMS established that the SNF market basket will be updated by 2.4% as required by the Bipartisan Budget Act of 2018. CMS finalized a payment system called the Patient-Driven Payment Model ("PDPM") to replace the Resource Utilization Group ("RUG-IV") model. The PDPM is an updated version of the 2017 Advanced Notice of Proposed Rulemaking Resident Classification System Version 1 ("RCS-1"). CMS notes RCS-1 was revised based on stakeholder input. The implementation date for the final system is October 1, 2019. CMS will use a budget neutrality factor to satisfy the requirement that PDPM be budget neutral relative to RUG-IV. CMS stated that it intends for the new model to not to change the aggregate amount of Medicare payments to SNFs, but to more accurately reflect resource utilization without incentivizing inappropriate care delivery.


24


Contractual Obligations and Commercial Commitments
We have certain contractual obligations of continuing operations as of June 30, 2018, summarized by the period in which payment is due, as follows (dollar amounts in thousands):
Contractual Obligations
Total
 
Less than
1  year
 
1 to 3
Years
 
3 to 5
Years
 
After
5 Years
Long-term debt obligations (1)
$
100,846

 
$
17,722

 
$
83,089

 
$
35

 
$
—

Settlement obligations (2)
824

 
824

 
—

 
—

 
—

Elimination of Preferred Stock Conversion feature (3)
172

 
172

 
—

 
—

 
—

Operating leases (4)
1,046,148

 
58,751

 
120,826

 
124,263

 
742,308

Required capital expenditures under operating leases (5)
10,667

 
1,172

 
2,344

 
2,344

 
4,807

Total
$
1,158,657

 
$
78,641

 
$
206,259

 
$
126,642

 
$
747,115

 
(1)
Long-term debt obligations include scheduled future payments of principal and interest of long-term debt and amounts outstanding on our capital lease obligations. Our long-term debt obligations decreased $2.6 million between December 31, 2017 and June 30, 2018. See Note 5, "Long-Term Debt and Interest Rate Swap," to the interim consolidated financial statements included in this report for additional information.
(2)
Settlement obligations relate to professional liability cases that are expected to be paid within the next twelve months. The professional liabilities are included in our current portion of self-insurance reserves.
(3)
Payments to Omega Health Investors ("Omega"), from which we lease 35 nursing centers, for the elimination of the preferred stock conversion feature in connection with restructuring the preferred stock and master lease agreements. Monthly payments of approximately $57,000 will be made through the end of the initial lease period that ends in September 2018.
(4)
Represents lease payments under our operating lease agreements. Assumes all renewal periods are enacted. Our operating lease obligations decreased $19.5 million between December 31, 2017 and June 30, 2018.
(5)
Includes annual expenditure requirements under operating leases. Our required capital expenditures decreased $1.2 million between December 31, 2017 and June 30, 2018.
We have employment agreements with certain members of management that provide for the payment to these members of amounts up to two times their annual salary in the event of a termination without cause, a constructive discharge (as defined therein), or upon a change of control of the Company (as defined therein). The maximum contingent liability under these agreements is approximately $1.9 million as of June 30, 2018. The terms of such agreements are for one year and automatically renew for one year if not terminated by us or the employee. In addition, upon the occurrence of any triggering event, those certain members of management may elect to require that we purchase equity awards granted to them for a purchase price equal to the difference in the fair market value of our common stock at the date of termination versus the stated equity award exercise price. Based on the closing price of our common stock on June 30, 2018, the potential contingent liability for the repurchase of the equity grants is $0.1 million.
Kelly Gill retired as Chief Executive Officer, effective July 6, 2018. In connection with his retirement, we recorded approximately $1.2 million in severance related expenses in the second quarter of 2018 in accordance with Mr. Gill's employment agreement. 


25


Results of Operations
The following tables present the unaudited interim consolidated statements of operations and related data for the three and six month periods ended June 30, 2018 and 2017:
 
(in thousands)
Three Months Ended June 30,
 
2018
 
2017
 
Change
 
%
PATIENT REVENUES, net
$
141,082

 
$
142,550

 
$
(1,468
)
 
(1.0
)%
EXPENSES:
 
 
 
 
 
 
 
Operating
111,440

 
113,166

 
(1,726
)
 
(1.5
)%
Lease and rent expense
13,725

 
13,763

 
(38
)
 
(0.3
)%
Professional liability
3,182

 
2,724

 
458

 
16.8
 %
General and administrative
9,295

 
8,221

 
1,074

 
13.1
 %
Depreciation and amortization
2,847

 
2,620

 
227

 
8.7
 %
Total expenses
140,489

 
140,494

 
(5
)
 
—
 %
OPERATING INCOME
593

 
2,056

 
(1,463
)
 
(71.2
)%
OTHER INCOME (EXPENSE):
 
 
 
 
 
 
 
Gain on sale of investment in unconsolidated affiliate

308

 
—

 
308

 
(100.0
)%
Other income
28

 
—

 
28

 
100.0
 %
Interest expense, net
(1,661
)
 
(1,541
)
 
(120
)
 
(7.8
)%
 
(1,325
)
 
(1,541
)
 
216

 
14.0
 %
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
(732
)
 
515

 
(1,247
)
 
(242.1
)%
BENEFIT (PROVISION) FOR INCOME TAXES
425

 
(134
)
 
559

 
417.2
 %
INCOME (LOSS) FROM CONTINUING OPERATIONS
$
(307
)
 
$
381

 
$
(688
)
 
(180.6
)%

(in thousands)
Six Months Ended June 30,
 
2018
 
2017
 
Change
 
%
PATIENT REVENUES, net
$
282,367

 
$
284,050

 
$
(1,683
)
 
(0.6
)%
EXPENSES:
 
 
 
 
 
 
 
Operating
223,718

 
223,833

 
(115
)
 
(0.1
)%
Lease and rent expense
27,438

 
27,506

 
(68
)
 
(0.2
)%
Professional liability
5,957

 
5,394

 
563

 
10.4
 %
General and administrative
17,434

 
17,194

 
240

 
1.4
 %
Depreciation and amortization
5,728

 
5,107

 
621

 
12.2
 %
Total expenses
280,275

 
279,034

 
1,241

 
0.4
 %
OPERATING INCOME
2,092

 
5,016

 
(2,924
)
 
(58.3
)%
OTHER INCOME (EXPENSE):
 
 
 
 
 
 
 
Gain on sale of investment in unconsolidated affiliate

308

 
733

 
(425
)
 
(100.0
)%
Other income
79

 
—

 
79

 
100.0
 %
Interest expense, net
(3,330
)
 
(3,024
)
 
(306
)
 
(10.1
)%
 
(2,943
)
 
(2,291
)
 
(652
)
 
(28.5
)%
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
(851
)
 
2,725

 
(3,576
)
 
(131.2
)%
BENEFIT (PROVISION) FOR INCOME TAXES
463

 
(996
)
 
1,459

 
146.5
 %
INCOME (LOSS) FROM CONTINUING OPERATIONS
$
(388
)
 
$
1,729

 
$
(2,117
)
 
(122.4
)%


26


Percentage of Net Revenues
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2018
 
2017
 
2018
 
2017
PATIENT REVENUES, net
100.0
 %
 
100.0
%
 
100.0
 %
 
100.0
%
EXPENSES:
 
 
 
 
 
 
 
Operating
79.0

 
79.4

 
79.2

 
78.8

Lease and rent expense
9.7

 
9.7

 
9.7

 
9.7

Professional liability
2.3

 
1.9

 
2.1

 
1.9

General and administrative
6.6

 
5.8

 
6.2

 
6.1

Depreciation and amortization
2.0

 
1.8

 
2.0

 
1.8

Total expenses
99.6

 
98.6

 
99.2

 
98.3

OPERATING INCOME
0.4

 
1.4

 
0.8

 
1.7

OTHER INCOME (EXPENSE):
 
 
 
 
 
 
 
Gain on sale of investment in unconsolidated affiliate
0.2

 
—

 
0.1

 
0.3

Other income
—

 
—

 
—

 
—

Interest expense, net
(1.1
)
 
(1.1
)
 
(1.2
)
 
(1.1
)
 
(0.9
)
 
(1.1
)
 
(1.1
)
 
(0.8
)
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
(0.5
)
 
0.3

 
(0.3
)
 
0.9

BENEFIT (PROVISION) FOR INCOME TAXES
0.3

 
(0.1
)
 
0.2

 
(0.4
)
INCOME FROM CONTINUING OPERATIONS
(0.2
)%
 
0.2
%
 
(0.1
)%
 
0.5
%

27


Three Months Ended June 30, 2018 Compared With Three Months Ended June 30, 2017
Patient Revenues
Patient revenues were $141.1 million and $142.6 million for the three months ended June 30, 2018 and 2017, respectively, a decrease of $1.5 million. The following summarizes the revenue fluctuations attributable to our portfolio growth (in thousands):
 
Three Months Ended June 30,
 
2018
2017
 

 
As reported
 
As adjusted to Legacy GAAP
 
As reported
 
Change
Same-store revenue
$
138,747

 
$
142,174

 
$
142,550

 
$
(376
)
2017 acquisition revenue
2,335

 
2,335

 
—

 
2,335

Total revenue
$
141,082

 
$
144,509

 
$
142,550

 
$
1,959

The difference between patient revenues for the second quarter of 2018 is due to the implementation of ASC 606. Refer to Note 4 "Revenue Recognition" to the interim consolidated financial statements.
The overall increase in revenues as adjusted to legacy GAAP of $2.0 million is primarily attributable to revenue contributions from the acquisition of the Park Place operations during the second quarter of 2018 of $2.3 million.
On a same-store center basis, the average Medicare and Medicaid rate per patient day for the second quarter of 2018 increased compared to the second quarter of 2017, resulting in increases in revenue of $0.1 million and $1.3 million, respectively, or 0.4% and 1.8%, respectively. Our same-store Medicare average daily census for the second quarter of 2018 decreased $4.1 million or 12.5%. Conversely, our Managed Care average daily census for the second quarter of 2018 increased $1.3 million or 15.0%. Our ancillary revenue for the second quarter of 2018 increased $1.3 million.
The following table summarizes key revenue and census statistics for continuing operations for each period:
 
 
Three Months Ended June 30,
 
2018
 
2017
Skilled nursing occupancy
79.8
%
 
79.8
%
As a percent of total census:
 
 
 
Medicare census
10.6
%
 
12.0
%
Medicaid census
68.9
%
 
68.6
%
Managed Care census
4.2
%
 
3.6
%
As a percent of total revenues:
 
 
 
Medicare revenues
25.0
%
 
27.3
%
Medicaid revenues
52.0
%
 
51.6
%
Managed Care revenues
8.2
%
 
7.0
%
Average rate per day:
 
 
 
Medicare
$
455.29

  
$
453.02

Medicaid
$
177.58

  
$
173.92

Managed Care
$
397.49

  
$
391.60


28


Operating Expense
Operating expense decreased in the second quarter of 2018 to $111.4 million as compared to $113.2 million in the second quarter of 2017. Operating expense decreased as a percentage of revenue at 79.0% for the second quarter of 2018 as compared to 79.4% for the second quarter of 2017. The following table summarizes the expense increases attributable to our portfolio growth (in thousands):
 
Three Months Ended June 30,
 
2018
2017
 

 
As reported
 
As adjusted to Legacy GAAP
 
As reported
 
Change
Same-store operating expense
$
109,758

 
$
113,547

 
$
113,166

 
$
381

2017 acquisition expense
1,682

 
1,682

 
—

 
1,682

Total expense
$
111,440

 
$
115,229

 
$
113,166

 
$
2,063

The overall increase in operating expense of $2.1 million is partially attributable to the acquisition of the Park Place operations during the second quarter of 2018 of $1.7 million.
On a same-store center basis, operating expenses increased by $0.4 million, which is attributable to unfavorable variances in salaries and related taxes and maintenance and utilities of $1.1 million and $0.2 million, respectively, in second quarter of 2018 compared to the second quarter of 2017.
One of the largest components of operating expenses is wages, which increased to $67.8 million during the second quarter of 2018 as compared to $65.8 million in the second quarter of 2017, which is due primarily to acquisition activity.
Lease Expense
Lease expense in the second quarter of 2018 remained consisted with the second quarter of 2017 at $13.7 million.
Professional Liability
Professional liability expense was $3.2 million and $2.7 million in the second quarters of 2018 and 2017, respectively. Our cash expenditures for professional liability costs of continuing operations were $1.7 million and $2.3 million for the second quarters of 2018 and 2017, respectively. Professional liability expense and cash expenditures fluctuate from year to year based respectively on the results of our third-party professional liability actuarial studies and on the costs incurred in defending and settling existing claims. See “Liquidity and Capital Resources” for further discussion of the accrual for professional liability.
General and Administrative Expense
General and administrative expense was $9.3 million in the second quarter of 2018 as compared to $8.2 million in the second quarter of 2017. General and administrative expense increased as a percentage of revenue to 6.6% in the second quarter of 2018 from 5.8% in the second quarter of 2017. The increase in general and administrative expense is attributable to $1.2 million of severance expense recorded in the second quarter of 2018.
Depreciation and Amortization
Depreciation and amortization expense was approximately $2.8 million in the second quarter of 2018 as compared to $2.6 million in 2017. The increase in depreciation expense relates to the fixed asset acquisition of a center located in Selma, Alabama during the third quarter of 2017 and other capital expenditures.
Gain on sale of investment in unconsolidated affiliate
Gain on the sale of investment in unconsolidated affiliate was $0.3 million for the three months ended June 30, 2018. The Company and its partners entered into an asset purchase agreement to sell the pharmacy joint venture in the fourth quarter of 2016. The subsequent income related to the final liquidation of remaining net assets affiliated with the partnership.
Interest Expense, Net
Interest expense was $1.7 million in the second quarter of 2018 and $1.5 million in the second quarter of 2017, an increase of $0.2 million. The increase was primarily attributable to the amendment of the term loan facility that occurred in June 2017.
Income (loss) from Continuing Operations before Income Taxes; Income from Continuing Operations per Common Share
As a result of the above, continuing operations reported a loss of $0.7 million before income taxes for the second quarter of 2018 as compared to income of $0.5 million for the second quarter of 2017. The benefit for income taxes was $0.4 million for the second quarter of 2018, and the provision for income taxes was $0.1 million for the second quarter of 2017. Both basic and diluted loss

29


per common share from continuing operations were $0.05 for the second quarter of 2018 as compared to both basic and diluted income per common share from continuing operations of $0.06 in the second quarter of 2017.


30


Six Months Ended June 30, 2018 Compared With Six Months Ended June 30, 2017
Patient Revenues
Patient revenues were $282.4 million and $284.1 million for the six months ended June 30, 2018 and 2017, respectively, a decrease of $1.7 million. The following table summarizes the revenue fluctuations attributable to our portfolio growth (in thousands):
 
Six Months Ended June 30,
 
2018
 
2017
 
 
 
As reported
 
As adjusted to Legacy GAAP
 
As reported
 
Change
Same-store revenue
$
277,650

 
$
284,284

 
$
284,050

 
$
234

2017 acquisition revenue
4,717

 
4,717

 
—

 
4,717

Total revenue
$
282,367

 
$
289,001

 
$
284,050

 
$
4,951

The change in patient revenues for the second quarter of 2018 is due to the implementation of ASC 606. Refer to Note 4 "Revenue Recognition" to the interim consolidated financial statements.
The overall increase in revenues as adjusted to legacy GAAP of $5.0 million is primarily attributable to revenue contributions from the acquisition of the Park Place operations during the first quarter of 2018 of $4.7 million.
On a same-store basis, our Medicare and Medicaid average daily census for the six months ended June 30, 2018 decreased compared to the six months ended June 30, 2017, resulting in decreases in revenue of $4.7 million and $0.4 million, respectively, or 7.2% and 0.3%, respectively. Conversely, our Managed Care average daily census for the six months ended June 30, 2018 increased $2.2 million or 12.3%.The average Medicaid, Medicare and Managed Care rate per patient day for same-store centers in 2018 increased $2.4 million, $0.4 million, and $0.4 million or 1.7%, 0.6%, and 2.2%, respectively.
The following table summarizes key revenue and census statistics for continuing operations for each period:
 
 
Six Months Ended June 30,
 
 
 
2018
 
 
 
2017
 
 
Skilled nursing occupancy
79.8
%
 
 
 
80.0
%
 
 
As a percent of total census:
 
 
 
 
 
 
 
Medicare census
11.1
%
 
 
 
11.8
%
 
 
Medicaid census
68.4
%
 
 
 
68.6
%
 
 
Managed Care census
4.3
%
 
 
 
3.8
%
 
 
As a percent of total revenues:
 
 
 
 
 
 
 
Medicare revenues
25.7
%
 
 
 
27.1
%
 
 
Medicaid revenues
51.4
%
 
 
 
51.5
%
 
 
Managed Care revenues
8.3
%
 
 
 
7.3
%
 
 
Average rate per day:
 
 
 
 
 
 
 
Medicare
$
455.51

 
  
 
$
452.15

 
 
Medicaid
$
177.19

 
  
 
$
173.83

 
 
Managed Care
$
394.64

 
  
 
$
386.31

 
 

31


Operating Expense
Operating expense decreased for the six months ended June 30, 2018 to $223.7 million as compared to $223.8 million for the six months ended June 30, 2017. Operating expense increased as a percentage of revenue at 79.2% in 2018 as compared to 78.8% in 2017. The following table summarizes the expense increases attributable to our portfolio growth (in thousands):
 
Six Months Ended June 30,
 
2018
2017
 
 
 
As reported
 
As adjusted to Legacy GAAP
 
As reported
 
Change
Same-store operating expense
$
220,432

 
$
227,684

 
$
223,833

 
$
3,851

2017 acquisition expense
3,286

 
3,286

 
—

 
3,286

Total expense
$
223,718

 
$
230,970

 
$
223,833

 
$
7,137

The overall increase in operating expense of $7.1 million is partially attributable to the acquisition of the Park Place operations for the six months ended June 30, 2018 of $3.3 million.
On a same-store center basis, operating expenses increased by $3.9 million, which is attributable to a provider tax refund of $2.2 million from the state of Kentucky during the first quarter of 2017. Additionally, our salaries and related taxes increased by $3.2 million, which is due primarily to acquisition activity. These increases were partially offset by a decrease in health insurance costs and workers' compensation of $1.0 million and $0.4 million, respectively.
One of the largest components of operating expenses is wages, which increased to $134.9 million during 2018 as compared to $130.8 million in 2017, which, consistent with above, is due primarily to acquisition activity.
Lease Expense
Lease expense remained relatively consistent for the six months ended June 30, 2018 of $27.4 million as compared to $27.5 million for the six months ended June 30, 2017.
Professional Liability
Professional liability expense was $6.0 million and $5.4 million for the six months ended June 30, 2018 and 2017, respectively. Our cash expenditures for professional liability costs of continuing operations were $2.8 million and $4.3 million for the six months ended June 30, 2018 and 2017, respectively. Professional liability expense and cash expenditures fluctuate from year to year based respectively on the results of our third-party professional liability actuarial studies and on the costs incurred in defending and settling existing claims. See “Liquidity and Capital Resources” for further discussion of the accrual for professional liability.
General and Administrative Expense
General and administrative expense was $17.4 million for the six months ended June 30, 2018 as compared to $17.2 million for the six months ended June 30, 2017, an increase of $0.2 million. As a percentage of revenue, general and administrative expense increased from 6.1% in 2017 to 6.2% in 2018. The increase in general and administrative expense is attributable to $1.2 million of severance expense recorded in the second quarter of 2018.
Depreciation and Amortization
Depreciation and amortization expense was approximately $5.7 million in 2018 as compared to $5.1 million in 2017. The increase in depreciation expense relates to fixed assets at the newly acquired centers and other capital expenditures.
Gain on sale of investment in unconsolidated affiliate
Gain on the sale of investment in unconsolidated affiliate was $0.3 million and $0.7 million for the six months ended June 30, 2018 and 2017, respectively. The additional gains recognized for the six months ended June 30, 2018 and 2017 are related to the final liquidation of remaining net assets affiliated with the partnership.
Interest Expense, Net
Interest expense was $3.3 million for the six months ended June 30, 2018 and $3.0 million for the six months ended June 30, 2017, an increase of $0.3 million. The increase was primarily attributable to the amendment of the term loan facility that occurred in June 2017.

32


Income (loss) from Continuing Operations before Income Taxes; Income from Continuing Operations per Common Share
As a result of the above, continuing operations reported a loss of $0.9 million before income taxes for the six months ended June 30, 2018 as compared to income of $2.7 million for the six months ended June 30, 2017. The benefit for income taxes was $0.5 million for the six months ended June 30, 2018, and the provision for income taxes was $1.0 million for the six months ended June 30, 2017. Both basic and diluted loss per common share from continuing operations were $0.06 for the six months ended June 30, 2018 as compared to basic and diluted income per common share from continuing operations of $0.28 and $0.27, respectively, for the six months ended June 30, 2017.
Liquidity and Capital Resources
Liquidity
Our primary source of liquidity is the net cash flow provided by the operating activities of our centers. We believe that these internally generated cash flows will be adequate to service existing debt obligations, fund required capital expenditures as well as provide cash flows for investing opportunities. In determining priorities for our cash flow, we evaluate alternatives available to us and select the ones that we believe will most benefit us over the long-term. Options for our use of cash include, but are not limited to, capital improvements, dividends, purchase of additional shares of our common stock, acquisitions, payment of existing debt obligations as well as initiatives to improve nursing center performance. We review these potential uses and align them to our cash flows with a goal of achieving long-term success.
Net cash provided by operating activities of continuing operations totaled $6.6 million for the six months ended June 30, 2018, compared to net cash provided by operating activities of continuing operations of $2.1 million in the same period of 2017. The primary driver of the increase in cash provided by operating activities from continuing operations is due to the timing of accounts receivable collections.
Our cash expenditures related to professional liability claims of continuing operations were $2.8 million and $4.3 million for six months ended June 30, 2018 and 2017, respectively. Although we work diligently to limit the cash required to settle and defend professional liability claims, a significant judgment entered against us in one or more legal actions could have a material adverse impact on our cash flows and could result in our being unable to meet all of our cash needs as they become due.
Investing activities of continuing operations used cash of $3.6 million and $12.7 million for the six months ended in 2018 and 2017, respectively. The fluctuation is due to the funds held in escrow of $8.7 million for the purchase of a center in Selma, Alabama for the six months ended 2017.
Financing activities of continuing operations used cash of $2.1 million for the six months ended June 30, 2018 compared to cash provided of $10.6 million for the six months ended June 30, 2017. The decrease is primarily due to funds held in escrow for the six months ended 2017.

Dividends
On July 26, 2018, the Board of Directors declared a quarterly dividend of $0.055 per common share payable to shareholders of record as of September 30, 2018, to be paid on October 16, 2018. While the Board of Directors intends to pay quarterly dividends, the Board will make the determination of the amount of future cash dividends, if any, to be declared and paid based on, among other things, the Company’s financial condition, funds from operations, the level of its capital expenditures and its future business prospects and opportunities.
Professional Liability
The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. On a per claim basis, coverage for losses in excess of those covered by SHC is maintained through unaffiliated commercial reinsurance carriers. All of the Company's nursing centers in Florida and Tennessee are now covered under the captive insurance policies along with many of the nursing centers in Alabama, Kentucky, and Texas. The insurance coverage provided for these centers under the SHC policy include coverage limits of $0.5 million per medical incident with a sublimit per center of $1.0 million and total annual aggregate policy limits of $5.0 million. All other centers within the Company’s portfolio are covered through various commercial insurance policies which provide similar coverage limits per medical incident, per location, and on an aggregate basis for covered centers. The deductibles for these policies are covered through the insurance subsidiary.

33


As of June 30, 2018, we have recorded total liabilities for reported and settled professional liability claims and estimates for incurred, but unreported claims of $24.2 million. Our calculation of this estimated liability is based on an assumption that the Company will not incur a severely adverse judgment with respect to any asserted claim; however, a significant judgment could be entered against us in one or more of these legal actions, and such a judgment could have a material adverse impact on our financial position and cash flows.
Capital Resources
As of June 30, 2018, we had $88.7 million of outstanding long-term debt and capital lease obligations. The $88.7 million total includes $0.9 million in capital lease obligations and $15.0 million currently outstanding on the revolving credit facility. The balance of the long-term debt is comprised of $72.8 million owed on our mortgage loan, which includes $63.6 million on the term loan facility, $9.0 million on the acquisition loan facility and $0.2 million notes payable to finance equipment.
On February 26, 2016, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated April 30, 2013. The Credit Agreement increases the Company's borrowing capacity to $100.0 million allocated between a $72.5 million Mortgage Loan ("Amended Mortgage Loan") and a $27.5 million Revolver ("Amended Revolver"). The Amended Mortgage Loan consists of a $60 million term loan facility and a $12.5 million acquisition loan facility. Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of $2.2 million and are being amortized over the five-year term of the agreements.
Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original balance of $72.5 million with a five-year maturity through February 26, 2021, and a $27.5 million Amended Revolver through February 26, 2021. The Amended Mortgage Loan has a term of five years, with principal and interest payable monthly based on a 25-year amortization. Interest on the term and acquisition loan facilities is based on LIBOR plus 4.0% and 4.75%, respectively. A portion of the Amended Mortgage Loan is effectively fixed at 5.79% pursuant to an interest rate swap with an initial notional amount of $30.0 million. As of June 30, 2018, the interest rate related to the Amended Mortgage Loan was 6.00%. The Amended Mortgage Loan is secured by eighteen owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized and cross-defaulted. The Company’s Amended Revolver has an interest rate of LIBOR plus 4.0% and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions.
Effective October 3, 2016, the Company entered into the Second Amendment ("Second Revolver Amendment") to amend the Amended Revolver. The Second Revolver Amendment increased the Amended Revolver capacity from the $27.5 million in the Amended Revolver to $52.3 million; provided that the maximum revolving facility be reduced to $42.3 million on August 1, 2017. Subsequently, on June 30, 2017, the Company executed a Fourth Amendment (the "Fourth Revolver Amendment") to amend the Amended Revolver, which modifies the capacity of the revolver to remain at $52.3 million.
On December 29, 2016, the Company executed a Third Amendment ("Third Revolver Amendment") to amend the Amended Revolver. The Third Amendment modifies the terms of the Amended Mortgage Loan Agreement by increasing the Company’s letter of credit sublimit from $10.0 million to $15.0 million.
Effective June 30, 2017, the Company entered into a Second Amendment (the "Second Term Amendment") to amend the Amended Mortgage Loan. The Second Term Amendment amends the terms of the Amended Mortgage Loan Agreement by increasing the Company's term loan facility by $7.5 million.
Effective February 27, 2018, the Company executed a Fifth Amendment to the Amended Revolver and a Third Amendment to the Amended Mortgage Loan. Under the terms of the Amendments, the minimum fixed charge coverage ratio shall not be less than 1.01 to 1.00 as of March 31, 2018 and for each quarter thereafter.
As of June 30, 2018, the Company had $15.0 million borrowings outstanding under the Amended Revolver compared to $16.0 outstanding as of December 31, 2017. The outstanding borrowings on the revolver primarily compensate for accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through the change in ownership process with CMS. Annual fees for letters of credit issued under the Amended Revolver are 3.00% of the amount outstanding. The Company has eleven letters of credit with a total value of $13.7 million outstanding as of June 30, 2018. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of $36.9 million, the balance available for borrowing under the Amended Revolver was $8.2 million at June 30, 2018.
Our lending agreements contain various financial covenants, the most restrictive of which relates to debt service coverage ratios. We are in compliance with all such covenants at June 30, 2018.

34


Our calculated compliance with financial covenants is presented below:
 
 
Requirement
  
Level at
June 30, 2018
Minimum fixed charge coverage ratio
1.01:1.00
 
1.09:1.00
Minimum adjusted EBITDA
$13.0 million
 
$19.2 million
EBITDAR (mortgaged centers)
$10.0 million
 
$17.2 million
Current ratio (as defined in agreement)
1.00:1.00
 
1.24:1.00
As part of the debt agreements entered into in February 2016, we amended our interest rate swap agreement with a member of the bank syndicate as the counterparty. The interest rate swap agreement has the same effective date and maturity date as the Amended Mortgage Loan, and carries an initial notional amount of $30.0 million. The interest rate swap agreement requires us to make fixed rate payments to the bank calculated on the applicable notional amount at an annual fixed rate of 5.79% while the bank is obligated to make payments to us based on LIBOR on the same notional amounts. We entered into the interest rate swap agreement to mitigate the variable interest rate risk on our outstanding mortgage borrowings.
Off-Balance Sheet Arrangements
We have eleven letters of credit outstanding with an aggregate value of approximately $13.7 million as of June 30, 2018. The letters of credit serve as a security deposits for certain center leases. These letters of credit were issued under our revolving credit facility. Our accounts receivable serve as the collateral for this revolving credit facility.

Forward-Looking Statements
The foregoing discussion and analysis provides information deemed by management to be relevant to an assessment and understanding of our consolidated results of operations and financial condition. This discussion and analysis should be read in conjunction with our interim consolidated financial statements included herein. Certain statements made by or on behalf of us, including those contained in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere, are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those contemplated by the forward-looking statements made herein. Forward-looking statements are predictive in nature and are frequently identified by the use of terms such as "may," "will," "should," "expect," "believe," "estimate," "intend," and similar words indicating possible future expectations, events or actions. In addition to any assumptions and other factors referred to specifically in connection with such statements, other factors, many of which are beyond our ability to control or predict, could cause our actual results to differ materially from the results expressed or implied in any forward-looking statements including, but not limited to:
•
our ability to successfully integrate the operations of our new nursing center in Alabama, as well as successfully operate all of our centers,
•
our ability to increase census at our centers and occupancy rates at our centers,
•
changes in governmental reimbursement,
•
government regulation,
•
the impact of the Affordable Care Act, efforts to repeal or significantly modify the Affordable Care Act, and other health care reform initiatives,
•
any increases in the cost of borrowing under our credit agreements,
•
our ability to comply with covenants contained in those credit agreements,
•
our ability to comply with the terms of our master lease agreements,
•
our ability to renew or extend our leases at or prior to the end of the existing lease terms,
•
the outcome of professional liability lawsuits and claims,
•
our ability to control ultimate professional liability costs,
•
the accuracy of our estimate of our anticipated professional liability expense,
•
the impact of future licensing surveys,
•
the outcome of proceedings alleging violations of state or Federal False Claims Acts,
•
laws and regulations governing quality of care or other laws and regulations applicable to our business including HIPAA and laws governing reimbursement from government payors,
•
the costs of investing in our business initiatives and development,
•
our ability to control costs,
•
our ability to attract and retain qualified healthcare professionals,
•
changes to our valuation of deferred tax assets,
•
changing economic and competitive conditions,
•
changes in anticipated revenue and cost growth,
•
changes in the anticipated results of operations,
•
the effect of changes in accounting policies as well as others. 
Investors also should refer to the risks identified in this “Management's Discussion and Analysis of Financial Condition and Results of Operations” as well as risks identified in “Part I. Item 1A. Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2017, for a discussion of various risk factors of the Company and that are inherent in the health care industry. Given these risks and uncertainties, we can give no assurances that these forward-looking statements will, in fact, transpire and, therefore, caution investors not to place undue reliance on them. These assumptions may not materialize to the extent assumed, and risks and uncertainties may cause actual results to be different from anticipated results. These risks and uncertainties also may result in changes to the Company’s business plans and prospects. Such cautionary statements identify important factors that could cause our actual results to materially differ from those projected in forward-looking statements. In addition, we disclaim any intent or obligation to update these forward-looking statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The chief market risk factor affecting our financial condition and operating results is interest rate risk. As of June 30, 2018, we had outstanding borrowings of approximately $87.8 million, $59.5 million of which was subject to variable interest rates. In connection with our February 2016 financing agreement, we entered into an interest rate swap with an initial notional amount of $30.0 million to mitigate the floating interest rate risk of a portion of such borrowing. In the event that interest rates were to change 1%, the impact on future pre-tax cash flows would be approximately $0.6 million annually, representing the impact of increased or decreased interest expense on variable rate debt.

ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
As required by Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended (the Exchange Act), our management, including our chief executive officer and chief financial officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e)) as of June 30, 2018. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act, such as this Quarterly Report on Form 10-Q, is properly recorded, processed, summarized and reported within the time periods required by the Securities and Exchange Commission’s rules and forms. Management necessarily applied its judgment in assessing the costs and benefits of such controls and procedures that, by their nature, can provide only reasonable assurance regarding management’s control objectives. Management does not expect that its disclosure controls and procedures will prevent all errors and fraud. A control system, irrespective of how well it is designed and operated, can only provide reasonable assurance, and cannot guarantee that it will succeed in its stated objectives.

35


Based on an evaluation of the effectiveness of the design and operation of disclosure controls and procedures, our chief executive officer and chief financial officer concluded that, as of June 30, 2018, our disclosure controls and procedures were effective in reaching a reasonable level of assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time period specified in the Securities and Exchange Commission’s rules and forms.
Changes in Internal Control Over Financial Reporting
We completed certain changes to our accounting processes related to our implementation of ASC 606, which was adopted on January 1, 2018. We updated our control activities for the adoption of the new accounting standard and the new accounting processes and methodologies established to evaluate contracts with our customers and determine the transaction price to allocate to our performance obligations with those customers as required in the five-step revenue recognition model in ASC 606.
Other than the items described above, there have been no changes in our internal control over financial reporting during the quarter ended June 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.
The provision of health care services entails an inherent risk of liability. Participants in the health care industry are subject to lawsuits alleging malpractice, negligence, violations of false claims acts, product liability, or related legal theories, many of which involve large claims and significant defense costs. Like many other companies engaged in the long-term care profession in the United States, we have numerous pending liability claims, disputes and legal actions for professional liability and other related issues. It is expected that we will continue to be subject to such suits as a result of the nature of our business. Further, as with all health care providers, we are periodically subject to regulatory actions seeking fines and penalties for alleged violations of health care laws and are potentially subject to the increased scrutiny of regulators for issues related to compliance with health care fraud and abuse laws and with respect to the quality of care provided to residents of our facilities. Like other health care providers, in the ordinary course of our business, we are also subject to claims made by employees and other disputes and litigation arising from the conduct of our business.
As of June 30, 2018, we are engaged in 79 professional liability lawsuits. Eleven lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The ultimate
results of any of our professional liability claims and disputes cannot be predicted. We have limited, and sometimes no, professional liability insurance with regard to most of these claims. A significant judgment entered against us in one or more of these legal actions could have a material adverse impact on our financial position and cash flows.
In July 2013, the Company learned that the United States Attorney for the Middle District of Tennessee ("DOJ") had commenced a civil investigation of potential violations of the False Claims Act ("FCA"). In October 2014, the Company learned that the investigation was started by the filing under seal of a false claims action against the two centers that were the subject of the original civil investigative demand ("CID"). In connection with this matter, between July 2013 and early February 2016, the Company received three civil investigative demands (a form of subpoena) for documents and information. The Company has responded to those demands and also provided voluntarily additional information requested by the DOJ. The DOJ has also taken testimony from current and former employees of the Company. In May 2018, the Company learned that a second FCA complaint had been filed in late 2016 relating to the Company’s practices and policies for rehabilitation therapy at some of its facilities. The government’s investigation relates to the Company’s practices and policies for rehabilitation and other services at all of its facilities, for preadmission evaluation forms ("PAEs") required by TennCare and for Pre-Admission Screening and Resident Reviews ("PASRRs") required by the Medicare program.
In June 2016, the Company received an authorized investigative demand (a form of subpoena) for documents in connection with a criminal investigation by the DOJ related to our practices with respect to PAEs and PASRRs, and the Company has provided documents responsive to this subpoena and continues to provide additional information as requested.
The Company cannot predict the outcome of these investigations or the related lawsuits under the False Claims Act,, and the outcome could have a materially adverse effect on the Company, including the imposition of treble damages, criminal charges, fines, penalties and/or a corporate integrity agreement. Additionally, the uncertainty regarding the outcome of these investigations makes it more difficult for the Company to pursue strategic possibilities, longer term initiatives or to make significant financial commitments outside of the normal course of its business. The Company is committed to provide caring and professional services to its patients and residents in compliance with applicable laws and regulations.
In January 2009, a purported class action complaint was filed in the Circuit Court of Garland County, Arkansas against the Company and certain of its subsidiaries and Garland Nursing & Rehabilitation Center (the “Center”). The Company answered the original complaint in 2009, and there was no other activity in the case until May 2017. At that time, plaintiff filed an amended complaint asserting new causes of action. The amended complaint alleges that the defendants breached their statutory and contractual obligations to the patients of the Center over a multi-year period by failing to meet minimum staffing requirements, failing to otherwise adequately staff the Center and failing to provide a clean and safe living environment in the Center. The Company has filed an answer to the amended complaint denying plaintiffs’ allegations and has asked the Court to dismiss the new causes of action asserted in the amended complaint because the Company was prejudiced by plaintiff’s long delay in filing the amended complaint. The Court has not yet ruled on the motion to dismiss, so the lawsuit remains in its early stages and has not yet be certified by the court as a class action. The Company intends to defend the lawsuit vigorously.
We cannot currently predict with certainty the ultimate impact of any of the above cases on our financial condition, cash flows or results of operations. Our reserve for professional liability expenses does not include any amounts for the pending DOJ investigation or the purported class action against the Arkansas center. An unfavorable outcome in any of these lawsuits, any of our professional liability actions, any regulatory action, or any investigation or lawsuit alleging violations of fraud and abuse laws or of elderly abuse laws or any state or Federal False Claims Act law could subject us to fines, penalties and damages, including exclusion from the Medicare or Medicaid programs, and could have a material adverse impact on our financial condition, cash flows or results of operations.
ITEM 1A. RISK FACTORS.
In addition to the other information contained in this Quarterly Report, the risks and uncertainties that we believe could materially affect our business, financial condition or future results and are most important for you to consider are discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March 1, 2018. Additional risks and uncertainties which are not presently known to us, which we currently deem immaterial or which are similar to those faced by other companies in our industry or business in general, may also materially and adversely affect any of our business, financial position or future results.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES.
None.
ITEM 4. MINE SAFETY DISCLOSURE.
Not applicable.
ITEM 5. OTHER INFORMATION.
None.

ITEM 6. EXHIBITS
The following exhibits are filed as part of this report on Form 10-Q.

36


 
 
 
Exhibit
Number
  
Description of Exhibits
3.1

  
Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement No. 33-76150 on Form S-1 filed in paper - hyperlink is not required pursuant to Rule 105 of Regulation S-T).
 
 

  
Certificate of Designation of Registrant (incorporated by reference to Exhibit 3.5 to the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2006).
 
 
3.3

  
Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement No. 33-76150 on Form S-1 filed in paper - hyperlink is not required pursuant to Rule 105 of Regulation S-T).
 
 

  
Bylaw Amendment adopted November 5, 2007 (incorporated by reference to Exhibit 3.4 to the Company’s annual report on Form 10-K for the year ended December 31, 2007).
 
 
3.5

  
Amendment to Certificate of Incorporation dated March 23, 1995 (incorporated by reference to Exhibit A of Exhibit 1 to the Company’s Form 8-A filed March 30, 1995 filed in paper - hyperlink is not required pursuant to Rule 105 of Regulation S-T).
 
 

  
Certificate of Designation of Registrant (incorporated by reference to Exhibit 3.4 to the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2001).
 
 

 
Certificate of Ownership and Merger of Diversicare Healthcare Services, Inc. with and into Advocat Inc. (incorporated by reference to Exhibit 3.1 to the Company's current report on Form 8-K filed March 14, 2013).
 
 
 

 
Amendment to Certificate of Incorporation dated June 9, 2016 (incorporated by reference to Exhibit 3.8 to the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2016).
 
 
 

 
Bylaw Second Amendment adopted April 14, 2016.
 
 
 
4.1

 
Form of Common Stock Certificate (incorporated by reference to Exhibit 4 to the Company's Registration Statement No. 33-76150 on Form S-1 filed in paper - hyperlink is not required pursuant to Rule 105 of Regulation S-T).
 
 
 

 
Kelly Gill Separation Agreement
 
 
 

  
Certification of Chief Executive and Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).
 
 

  
Certification of Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b).
 
 
101.INS

  
XBRL Instance Document
 
 
101.SCH

  
XBRL Taxonomy Extension Schema Document
 
 
101.CAL

  
XBRL Taxonomy Extension Calculation Linkbase Document
 
 
101.LAB

  
XBRL Taxonomy Extension Labels Linkbase Document
 
 
101.PRE

  
XBRL Taxonomy Extension Presentation Linkbase Document


37


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
 
 
 
Diversicare Healthcare Services, Inc.
 
 
 
August 2, 2018
 
 
 
 
 
 
 
By:
 
/s/ James R. McKnight, Jr.
 
 
 
James R. McKnight, Jr.
 
 
 
President and Chief Executive Officer, Principal Financial Officer and
 
 
 
An Officer Duly Authorized to Sign on Behalf of the Registrant
 
 
 

38
 EX-10.1 2 dvcr-ex101xkellygillsevera.htm EXHIBIT 10.1 Exhibit


SEPARATION AGREEMENT AND GENERAL RELEASE

This Separation Agreement and General Release (“Agreement”) is hereby entered into by and between Kelly Gill (“Executive”) and Diversicare Healthcare Services, Inc. (formerly known as Advocat Inc.), (hereinafter referred to as the “Company”) (collectively referred to hereinafter as “the Parties”).

WHEREAS, Executive and the Company entered into an Amended and Restated Employment Agreement effective as of April 1, 2012, as amended by Amendment No. 1 dated March 1, 2013 (“Employment Agreement” attached as Exhibit A);

WHEREAS, Executive and the Company have agreed that Executive shall resign from Executive’s position as Chief Executive Officer and Director of the Company and all positions Executive holds as an officer or director of any of the Company’s subsidiaries, effective July 6, 2018 (the “Resignation Date”); and

WHEREAS, the Company and Executive do not anticipate that there will be any disputes between them or legal claims arising out of Executive’s resignation from employment with the Company, but nevertheless, desire to ensure a completely amicable parting and to settle fully and finally any and all differences or claims that might arise out of Executive’s employment.

NOW, THEREFORE, it is hereby agreed that:

1.Payment Upon Resignation. On the next regularly scheduled pay day following the Resignation Date, the Company shall pay to Employee: (i) any earned or accrued, but unpaid Base Salary and vacation through the Resignation Date; and (ii) any unreimbursed business expenses accrued through the Resignation Date. The Company will deduct normal withholdings for federal and state income taxes and payroll taxes. Employee acknowledges that he is not owed any additional compensation, benefits, or payment by virtue of his employment, or termination of employment, except as provided pursuant to any benefit plans in which Employee has participated.

2.Separation Benefits. In exchange for the general release of claims and other good and valuable consideration, and only after the expiration of the seven day revocation period described in Section 13 below, the Company agrees to pay and provide to Executive the following:

The Company shall pay Executive in a lump sum an amount equivalent to twelve (12) months of Executive’s Base Salary, and an amount equal to $266,539.55 representing earned but unpaid 2018 incentive compensation, from which all proper taxes and withholdings will be taken, payable upon execution of this Agreement and expiration of the seven (7) day Revocation Period described below (“Salary Benefits”). The Company will also continue to provide group hospitalization, health, dental care and life insurance benefits that are in effect as of the Resignation Date as described in the Employment Agreement for a period of eighteen (18) months following the Resignation Date (collectively referred to with Salary Benefits as “Benefits”). Executive agrees that the Benefits are in addition to any compensation Executive has earned from the Company, and that Executive would not be entitled to the Benefits but for Executive’s execution of this Agreement.





In accordance with the 2010 Long-Term Incentive Plan and Section VIII(A) of the Employment Agreement, all unvested options (“Options”), SARs or restricted stock or restricted stock units granted to Executive under the Company’s 2005 Long-Term Incentive Plan, 2010 Long-Term Incentive Plan or other stock option program or plan (the “Plan”) shall be deemed vested, and the Company shall cause each Option, whether such Option vested prior to the Resignation Date or pursuant to this Agreement, to remain exercisable until October 6, 2018 and each SAR, whether such SAR vested prior to the Resignation Date or pursuant to this Agreement, to remain exercisable until January 15, 2019. Any restricted units that are held by the Executive on the Resignation Date shall become fully vested and settled in accordance with their terms. The outstanding Options, SARs, restricted stock and restricted stock units are detailed on the attached Exhibit B. As provided in Section VIII(E) of the Employment Agreement, Executive may require the Company to repurchase his vested Options and/or SARs for an amount equal to the difference between the fair market value of a share of the Company’s common stock on the Resignation Date and the per share exercise price set forth in the Option or SAR times the number of shares granted under the Option or SAR. The Company and Executive agree that Executive shall have until October 6, 2018 to give the Company written notice of his intent to exercise this right.

3.    General Release of Claims. (a) In consideration for the Company’s payment of the Benefits to the Executive as set forth in this Agreement, and for other good and valuable consideration, the Executive hereby releases and forever discharges the Company and each of its predecessors, assigns, former and current executives, representatives, partners, owners, parent companies, subsidiaries, affiliates, including any and all persons acting with any of them (collectively “Releasees”), from any and all causes of action, covenants, contracts, bonuses, agreements, claims, charges, complaints and demands whatsoever in law or equity, which the Executive (and the Executive’s heirs, executors, administrators, successors and/or assigns) may now have or hereafter may have had by reason of any matter, arising out of the Executive’s employment with the Company and the termination thereof, up to and including the date of this Agreement, except for the rights and obligations created by this Agreement.

(b) Without limiting the generality of the foregoing, this Agreement is intended to and shall release Releasees from any and all claims, whether known or unknown, which the Executive ever had or may have against any Releasee with respect to the Executive’s employment, the terms and conditions of that employment, and/or the termination thereof, including without limitation those arising under the Civil Rights Act of 1866, 42 U.S.C.A. Section 1981, the Civil Rights Act of 1964, as amended, 42 U.S.C.A. Section 2000e, et seq., the Age Discrimination in Employment Act of 1967, as amended, 29 U.S.C.A. Section 645 et seq., the National Labor Relations Act, 29 U.S.C.A. Section 151 et seq., the Fair Labor Standards Act, 29 U.S.C.A. Section 201 et seq., the Labor Management Reporting and Disclosure Act of 1959, as amended, 29 U.S.C.A. Section 401 et seq., the Americans with Disabilities Act, 42 U.S.C.A. Section 14501, et. seq., and the Genetic Information Nondiscrimination Act (GINA), all claims under the Family and Medical Leave Act (FMLA), and/or any other federal, state, or local human rights, civil rights, wage-hour, pension, or labor laws, rules and/or regulation, public policy, contract or tort law, including any and all claims for attorneys’ fees, costs, disbursements, or any action similar thereto.

THE EXECUTIVE SPECIFICALLY ACKNOWLEDGES AND AGREES THAT BY EXECUTING THIS AGREEMENT, HE IS WAIVING ALL RIGHTS OR CLAIMS, IF ANY, THAT HE HAS OR

2



MAY HAVE UNDER THE AGE DISCRIMINATION IN EMPLOYMENT ACT, AS AMENDED, WHICH PROHIBITS DISCRIMINATION ON THE BASIS OF AGE.

4.    Covenant not to Sue. Executive hereby covenants and agrees not to file, commence or initiate any suits, grievances, demands or causes of action against the Releasees based upon or relating to any of the claims released and forever discharged pursuant to this Agreement. In accordance with 29 C.F.R. § 1625.23(b), this covenant not to sue is not intended to preclude Executive from bringing a lawsuit to challenge the validity of the release language contained in this Agreement. If Executive breaches this covenant not to sue, he hereby agrees to pay all of the reasonable costs and attorneys’ fees actually incurred by the Releasees in defending against such claims, demands or causes of action, together with such and further damages as may result, directly or indirectly, from that breach. Moreover, Executive agrees that he will not persuade or instruct any person to file a suit, claim or complaint with any state or federal court or administrative agency against the Releasees. The Parties agree that this Agreement will not prevent Executive from filing a charge of discrimination with the Equal Employment Opportunity Commission (“EEOC”) or otherwise participating in an EEOC investigation, provided that if the EEOC or any third party obtains an award of damages from the Company on Executive’s behalf, Executive agrees to turn over any such amounts to the Company.

5.    No Admission of Wrongdoing or Liability. Nothing contained in this Agreement shall constitute, or be construed as or is intended to be an admission or an acknowledgment by the Releasees of any wrongdoing or liability, all such wrongdoing and liability being expressly denied.
 
6.    Confidentiality. Executive agrees to maintain absolute confidentiality and secrecy concerning the terms of this Agreement and will not reveal, or disseminate by publication in any manner whatsoever this document or any matters pertaining to it to any other person, including but not limited to any past or present executive, officer or director of the Company or any media representative except as required by legal process. This confidentiality provision does not apply to communications necessary between immediate family members or legal and financial planners or tax preparers who are also bound by this confidentiality provision.

7.     Cooperation. Executive acknowledges and warrants that Executive is not aware of, or that Executive has fully disclosed to the Company in writing, any matters for which Executive was responsible or which came to Executive’s attention as an employee of the Company that might give rise to, evidence or support any claim of illegal or improper conduct, regulatory violation, unlawful discrimination, retaliation or other cause of action against Company or any other Releasee. The Executive shall cooperate with the Company and assist the Company on litigation matters following the date hereof, at the expense of the Company.
8.    Non-Disparagement. Executive agrees that he will not make any statements, publicly or otherwise, orally or in writing, disparaging the character, reputation or standing of the Company. Executive acknowledges that no provision of this Agreement is intended to prevent Executive from making a truthful report in good faith to any governmental agency with oversight authority over the Company.

9.    Company Property. All records, files, lists, including computer generated lists, data, drawings, documents, equipment and similar items relating to the Company’s business that Executive

3



generated or received from the Company remains the Company’s sole and exclusive property. Executive agrees to promptly return to the Company all property of the Company in his possession. Executive further represents that he has not copied or caused to be copied, printed out, or caused to be printed out any documents or other material originating with or belonging to the Company. Executive additionally represents that he will not retain in his possession any such documents or other materials.

10.     Restrictive Covenants. Executive acknowledges that he entered into restrictive covenants with the Company in Section IX of the Employment Agreement, and that in accordance with the terms of the Employment Agreement, he is subject to those obligations as they remain in full force and effect following separation of his employment with the Company according to their terms.

11.    Breach of Agreement. If either party brings a claim for breach of the terms of this Agreement, the prevailing party shall be entitled to its reasonable attorneys’ fees and expenses incurred in the prosecuting or defending such an action. This Agreement is to be governed by the laws of the State of Tennessee. The Parties agree that venue and jurisdiction for any legal action arising out of or in connection with this Agreement shall be exclusively with courts of the State of Tennessee located in Davidson County, Tennessee or the United States District Court for the Middle District of Tennessee.

12.    Binding Effect. This Agreement shall be binding upon and inure to the benefit of Executive and the Company, and their officers, directors, executives, agents, legal counsel, heirs, successors and assigns.

13.    Warranties/Representations. Executive hereby warrants and represents that:

A.
He has carefully read and fully understands the comprehensive terms and conditions of this Agreement and the releases set forth herein;

B.
He is executing this Agreement knowingly and voluntarily, without any duress, coercion or undue influence by the Company, its representatives, or any other person;

C.
He has been informed of his right to consult with legal counsel of his own choice before executing this Agreement;

D.
He has pending no claim, complaint, grievance or any document with any federal or state agency or any court seeking money damages or relief against the Company;

E.
The Benefits recited above constitute good and valuable consideration;

F.
He is fully satisfied with the terms and conditions of this Agreement including, without limitation, the consideration paid to him by the Company;

G.
He is not waiving rights or claims that may arise after the date this Agreement is executed;


4



H.
Except as specifically provided herein, he has been paid all compensation owed to him by the Company;

I.
He has had the right to consider the terms of this Agreement for a full 21 days and he hereby waives any and all rights to any further review period; and

J.
He has the right to revoke this Agreement within seven (7) calendar days after signing it (the “Revocation Period”) by providing during this seven (7) day period written notice of revocation to Board of Directors, Diversicare Healthcare Services, Inc., 1621 Galleria Blvd., Brentwood, TN 37027. If he revokes this Agreement during the seven-day period, the Agreement and all obligations hereunder become null and void in their entirety.

14.    Entire Agreement; Severability of Terms; Attorneys Fees; Consulting. This Agreement contains the entire understanding of the Parties as to the subject matter hereof and supersedes all prior and contemporaneous oral and written agreements and discussions with respect to the subject matter hereof, with the exception of the provisions of Section VIII F., IX, and X of the Employment Agreement, which remain in full-force and effect. In executing this Agreement, neither party relies on any term, condition, promise, or representation other than those expressed in this Agreement, including Exhibits A & B to this Agreement. This Agreement may be amended or modified only by an agreement in writing, signed by both Parties. If any provision of this Agreement is determined to be invalid or otherwise unenforceable, then that invalidity or unenforceability will not affect any other provision of this Agreement, which will continue and remain in full force and effect. The Company shall reimburse Executive for his reasonable attorneys’ fees and costs incurred in connection with this Agreement. The Executive will provide general operational and relationship consulting services to the Company as an independent contractor for a period of three (3) months following the date hereof, in exchange for payment of $10,000.00 per month. The Company may extend the consulting period for up to three (3) additional months on a month-to-month basis for the same monthly consideration.

15.    Compliance with the Older Worker Benefit Protection Act. Executive warrants and represents that he has been given the opportunity to review this Agreement with legal counsel and that he has had fair and full opportunity to consider its terms and enters into this Agreement willingly and knowingly and knows he has the right to review this Agreement for 21 days and to revoke it within seven (7) days after signing it. Executive has the right to sign this Agreement sooner than 21 days, and if he chooses to do so, he understands he is waiving his right to the full 21-day period.

16.    Counterparts; Electronic Signatures.  This Agreement may be executed by facsimile and/or electronic signature in two or more counterparts, each of which shall be deemed an original, but all of which when taken together shall constitute one and the same instrument.  Facsimile and electronic signatures shall, for all purposes, be treated as originals.


5



[Signatures follow on next page.]

Dated: July 10, 2018             _/s/ Kelly Gill_______________________
KELLY GILL


Dated: July 10, 2018
DIVERSICARE HEALTHCARE SERVICES, INC.

By: _/s/ James R. McKnight, Jr._________
JAMES R. MCKNIGHT, JR., CHIEF EXECUTIVE OFFICER                 


6



EXHIBIT A
Employment Agreement

See the Company's 2017 Form 10-K exhibit 10.28 for Kelly Gill's employment agreement and exhibit 10.31 for Mr. Gill's amended employment agreement.




EXHIBIT B
Outstanding Options, Restricted Stock and Restricted Stock Units

1.
Options/SARs                    Exercise Price

a.
50,000            $5.60
b.
35,000            $6.21
c.
15,000            $5.45

2.
Restricted Stock                                               Unvested, which will vest upon resignation

a.
25,000 granted 3/11/16                   8,333
b.
25,000 granted 3/13/17                          16,667
c.
25,000 granted 3/13/18                 25,000

3.
Restricted stock Units – Will vest upon resignation
 
a.
10,719     purchased 3/13/17        paid $90,900       or $8.48/share
b.
2,977.46 purchased 3/13/18        paid $20,604       or $6.92/share

4.
Accrued dividends (as of 6/30/18)
a.
386.53 on 2018 restricted stock
b.
623.55 on 2017 restricted stock
c.
521.21 on 2016 restricted stock
d.
401.32 on 2017 RSUs
e.
46.04 on 2018 RSUs





25060768.1


 EX-31.1 3 dvcr-ex311x63018certificat.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
CERTIFICATIONS PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
(i) CERTIFICATION
I, James R. McKnight, Jr., certify that:
1. I have reviewed this quarterly report on Form 10-Q of Diversicare Healthcare Services, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: August 2, 2018
 
 
/s/ James R. McKnight, Jr.
James R. McKnight, Jr.
President and Chief Executive Officer, Principal Financial Officer and
An Officer Duly Authorized to SIgn on Behalf of the Registrant



 EX-32 4 dvcr-ex32x63018certificati.htm EXHIBIT 32 Exhibit


Exhibit 32
CERTIFICATION OF QUARTERLY REPORT ON FORM 10-Q
OF DIVERSICARE HEALTHCARE SERVICES, INC.
FOR THE QUARTER ENDED JUNE 30, 2017
The undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the undersigned’s best knowledge and belief, the Quarterly Report on Form 10-Q for Diversicare Healthcare Services, Inc. (the “Company”) for the period ending June 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”):
(a)
fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(b)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
This Certification is executed as of August 2, 2018.

 
 
/s/ James R. McKnight, Jr.
James R. McKnight, Jr.
President and Chief Executive Officer, Principal Financial Officer and
An Officer Duly Authorized to SIgn on Behalf of the Registrant
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.



 EX-101.INS 5 avca-20180630.xml XBRL INSTANCE DOCUMENT 0000919956 2018-01-01 2018-06-30 0000919956 2018-07-30 0000919956 2018-06-30 0000919956 2017-12-31 0000919956 2018-04-01 2018-06-30 0000919956 2017-04-01 2017-06-30 0000919956 2017-01-01 2017-06-30 0000919956 2017-06-30 0000919956 2016-12-31 0000919956 srt:MaximumMember 2018-06-30 0000919956 srt:MinimumMember 2018-06-30 0000919956 avca:UnnamedPharmacyJointVentureMember 2016-10-01 2016-12-31 0000919956 2016-10-01 2016-12-31 0000919956 avca:UnnamedPharmacyJointVentureMember 2017-01-01 2017-06-30 0000919956 avca:UnnamedPharmacyJointVentureMember 2018-01-01 2018-06-30 0000919956 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-06-30 0000919956 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-06-30 0000919956 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-06-30 0000919956 avca:PrivatePayAndOtherMember 2018-01-01 2018-06-30 0000919956 avca:PrivatePayAndOtherMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2017-01-01 2017-06-30 0000919956 avca:MedicareMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-06-30 0000919956 avca:MedicareMember 2018-01-01 2018-06-30 0000919956 avca:ManagedCareMember 2018-01-01 2018-06-30 0000919956 avca:ManagedCareMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-06-30 0000919956 avca:MedicaidMember 2018-01-01 2018-06-30 0000919956 avca:MedicaidMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2017-01-01 2017-06-30 0000919956 avca:MedicareMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2017-01-01 2017-06-30 0000919956 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2017-01-01 2017-06-30 0000919956 avca:MedicaidMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-06-30 0000919956 avca:PrivatePayAndOtherMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-06-30 0000919956 avca:ManagedCareMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2017-01-01 2017-06-30 0000919956 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-04-01 2018-06-30 0000919956 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-04-01 2018-06-30 0000919956 us-gaap:AccountingStandardsUpdate201409Member avca:DifferenceBetweenRevenueGuidanceInEffectbeforeAndAfterTopic606AdjustmentForImplementationMember 2018-06-30 0000919956 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2017-04-01 2017-06-30 0000919956 avca:PrivatePayAndOtherMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-04-01 2018-06-30 0000919956 avca:MedicareMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-04-01 2018-06-30 0000919956 avca:MedicaidMember 2018-04-01 2018-06-30 0000919956 avca:MedicaidMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-04-01 2018-06-30 0000919956 avca:PrivatePayAndOtherMember 2018-04-01 2018-06-30 0000919956 avca:MedicaidMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2017-04-01 2017-06-30 0000919956 avca:MedicareMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2017-04-01 2017-06-30 0000919956 avca:MedicareMember 2018-04-01 2018-06-30 0000919956 avca:ManagedCareMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-04-01 2018-06-30 0000919956 avca:ManagedCareMember 2018-04-01 2018-06-30 0000919956 avca:ManagedCareMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2017-04-01 2017-06-30 0000919956 avca:PrivatePayAndOtherMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2017-04-01 2017-06-30 0000919956 us-gaap:AccountingStandardsUpdate201409Member avca:DifferenceBetweenRevenueGuidanceInEffectbeforeAndAfterTopic606AdjustmentForImplicitPriceConcessionOfBadDebtExpenseMember 2018-01-01 2018-06-30 0000919956 us-gaap:AccountingStandardsUpdate201409Member avca:DifferenceBetweenRevenueGuidanceInEffectbeforeAndAfterTopic606AdjustmentForImplicitPriceConcessionOfBadDebtExpenseMember 2018-04-01 2018-06-30 0000919956 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-06-30 0000919956 us-gaap:AccountingStandardsUpdate201409Member avca:DifferenceBetweenRevenueGuidanceInEffectbeforeAndAfterTopic606TaxAdjustmentMember 2018-06-30 0000919956 us-gaap:AccountingStandardsUpdate201409Member avca:DifferenceBetweenRevenueGuidanceInEffectbeforeAndAfterTopic606AllowanceForDoubtfulAccountsMember 2018-06-30 0000919956 us-gaap:AccountingStandardsUpdate201409Member avca:DifferenceBetweenRevenueGuidanceInEffectbeforeAndAfterTopic606AdjustmentForImplementationMember 2018-04-01 2018-06-30 0000919956 us-gaap:AccountingStandardsUpdate201409Member avca:DifferenceBetweenRevenueGuidanceInEffectbeforeAndAfterTopic606AdjustmentForImplementationMember 2018-01-01 2018-06-30 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember 2018-06-30 0000919956 us-gaap:InterestRateSwapMember 2018-06-30 0000919956 avca:AmendedandRestatedCreditAgreementMember 2018-06-30 0000919956 avca:SelmaNursingCentersMember us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember avca:MortgageTermLoanMember 2017-06-30 0000919956 us-gaap:LetterOfCreditMember avca:AmendedandRestatedCreditAgreementMember 2016-12-29 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember us-gaap:InterestRateSwapMember 2016-02-26 0000919956 us-gaap:LetterOfCreditMember avca:AmendedandRestatedCreditAgreementMember 2016-12-28 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember 2018-06-30 0000919956 us-gaap:LineOfCreditMember avca:AmendedandRestatedCreditAgreementMember 2016-02-26 2016-02-26 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember 2016-02-26 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember avca:OmegaHealthcareInvestorsIncMember 2018-06-30 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember 2016-02-26 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember avca:MortgageRevolvingCreditFacilityMember 2016-02-26 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember avca:MortgageTermLoanMember us-gaap:LondonInterbankOfferedRateLIBORMember 2016-02-26 2016-02-26 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2016-02-26 2016-02-26 0000919956 us-gaap:LineOfCreditMember avca:AmendedandRestatedCreditAgreementMember 2016-02-26 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember 2017-06-30 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember 2017-12-31 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember 2016-02-26 2016-02-26 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember avca:MortgageTermLoanMember 2016-02-26 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember 2018-01-01 2018-03-31 0000919956 avca:AmendedandRestatedCreditAgreementMember 2016-02-26 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember avca:MortgageTermLoanMember 2018-06-30 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember 2016-10-03 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember avca:MortgageRevolvingCreditFacilityMember 2018-06-30 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember avca:MortgageRevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2016-02-26 2016-02-26 0000919956 us-gaap:LetterOfCreditMember avca:AmendedandRestatedCreditAgreementMember 2016-02-26 2016-02-26 0000919956 us-gaap:RevolvingCreditFacilityMember avca:AmendedandRestatedCreditAgreementMember 2017-08-01 0000919956 us-gaap:MortgagesMember avca:AmendedandRestatedCreditAgreementMember avca:MortgageTermLoanMember 2016-02-26 0000919956 avca:PotentialViolationsofFalseClaimsActMember us-gaap:UnfavorableRegulatoryActionMember 2013-07-01 2016-02-29 0000919956 avca:SHCRiskCarriersIncMember us-gaap:ProfessionalMalpracticeLiabilityMember 2018-01-01 2018-06-30 0000919956 us-gaap:ProfessionalMalpracticeLiabilityMember 2018-06-30 0000919956 avca:PrefundedDeductiblePolicyMember 2018-06-30 0000919956 avca:TrialOrArbitrationScheduleTimeframeMember 2018-06-30 0000919956 avca:PotentialViolationsofFalseClaimsActMember us-gaap:UnfavorableRegulatoryActionMember 2014-10-31 0000919956 avca:PrefundedDeductiblePolicyMember 2018-01-01 2018-06-30 0000919956 avca:TwoThousandAndEightStockPurchasePlanMember 2016-05-31 0000919956 avca:TwoThousandAndEightStockPurchasePlanMember 2018-01-01 2018-06-30 0000919956 avca:TwoThousandAndTenLongTermIncentivePlanMember 2017-05-31 0000919956 avca:TwoThousandAndEightStockPurchasePlanMember 2016-06-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember 2018-01-01 2018-06-30 0000919956 us-gaap:RestrictedStockMember 2018-01-01 2018-06-30 0000919956 us-gaap:RestrictedStockMember 2017-01-01 2017-06-30 0000919956 avca:TwoThousandAndTenLongTermIncentivePlanMember 2017-06-30 0000919956 us-gaap:EmployeeStockMember 2018-01-01 2018-06-30 0000919956 us-gaap:EmployeeStockMember 2018-06-30 0000919956 us-gaap:EmployeeStockMember 2017-12-31 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember 2018-06-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember 2017-12-31 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember avca:StockOptionsExercisePriceRangeOneMember 2018-06-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember avca:StockOptionsExercisePriceRangeTwoMember 2018-06-30 0000919956 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-06-30 0000919956 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0000919956 us-gaap:RestrictedStockUnitsRSUMember 2018-06-30 0000919956 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2018-01-01 2018-06-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2018-01-01 2018-06-30 0000919956 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2018-01-01 2018-06-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2018-01-01 2018-06-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2018-01-01 2018-06-30 0000919956 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2018-01-01 2018-06-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember avca:StockOptionsExercisePriceRangeOneMember 2018-01-01 2018-06-30 0000919956 avca:StockOptionsAndStockAppreciationRightsSarsMember avca:StockOptionsExercisePriceRangeTwoMember 2018-01-01 2018-06-30 0000919956 avca:SelmaNursingCentersMember 2017-07-01 0000919956 avca:SelmaNursingCentersMember 2017-07-01 2017-07-01 0000919956 avca:TrendHealthandRehabofCarthageLLCTrendHealthMember 2017-01-01 2017-12-31 0000919956 2018-01-01 2018-03-31 0000919956 avca:SelmaNursingCentersMember 2017-12-31 0000919956 avca:SelmaNursingCentersMember 2017-01-01 2017-12-31 0000919956 us-gaap:ChiefExecutiveOfficerMember 2018-04-01 2018-06-30 iso4217:USD avca:state avca:lawsuit avca:facility avca:civil_investigative_demand xbrli:pure avca:center iso4217:USD xbrli:shares avca:bed avca:letter_of_credit xbrli:shares avca:investment 6691000 6499000 145000 18 1.01 600000 0 200000 0.03 P25Y 7500000 2 3000000 1000000 4338000 2775000 -194000 8456 103 76 58 18 79 11 1 11 497 320 48 3 -94000 -78000 304000 916000 0.070 0.516 0.273 0.141 1 0.073 0.515 0.271 0.141 1 1 0.094 0.082 0.465 0.520 0.197 0.250 0.244 0.148 1 1 0.097 0.083 0.459 0.514 0.204 0.257 0.240 0.146 1 0 206000 6.41 10.81 0 206000 211000 226000 6.64 6.56 9.32 5.56 9.59 9.95 9.28 8.81 206000 15000 0.00 8.14 206000 40000 166000 226000 60000 166000 0 7.14 7.15 30000 P2Y 1030000 false --12-31 Q2 2018 2018-06-30 10-Q 0000919956 6536158 Smaller Reporting Company Diversicare Healthcare Services, Inc. 28135000 30000000 14080000 14969000 63591000 -618000 16050000 15432000 79023000 64929000 63591000 78345000 81184000 709000 1013000 412000 22720000 23249000 504000 259000 765000 14235000 46000 226000 167569000 168189000 72658000 73848000 25707000 40040000 45000 20000 140000 925000 925000 8750000 9675000 8435000 335000 760000 7000 0 4263000 3900000 3524000 3811000 -363000 287000 0 0 0 0 -329000 -632000 680000 380000 0.055 0.11 0.055 0.110 0.01 0.01 20000000 20000000 6687000 6768000 6455000 6536000 67000 68000 383000 1853000 -215000 -110000 113166000 223833000 111440000 3789000 115229000 223718000 7252000 230970000 140494000 279034000 140489000 3789000 144278000 280275000 7252000 287527000 0.0475 0.04 0.04 0.068 0.0600 0.0579 P5Y P5Y 137000 114000 2162000 15154000 15052000 403000 -34000 2620000 5107000 2847000 5728000 606000 18000 27000 0 11000 0 13269000 0.06 0.27 -0.05 -0.06 0.06 0.26 -0.05 -0.06 20013000 20059000 1366000 0 733000 733000 308000 308000 308000 3080000 8221000 17194000 9295000 17434000 381000 1729000 -307000 -388000 515000 2725000 -732000 -851000 0.06 0.28 -0.05 -0.06 0.06 0.27 -0.05 -0.06 -28000 -43000 -4000 -26000 0.00 -0.01 0.00 0.00 0.00 -0.01 0.00 134000 996000 -425000 -463000 625000 321000 537000 1298000 -2647000 2072000 -620000 2651000 7313000 -342000 -309000 1722000 1541000 3024000 1661000 3330000 2563000 2920000 13714000 167569000 168189000 64267000 64577000 96840000 97455000 461000 461000 1615000 8177000 52250000 36891000 100000000 72500000 12500000 60000000 27500000 10000000 15000000 52250000 42250000 72630000 9000000 63630000 16000000 15000000 74603000 74236000 13065000 12760000 0.0579 3 5000000 500000 500000 24229000 2724000 5394000 3182000 5957000 10569000 -2108000 10569000 -2108000 -12694000 -3588000 -12694000 -3588000 1762000 5983000 2091000 6615000 353000 1686000 -311000 -414000 353000 1686000 -311000 -414000 -1541000 -2291000 -1325000 -2943000 10 2056000 5016000 593000 2092000 13763000 27506000 250000 13725000 27438000 3725000 5106000 30000 167000 96000 304000 116000 233000 38000 151000 146000 400000 134000 455000 7856000 7284000 8779000 5826000 -247000 -283000 0 0 28000 79000 692000 702000 226000 137000 327000 337000 8673000 0 5121000 3896000 3248000 3672000 26074000 8203000 1100000 308000 147549000 135485000 69204000 54301000 4187000 0 375000 1456000 14166000 9057000 -14534000 -15673000 618000 -198000 420000 -15253000 142550000 284050000 141082000 -362000 3789000 3427000 144509000 282367000 -618000 7252000 6634000 289001000 9959000 73510000 38900000 20181000 142550000 20764000 146383000 76911000 39992000 284050000 141082000 13303000 11888000 65603000 75216000 27863000 36079000 34313000 21326000 144509000 282367000 27515000 23980000 129489000 148431000 57614000 74217000 67749000 42373000 289001000 8792000 9044000 13458000 17393000 1172000 504000 765000 7000 9.62 88000 16000 90000 90000 8.14 8.14 44000 164000 44000 171000 1000 3000 17000 79000 8.91 10.27 350000 150000 8.14 2.37 10.80 6.21 0.33 0.33 0.33 0.33 0.33 0.33 P10Y 0.85 6462000 6157000 232000 232000 2500000 2500000 6472000 6458000 6370000 6342000 6294000 6263000 6370000 6342000 593000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">LONG-TERM DEBT AND INTEREST RATE SWAP</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has agreements with a syndicate of banks for a mortgage term loan ("Original Mortgage Loan") and the Company&#8217;s revolving credit agreement ("Original Revolver"). On February 26, 2016, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated April 30, 2013. The Credit Agreement increased the Company's borrowing capacity to </font><font style="font-family:inherit;font-size:10pt;">$100,000</font><font style="font-family:inherit;font-size:10pt;"> allocated between a </font><font style="font-family:inherit;font-size:10pt;">$72,500</font><font style="font-family:inherit;font-size:10pt;"> Mortgage Loan ("Amended Mortgage Loan") and a </font><font style="font-family:inherit;font-size:10pt;">$27,500</font><font style="font-family:inherit;font-size:10pt;"> Revolver ("Amended Revolver"). The Amended Mortgage Loan consists of a </font><font style="font-family:inherit;font-size:10pt;">$60,000</font><font style="font-family:inherit;font-size:10pt;"> term loan facility and a </font><font style="font-family:inherit;font-size:10pt;">$12,500</font><font style="font-family:inherit;font-size:10pt;"> acquisition loan facility. Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of </font><font style="font-family:inherit;font-size:10pt;">$2,162</font><font style="font-family:inherit;font-size:10pt;"> and are being amortized over the </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year term of the agreements. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original principal balance of </font><font style="font-family:inherit;font-size:10pt;">$72,500</font><font style="font-family:inherit;font-size:10pt;"> with a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year maturity through February 26, 2021, and a </font><font style="font-family:inherit;font-size:10pt;">$27,500</font><font style="font-family:inherit;font-size:10pt;"> Amended Revolver through February 26, 2021. The Amended Mortgage Loan has a term of </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years, with principal and interest payable monthly based on a </font><font style="font-family:inherit;font-size:10pt;">25</font><font style="font-family:inherit;font-size:10pt;">-year amortization. Interest on the term and acquisition loan facilities is based on LIBOR plus </font><font style="font-family:inherit;font-size:10pt;">4.0%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">4.75%</font><font style="font-family:inherit;font-size:10pt;">, respectively. A portion of the Amended Mortgage Loan is effectively fixed at </font><font style="font-family:inherit;font-size:10pt;">5.79%</font><font style="font-family:inherit;font-size:10pt;"> pursuant to an interest rate swap with an initial notional amount of </font><font style="font-family:inherit;font-size:10pt;">$30,000</font><font style="font-family:inherit;font-size:10pt;">. The Amended Mortgage Loan balance was </font><font style="font-family:inherit;font-size:10pt;">$72,630</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, consisting of </font><font style="font-family:inherit;font-size:10pt;">$63,630</font><font style="font-family:inherit;font-size:10pt;"> on the term loan facility with an interest rate of </font><font style="font-family:inherit;font-size:10pt;">6.00%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$9,000</font><font style="font-family:inherit;font-size:10pt;"> on the acquisition loan facility with an interest rate of </font><font style="font-family:inherit;font-size:10pt;">6.8%</font><font style="font-family:inherit;font-size:10pt;">. The Amended Mortgage Loan is secured by </font><font style="font-family:inherit;font-size:10pt;">eighteen</font><font style="font-family:inherit;font-size:10pt;"> owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized and cross-defaulted. The Company&#8217;s Amended Revolver has an interest rate of LIBOR plus </font><font style="font-family:inherit;font-size:10pt;">4.0%</font><font style="font-family:inherit;font-size:10pt;"> and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective October 3, 2016, the Company entered into the Second Amendment ("Second Revolver Amendment") to amend the Amended Revolver. The Second Revolver Amendment increased the Amended Revolver capacity from the&#160;</font><font style="font-family:inherit;font-size:10pt;">$27,500</font><font style="font-family:inherit;font-size:10pt;">&#160;in the Amended Revolver to&#160;</font><font style="font-family:inherit;font-size:10pt;">$52,250</font><font style="font-family:inherit;font-size:10pt;">; provided that the maximum revolving facility be reduced to </font><font style="font-family:inherit;font-size:10pt;">$42,250</font><font style="font-family:inherit;font-size:10pt;"> on August 1, 2017. Subsequently, on June 30, 2017, the Company executed a Fourth Amendment (the "Fourth Revolver Amendment") to amend the Amended Revolver, which modifies the capacity of the revolver to remain at </font><font style="font-family:inherit;font-size:10pt;">$52,250</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 29, 2016, the Company executed a Third Amendment ("Third Revolver Amendment") to amend the Amended Revolver. The Third Amendment modified the terms of the Amended Mortgage Loan Agreement by increasing the Company&#8217;s letter of credit sublimit from&#160;</font><font style="font-family:inherit;font-size:10pt;">$10,000</font><font style="font-family:inherit;font-size:10pt;">&#160;to&#160;</font><font style="font-family:inherit;font-size:10pt;">$15,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective June 30, 2017, the Company entered into a Second Amendment ("Second Term Amendment") to amend the Amended Mortgage Loan. The Second Term Amendment amended the terms of the Amended Mortgage Loan Agreement by increasing the Company's term loan facility by </font><font style="font-family:inherit;font-size:10pt;">$7,500</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective February 27, 2018, the Company executed a Fifth Amendment to the Amended Revolver and a Third Amendment to the Amended Mortgage Loan. Under the terms of the Amendments, the minimum fixed charge coverage ratio shall not be less than </font><font style="font-family:inherit;font-size:10pt;">1.01</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">1.00</font><font style="font-family:inherit;font-size:10pt;"> as of March 31, 2018 and for each quarter thereafter. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">$15,000</font><font style="font-family:inherit;font-size:10pt;"> borrowings outstanding under the Amended Revolver compared to </font><font style="font-family:inherit;font-size:10pt;">$16,000</font><font style="font-family:inherit;font-size:10pt;"> outstanding as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. The outstanding borrowings on the revolver were used primarily to compensate for accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through the change in ownership process with Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;). Annual fees for letters of credit issued under the Amended Revolver are </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;"> of the amount outstanding. The Company has </font><font style="font-family:inherit;font-size:10pt;">eleven</font><font style="font-family:inherit;font-size:10pt;"> letters of credit with a total value of </font><font style="font-family:inherit;font-size:10pt;">$13,714</font><font style="font-family:inherit;font-size:10pt;"> outstanding as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of </font><font style="font-family:inherit;font-size:10pt;">$36,891</font><font style="font-family:inherit;font-size:10pt;"> the balance available for borrowing under the Amended Revolver was </font><font style="font-family:inherit;font-size:10pt;">$8,177</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s debt agreements contain various financial covenants, the most restrictive of which relates to debt service coverage ratios. The Company is in compliance with all such covenants at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Rate Swap Transaction</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the debt agreements entered into in April 2013, the Company entered into an interest rate swap agreement with a member of the bank syndicate as the counterparty. The Company designated its interest rate swap as a cash flow hedge and the earnings component of the hedge, net of taxes, is reflected as a component of other comprehensive income (loss). In conjunction with the February 26, 2016 amendment to the Credit Agreement, the Company amended the terms of its interest rate swap. The interest rate swap agreement has the same effective date and maturity date as the Amended Mortgage Loan, and has an amortizing notional amount that was </font><font style="font-family:inherit;font-size:10pt;">$28,135</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. The interest rate swap agreement requires the Company to make fixed rate payments to the bank calculated on the applicable notional amount at an annual fixed rate of </font><font style="font-family:inherit;font-size:10pt;">5.79%</font><font style="font-family:inherit;font-size:10pt;"> while the bank is obligated to make payments to the Company based on LIBOR on the same notional amount. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company assesses the effectiveness of its interest rate swap on a quarterly basis, and at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company determined that the interest rate swap was highly effective. The interest rate swap valuation model indicated a net asset of </font><font style="font-family:inherit;font-size:10pt;">$606</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. The fair value of the interest rate swap is included in &#8220;other noncurrent assets&#8221; on the Company&#8217;s interim consolidated balance sheet. The asset related to the change in the interest rate swap included in accumulated other comprehensive income at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> is </font><font style="font-family:inherit;font-size:10pt;">$412</font><font style="font-family:inherit;font-size:10pt;"> net of the income tax provision of </font><font style="font-family:inherit;font-size:10pt;">$194</font><font style="font-family:inherit;font-size:10pt;">. As the Company&#8217;s interest rate swap is not traded on a market exchange, the fair value is determined using a valuation based on a discounted cash flow analysis. This analysis reflects the contractual terms of the interest rate swap agreement and uses observable market-based inputs, including estimated future LIBOR interest rates. The interest rate swap valuation is classified in Level 2 of the fair value hierarchy, in accordance with the FASB guidance set forth in ASC 820, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interim consolidated financial statements for the three and six month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company&#8217;s financial position at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, and the results of operations for the three and </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, and cash flows for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">. The Company&#8217;s balance sheet information at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, was derived from its audited consolidated financial statements as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective January 1, 2018, we adopted the requirements of Accounting Standards Update ("ASU") No. 2014-09,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">Revenue from Contracts with Customers (Topic 606), as discussed in Notes 3 and 4 to the interim consolidated financial statements. All amounts and disclosures set forth in this Form 10-Q have been updated to comply with the new standard.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for the periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2017 Acquisition</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended December 31, 2017, the Company expanded its operations to acquire a center that complements its current portfolio. On June 8, 2017, the Company entered into an Asset Purchase Agreement (the "Purchase Agreement") with Park Place Nursing and Rehabilitation Center, LLC, Dunn Nursing Home, Inc., Wood Properties of Selma LLC, and Homewood of Selma, LLC to acquire a </font><font style="font-family:inherit;font-size:10pt;">103</font><font style="font-family:inherit;font-size:10pt;">-bed skilled nursing center in Selma, Alabama, for an aggregate purchase price of </font><font style="font-family:inherit;font-size:10pt;">$8,750</font><font style="font-family:inherit;font-size:10pt;">. In connection with the funding of the acquisition, on June 30, 2017, the Company amended the terms of its Second Amended and Restated Term Loan Agreement to increase the facility by </font><font style="font-family:inherit;font-size:10pt;">$7,500</font><font style="font-family:inherit;font-size:10pt;">, which is described in Note 5 to the interim consolidated financial statements herein. The acquisition transaction closed on July 1, 2017. In accordance with ASC 805, this transaction was accounted for as a business combination, which resulted in the expensing of $</font><font style="font-family:inherit;font-size:10pt;">140</font><font style="font-family:inherit;font-size:10pt;"> of acquisition costs and a $</font><font style="font-family:inherit;font-size:10pt;">925</font><font style="font-family:inherit;font-size:10pt;"> recorded gain on bargain purchase for the Company for the year ended December 31, 2017. The operating results of the acquired center have been included in the Company's consolidated statement of operations since the acquisition date. Supplemental pro forma information regarding the acquisition is not material to the consolidated financial statements. The allocation of the purchase price to the net assets acquired is as follows:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:53.125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Park Place</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase Price</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on bargain purchase</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">925</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,675</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allocation:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Building</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,435</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">760</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land Improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture, Fixtures and Equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">335</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,675</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2018 Assets Held for Sale</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the first quarter of 2018, </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> of the Company's skilled nursing facilities met the accounting criteria to be classified as held for sale, but did not meet the accounting criteria to be reported as discontinued operations. The Company is selling the property and equipment affiliated with these centers. The recorded values of these centers' assets are $</font><font style="font-family:inherit;font-size:10pt;">13,269</font><font style="font-family:inherit;font-size:10pt;">. The centers' assets are classified as held for sale in the accompanying interim consolidated balance sheets. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2017 Lease Termination</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 30, 2017, the Company entered into an Agreement with Trend Health and Rehab of Carthage, LLC ("Trend Health") to terminate the lease and the Company's right of possession of the center in Carthage, Mississippi. In consideration of the early termination of the lease, Trend Health provided the Company with a </font><font style="font-family:inherit;font-size:10pt;">$250</font><font style="font-family:inherit;font-size:10pt;"> cash termination payment which is included in lease termination receipts in the accompanying interim consolidated statements of operations for the year ended December&#160;31, 2017. For accounting purposes, this transaction was not reported as a discontinued operation as this disposal did not represent a strategic shift that has (or will have) a major effect on the Company's operations and financial results.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2016 Sale of Investment in Unconsolidated Affiliate</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 28, 2016, the Company and its partners entered into an asset purchase agreement to sell the pharmacy joint venture. The sale resulted in a&#160;</font><font style="font-family:inherit;font-size:10pt;">$1,366</font><font style="font-family:inherit;font-size:10pt;">&#160;gain in the fourth quarter of 2016. Subsequently, the Company recognized additional gains of </font><font style="font-family:inherit;font-size:10pt;">$308</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$733</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">-month periods ended June 30, 2018 and 2017, respectively, related to the liquidation of remaining assets affiliated with the partnership.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company had </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> equity method investee, which was sold during the fourth quarter of 2016. The sale resulted in a&#160;</font><font style="font-family:inherit;font-size:10pt;">$1,366</font><font style="font-family:inherit;font-size:10pt;">&#160;gain in the fourth quarter of 2016. Subsequently, the Company recognized additional gains of </font><font style="font-family:inherit;font-size:10pt;">$308</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$733</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">-month periods ended June 30, 2018 and 2017, respectively, related to the liquidation of remaining assets affiliated with the partnership. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interim consolidated financial statements for the three and six month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company&#8217;s financial position at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, and the results of operations for the three and </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, and cash flows for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">. The Company&#8217;s balance sheet information at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, was derived from its audited consolidated financial statements as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective January 1, 2018, we adopted the requirements of Accounting Standards Update ("ASU") No. 2014-09,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">Revenue from Contracts with Customers (Topic 606), as discussed in Notes 3 and 4 to the interim consolidated financial statements. All amounts and disclosures set forth in this Form 10-Q have been updated to comply with the new standard.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The results of operations for the periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes revenue from contracts with customers by payor source for the periods presented (dollar amounts in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017(1)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As Adjusted to Legacy GAAP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As reported</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,603</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,216</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,510</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,863</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,079</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,900</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Managed Care</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,303</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,888</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,959</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Private Pay and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,313</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,326</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,181</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141,082</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">144,509</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,550</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017(1)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As Adjusted to Legacy GAAP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As reported</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,614</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,217</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,911</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Managed Care</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,515</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,980</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,764</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Private Pay and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,749</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,373</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,992</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">282,367</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">289,001</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">284,050</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) As noted above, prior period amounts have not been adjusted under the application of the modified retrospective method.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">STOCK-BASED COMPENSATION</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Overview of Plans</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (&#8220;Stock Purchase Plan&#8221;). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers. The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (&#8220;RSU's&#8221;) at </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;"> of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period. In June 2016, our shareholders approved an amendment to the Stock Purchase Plan to increase the number of shares of our common stock authorized under the Plan from </font><font style="font-family:inherit;font-size:10pt;">150</font><font style="font-family:inherit;font-size:10pt;"> shares to </font><font style="font-family:inherit;font-size:10pt;">350</font><font style="font-family:inherit;font-size:10pt;"> shares. No grants can be made under the Stock Purchase Plan after April 25, 2028.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (&#8220;2010 Plan&#8221;), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. In June 2017, our shareholders approved an amendment to the Long-Term Incentive Plan to increase the number of shares of our common stock authorized under the Plan from </font><font style="font-family:inherit;font-size:10pt;">380</font><font style="font-family:inherit;font-size:10pt;"> shares to </font><font style="font-family:inherit;font-size:10pt;">680</font><font style="font-family:inherit;font-size:10pt;"> shares. No grants can be made under the 2010 Plan after May 31, 2027.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity Grants and Valuations</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Compensation Committee of the Board of Directors approved grants totaling approximately </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">88</font><font style="font-family:inherit;font-size:10pt;"> shares of restricted common stock to certain employees and members of the Board of Directors, respectively. The fair value of restricted shares is determined as the quoted market price of the underlying common shares at the date of the grant. The restricted shares typically vest </font><font style="font-family:inherit;font-size:10pt;">33%</font><font style="font-family:inherit;font-size:10pt;"> on the first, second and third anniversaries of the grant date. Generally, unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. Upon vesting, all restrictions are removed.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Compensation Committee of the Board of Directors also approved grants of Stock Only Stock Appreciation Rights (&#8220;SOSARs&#8221;) and Stock Options at the market price of the Company's common stock on the grant date. The SOSARs and Options vest </font><font style="font-family:inherit;font-size:10pt;">33%</font><font style="font-family:inherit;font-size:10pt;"> on the first, second and third anniversaries of the grant date, and expire </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> years from the grant date. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In computing the fair value estimates using the Black-Scholes-Merton valuation method, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized activity of the equity compensation plans is presented below: </font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:65.625%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options/</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SOSARs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired or cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.81</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.56</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable, June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">206</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.41</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:65.8203125%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(79</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.27</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">171</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.81</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.9921875%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.91</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.28</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The SOSARs and Options were valued and recorded in the same manner, and, other than amounts that may be settled pursuant to employment agreements with certain members of management, will be settled with issuance of new stock for the difference between the market price on the date of exercise and the exercise price. The Company estimated the total recognized and unrecognized compensation related to SOSARs and stock options using the Black-Scholes-Merton equity grant valuation model.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In computing the fair value estimates using the Black-Scholes-Merton valuation model, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information regarding stock options and SOSAR grants outstanding as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Range of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-Grants</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">$8.14 to $10.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.37 to $6.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.56</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">206</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">206</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">206</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense is non-cash and is included as a component of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. The Company recorded total stock-based compensation expense of </font><font style="font-family:inherit;font-size:10pt;">$765</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$504</font><font style="font-family:inherit;font-size:10pt;"> in the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized activity of the equity compensation plans is presented below: </font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:65.625%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options/</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SOSARs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired or cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.81</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.56</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable, June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">206</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.41</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">EARNINGS PER COMMON SHARE</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information with respect to basic and diluted net income per common share is presented below in thousands, except per share:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(388</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,729</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations, net of income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(311</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">353</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(414</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,686</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share &#8211; basic</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share &#8211; basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.05</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.27</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share &#8211; diluted</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share &#8211; diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.05</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.26</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted Average Common Shares Outstanding:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,370</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,342</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,263</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,370</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,472</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,342</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,458</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effects of </font><font style="font-family:inherit;font-size:10pt;">226</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">46</font><font style="font-family:inherit;font-size:10pt;"> SOSARs and options outstanding were excluded from the computation of diluted earnings per common share in the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively, because these securities would have been anti-dilutive.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">COMMITMENTS AND CONTINGENCIES</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Professional Liability and Other Liability Insurance</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (&#8220;SHC&#8221;), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. All of the Company's nursing centers in Florida, and Tennessee are now covered under the captive insurance policies along with many of the nursing centers in Alabama, Kentucky, and Texas. The insurance coverage provided for these centers under the SHC policy provides coverage limits of at least </font><font style="font-family:inherit;font-size:10pt;">$500</font><font style="font-family:inherit;font-size:10pt;"> per medical incident with a sublimit per center of </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> and total annual aggregate policy limits of </font><font style="font-family:inherit;font-size:10pt;">$5,000</font><font style="font-family:inherit;font-size:10pt;">. All other centers within the Company's portfolio are covered through various commercial insurance policies which provide similar coverage limits per medical incident, per location, and on an aggregate basis for covered centers. The deductibles for these policies are covered through the insurance subsidiary. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reserve for Estimated Self-Insured Professional Liability Claims</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because the Company&#8217;s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company&#8217;s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of </font><font style="font-family:inherit;font-size:10pt;">$24,229</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of this reserve. Since May 2012, Merlinos &amp; Associates, Inc. (&#8220;Merlinos&#8221;) has assisted management in the preparation of the appropriate accrual for incurred but not reported general and professional liability claims based on data furnished as of May 31 and November 30 of each year. Merlinos primarily utilizes historical data regarding the frequency and cost of the Company's past claims over a multi-year period, industry data and information regarding the number of occupied beds to develop its estimates of the Company's ultimate professional liability cost for current periods. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company&#8217;s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator&#8217;s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company&#8217;s evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company is engaged in </font><font style="font-family:inherit;font-size:10pt;">79</font><font style="font-family:inherit;font-size:10pt;"> professional liability lawsuits. </font><font style="font-family:inherit;font-size:10pt;">Eleven</font><font style="font-family:inherit;font-size:10pt;"> lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company&#8217;s cash expenditures for self-insured professional liability costs from continuing operations were </font><font style="font-family:inherit;font-size:10pt;">$2,775</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4,338</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company follows the FASB ASU, "Presentation of Insurance Claims and Related Insurance Recoveries," that clarifies that a health care entity should not net insurance recoveries against a related professional liability claim and that the amount of the claim liability should be determined without consideration of insurance recoveries. Accordingly, the estimated insurance recovery receivables are included within "Other Current Assets" and "Other Noncurrent Assets" on the Consolidated Balance Sheet. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> there are estimated insurance recovery receivables of </font><font style="font-family:inherit;font-size:10pt;">$3,080</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company&#8217;s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company&#8217;s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company&#8217;s reported earnings and financial position for the period in which the change in accrual is made.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Civil Investigative Demand ("CID") </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2013, the Company learned that the United States Attorney for the Middle District of Tennessee ("DOJ") had commenced a civil investigation of potential violations of the False Claims Act ("FCA").</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, the Company learned that the investigation was started by the filing under seal of a false claims action against the </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> centers that were subject of the original civil investigative demand ("CID"). In connection with this matter, between July 2013 and early February 2016, the Company received </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> civil investigative demands (a form of subpoena) for documents. The Company has responded to those demands and also provided voluntarily additional information requested by the DOJ. The DOJ has also taken testimony from current and former employees of the Company. In May 2018, the Company learned that a second FCA complaint had been filed in late 2016 relating to the Company&#8217;s practices and policies for rehabilitation therapy at some of its facilities. The government&#8217;s investigation relates to the Company&#8217;s practices and policies for rehabilitation and other services at all of its facilities, for preadmission evaluation forms ("PAEs") required by TennCare and for Pre-Admission Screening and Resident Reviews ("PASRRs") required by the Medicare program. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the Company received an authorized investigative demand (a form of subpoena) for documents in connection with a criminal investigation by the DOJ related to our practices with respect to PAEs and PASRRs, and the Company has provided documents responsive to this subpoena and continues to provide additional information as requested. The Company cannot predict the outcome of these investigations or the related lawsuits, and the outcome could have a materially adverse effect on the Company, including the imposition of treble damages, criminal charges, fines, penalties and/or a corporate integrity agreement. Additionally, the uncertainty regarding the outcome of this investigation makes it more difficult for the Company to pursue strategic possibilities, longer term initiatives or to make significant financial commitments outside of the normal course of its business. The Company is committed to provide caring and professional services to its patients and residents in compliance with applicable laws and regulations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Insurance</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to workers&#8217; compensation insurance, substantially all of the Company&#8217;s employees became covered under either a prefunded deductible policy or state-sponsored programs. The Company has been and remains a non-subscriber to the Texas workers&#8217; compensation system and is, therefore, completely self-insured for employee injuries with respect to its Texas operations. From June&#160;30, 2003 until June&#160;30, 2007, the Company&#8217;s workers&#8217; compensation insurance programs provided coverage for claims incurred with premium adjustments depending on incurred losses. For the period from July 1, 2007 until June 30, 2008, the Company is completely insured for workers' compensation exposure. From the period from July&#160;1, 2008 through </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company is covered by a prefunded deductible policy. Under this policy, the Company is self-insured for the first </font><font style="font-family:inherit;font-size:10pt;">$500</font><font style="font-family:inherit;font-size:10pt;"> per claim, subject to an aggregate maximum of </font><font style="font-family:inherit;font-size:10pt;">$3,000</font><font style="font-family:inherit;font-size:10pt;">. The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers&#8217; compensation claims is </font><font style="font-family:inherit;font-size:10pt;">$593</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. The Company has a non-current receivable for workers&#8217; compensation policies covering previous years of </font><font style="font-family:inherit;font-size:10pt;">$1,030</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. The non-current receivable is a function of payments paid to the Company&#8217;s insurance carrier in excess of the estimated level of claims expected to be incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to </font><font style="font-family:inherit;font-size:10pt;">$200</font><font style="font-family:inherit;font-size:10pt;"> per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims is </font><font style="font-family:inherit;font-size:10pt;">$1,615</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. The differences between actual settlements and reserves are included in expense in the period finalized.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">BUSINESS</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diversicare Healthcare Services, Inc. (together with its subsidiaries, &#8220;Diversicare&#8221; or the &#8220;Company&#8221;) provides long-term care services to nursing center patients in </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> states, primarily in the Southeast, Midwest, and Southwest. The Company&#8217;s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company&#8217;s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Mississippi, Missouri, Ohio, Tennessee, and Texas.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s continuing operations consist of </font><font style="font-family:inherit;font-size:10pt;">76</font><font style="font-family:inherit;font-size:10pt;"> nursing centers with </font><font style="font-family:inherit;font-size:10pt;">8,456</font><font style="font-family:inherit;font-size:10pt;"> licensed nursing beds. The Company owns </font><font style="font-family:inherit;font-size:10pt;">18</font><font style="font-family:inherit;font-size:10pt;"> and leases </font><font style="font-family:inherit;font-size:10pt;">58</font><font style="font-family:inherit;font-size:10pt;"> of its nursing centers. Our nursing centers range in size from </font><font style="font-family:inherit;font-size:10pt;">48</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">320</font><font style="font-family:inherit;font-size:10pt;"> licensed nursing beds. The licensed nursing bed count does not include </font><font style="font-family:inherit;font-size:10pt;">497</font><font style="font-family:inherit;font-size:10pt;"> licensed assisted and residential living beds.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">RECENT ACCOUNTING GUIDANCE</font></div><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Standards Adopted by the Company</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No.&#160;2014-09,&#160;Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. Topic 606 is effective for annual and interim reporting periods beginning after December 15, 2017. The Company adopted the requirements of this standard effective January 1, 2018. The Company elected to apply the modified retrospective approach with the cumulative transition effect recognized in beginning retained earnings as of the date of adoption. The impact of the implementation to the consolidated financial statements for periods subsequent to adoption is not material. See Note 4, "Revenue Recognition" for a discussion regarding revenue recognition under the new standard. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09,&#160;Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU was issued as part of the FASB Simplification Initiative and involves several aspects of accounting for share-based payment transactions, including the income tax consequences and classification on the statement of cash flows. We adopted this standard as of January 1, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15,&#160;Statement of Cash Flows (Topic 230). The ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The ASU is effective for annual and interim periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018 using a retrospective approach. The adoption did not have a material impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires that the Statement of Cash Flows explain the changes during the period of cash and cash equivalents inclusive of amounts categorized as Restricted Cash. As a result, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018. The adoption did not have a material impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) - Clarifying the Definition of a Business, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The adoption is effective for annual and interim periods beginning after December 15, 2017. The Company will evaluate future acquisitions under this guidance, which may result in future acquisitions being accounted for as asset acquisitions.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting.&#160;The amended standard specifies the modification accounting applicable to any entity which changes the terms or conditions of a share-based payment award. The new guidance is effective for all entities after December 15, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accounting Standards Recently Issued But Not Yet Adopted by the Company</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. Disclosures will be required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. We anticipate this standard will have a material impact on our consolidated financial position and results of operations. We have organized an implementation group of cross-functional departmental management to ensure the completeness of our lease information, analyze the appropriate classification of current leases under the new standard, and develop new processes to execute, approve and classify leases on an ongoing basis. We have also implemented software tools and processes to maintain lease information critical to applying the new standard. We are continuing to evaluate the extent of this anticipated impact on our consolidated financial position and results of operations and the quantitative and qualitative factors that will impact the Company as part of the adoption. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related notes.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which is intended to simplify and amend the application of hedge accounting to more clearly portray the economics of an entity&#8217;s risk management strategies in its financial statements. The new guidance will make more financial and nonfinancial hedging strategies eligible for hedge accounting and reduce complexity in fair value hedges of interest rate risk. The new guidance also changes how companies assess effectiveness and amends the presentation and disclosure requirements. The new guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally the entire change in the fair value of a hedging instrument will be required to be presented in the same income statement line as the hedged item. The new guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The new guidance is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those years. Early adoption is permitted in any interim period or fiscal year before the effective date. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU No. 2018-02, Income Statement- Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows entities the option to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act from accumulated other comprehensive income (OCI) to retained earnings. The new guidance allows the option to apply the guidance retrospectively or in the period of adoption. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 ("SAB No. 118"), which allowed SEC registrants to record provisional amounts in earnings for the year ended December 31, 2017 due to the complexities involved in accounting for the enactment of the Tax Cuts and Jobs Act. The Company recognized the estimated income tax effects of the Tax Cuts and Jobs Act in its 2017 Consolidated Financial Statements in accordance with SAB No. 118.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Standards Adopted by the Company</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No.&#160;2014-09,&#160;Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. Topic 606 is effective for annual and interim reporting periods beginning after December 15, 2017. The Company adopted the requirements of this standard effective January 1, 2018. The Company elected to apply the modified retrospective approach with the cumulative transition effect recognized in beginning retained earnings as of the date of adoption. The impact of the implementation to the consolidated financial statements for periods subsequent to adoption is not material. See Note 4, "Revenue Recognition" for a discussion regarding revenue recognition under the new standard. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09,&#160;Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU was issued as part of the FASB Simplification Initiative and involves several aspects of accounting for share-based payment transactions, including the income tax consequences and classification on the statement of cash flows. We adopted this standard as of January 1, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15,&#160;Statement of Cash Flows (Topic 230). The ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The ASU is effective for annual and interim periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018 using a retrospective approach. The adoption did not have a material impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires that the Statement of Cash Flows explain the changes during the period of cash and cash equivalents inclusive of amounts categorized as Restricted Cash. As a result, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018. The adoption did not have a material impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) - Clarifying the Definition of a Business, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The adoption is effective for annual and interim periods beginning after December 15, 2017. The Company will evaluate future acquisitions under this guidance, which may result in future acquisitions being accounted for as asset acquisitions.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting.&#160;The amended standard specifies the modification accounting applicable to any entity which changes the terms or conditions of a share-based payment award. The new guidance is effective for all entities after December 15, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accounting Standards Recently Issued But Not Yet Adopted by the Company</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. Disclosures will be required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. We anticipate this standard will have a material impact on our consolidated financial position and results of operations. We have organized an implementation group of cross-functional departmental management to ensure the completeness of our lease information, analyze the appropriate classification of current leases under the new standard, and develop new processes to execute, approve and classify leases on an ongoing basis. We have also implemented software tools and processes to maintain lease information critical to applying the new standard. We are continuing to evaluate the extent of this anticipated impact on our consolidated financial position and results of operations and the quantitative and qualitative factors that will impact the Company as part of the adoption. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related notes.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which is intended to simplify and amend the application of hedge accounting to more clearly portray the economics of an entity&#8217;s risk management strategies in its financial statements. The new guidance will make more financial and nonfinancial hedging strategies eligible for hedge accounting and reduce complexity in fair value hedges of interest rate risk. The new guidance also changes how companies assess effectiveness and amends the presentation and disclosure requirements. The new guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally the entire change in the fair value of a hedging instrument will be required to be presented in the same income statement line as the hedged item. The new guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The new guidance is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those years. Early adoption is permitted in any interim period or fiscal year before the effective date. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued ASU No. 2018-02, Income Statement- Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows entities the option to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act from accumulated other comprehensive income (OCI) to retained earnings. The new guidance allows the option to apply the guidance retrospectively or in the period of adoption. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 ("SAB No. 118"), which allowed SEC registrants to record provisional amounts in earnings for the year ended December 31, 2017 due to the complexities involved in accounting for the enactment of the Tax Cuts and Jobs Act. The Company recognized the estimated income tax effects of the Tax Cuts and Jobs Act in its 2017 Consolidated Financial Statements in accordance with SAB No. 118.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">REVENUE RECOGNITION</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 1, 2018, the Company adopted ASC 606 using the modified retrospective method for all contracts as of the date of adoption. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC 605, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;"> (ASC 605), which is also referred to herein as "legacy GAAP". The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of the Company's services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. ASC 606 requires companies to exercise more judgment and recognize revenue in accordance with the standard's core principle by applying the following five steps:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 1: Identify the contract with a customer.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 2: Identify the performance obligations in the contract. </font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 3: Determine the transaction price.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 4: Allocate the transaction price to the performance obligations in the contract. </font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Performance obligations are promises made in a contract to transfer a distinct good or service to the customer. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company has concluded that the contracts with patients and residents represent a bundle of distinct services that are substantially the same, with the same pattern of transfer to the customer. Accordingly, the promise to provide quality care is accounted for as a single performance obligation.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding state. It was determined that the contracts are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans). </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to determine the transaction price, the Company estimates the amount of variable consideration at the beginning of the contract using the expected value method. The estimates consider (i) payor type, (ii) historical payment trends, (iii) the maturity of the portfolio, and (iv) geographic payment trends throughout a class of similar payors. The Company typically enters into agreements with third-party payors that provide for payments at amounts different from the established charges. These arrangement terms provide for subsequent settlement and cash flows that may occur well after the service is provided. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. Changes in the Company's expectation of the amount it will receive from the patient or third-party payors will be recorded in revenue unless there is a specific event that suggests the patient or third-party payor no longer has the ability and intent to pay the amount due and, therefore, the changes in its estimate of variable consideration better represent an impairment, or bad debt. These estimates are re-assessed each reporting period, and any amounts allocated to a satisfied performance obligation are recognized as revenue or a reduction of revenue in the period in which the transaction price changes. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company satisfies its performance obligation by providing quality of care services to its patients and residents on a daily basis until termination of the contract. The performance obligation is recognized on a time elapsed basis, by day, for which the services are provided. For these contracts, the Company has the right to consideration from the customer in an amount that directly corresponds with the value to the customer of the Company's performance to date. Therefore, the Company recognizes revenue based on the amount billable to the customer in accordance with the practical expedient in ASC 606-10-55-18. Additionally, because the Company applied ASC 606 using certain practical expedients, the Company elected not to disclose the aggregate amount of the transaction price for unsatisfied, or partially unsatisfied, performance obligations for all contracts with an original expected length of one year or less.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurs costs related to patient/resident contracts, such as legal and advertising expenses. The contract costs are expensed as incurred. They are not expected to be recovered and are not chargeable to the patient/resident regardless of whether the contract is executed.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Statement Impact of Adopting ASC 606</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted ASC 606 using the modified retrospective method. The cumulative effect of applying the new guidance to all contracts with customers as of January 1, 2018 was not material to the interim consolidated financial statements. As a result of applying the modified retrospective method to adopt ASC 606, the following adjustments were made to our operating results:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Increase </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Decrease)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balances as if the previous accounting guidance was in effect</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Patient Revenues, net</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$141,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,789</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;text-decoration:underline;">(362</font><font style="font-family:inherit;font-size:9pt;">)</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,427</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(b)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$144,509</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Operating Expenses</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$111,440</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,789</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$115,229</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total Expenses</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$140,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,789</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$144,278</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Adjusts for the implicit price concession of bad debt expense.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Adjusts for the implementation of ASC 606.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Increase </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Decrease)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balances as if the previous accounting guidance was in effect</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Patient Revenues, net</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$282,367</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,252</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;text-decoration:underline;">(618</font><font style="font-family:inherit;font-size:9pt;">)</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,634</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(b)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$289,001</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Operating Expenses</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$223,718</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,252</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$230,970</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total Expenses</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$280,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,252</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$287,527</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Adjusts for the implicit price concession of bad debt expense.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Adjusts for the implementation of ASC 606.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Increase </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Decrease)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balances as if the previous accounting guidance was in effect</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts Receivable</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$63,591</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(618)</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;text-decoration:underline;">16,050</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,432</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(b)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$79,023</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accumulated Deficit</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$(15,673)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">618</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;text-decoration:underline;">(198)</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">420</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(c)</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$(15,253)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Adjusts for the implementation of ASC 606.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Adjusts for a direct reduction of accounts receivable that would have been reflected as allowance for doubtful accounts in the consolidated balance sheet prior to the adoption of ASC 606.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c) Reflects the tax adjustment for the ASC 606 adjustment of </font><font style="font-family:inherit;font-size:10pt;">$618</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Disaggregation of Revenue</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes revenue from contracts with customers by payor source for the periods presented (dollar amounts in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017(1)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As Adjusted to Legacy GAAP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As reported</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,603</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,216</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,510</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,863</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,079</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,900</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Managed Care</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,303</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,888</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,959</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Private Pay and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,313</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,326</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,181</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141,082</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">144,509</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,550</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017(1)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As Adjusted to Legacy GAAP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As reported</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicaid</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Medicare</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,614</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,217</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,911</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Managed Care</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,515</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,980</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,764</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Private Pay and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,749</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,373</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,992</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">282,367</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">289,001</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">284,050</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) As noted above, prior period amounts have not been adjusted under the application of the modified retrospective method.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 1, 2018, the Company adopted ASC 606 using the modified retrospective method for all contracts as of the date of adoption. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC 605, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;"> (ASC 605), which is also referred to herein as "legacy GAAP". The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of the Company's services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. ASC 606 requires companies to exercise more judgment and recognize revenue in accordance with the standard's core principle by applying the following five steps:</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 1: Identify the contract with a customer.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 2: Identify the performance obligations in the contract. </font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 3: Determine the transaction price.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 4: Allocate the transaction price to the performance obligations in the contract. </font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Performance obligations are promises made in a contract to transfer a distinct good or service to the customer. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company has concluded that the contracts with patients and residents represent a bundle of distinct services that are substantially the same, with the same pattern of transfer to the customer. Accordingly, the promise to provide quality care is accounted for as a single performance obligation.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding state. It was determined that the contracts are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans). </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to determine the transaction price, the Company estimates the amount of variable consideration at the beginning of the contract using the expected value method. The estimates consider (i) payor type, (ii) historical payment trends, (iii) the maturity of the portfolio, and (iv) geographic payment trends throughout a class of similar payors. The Company typically enters into agreements with third-party payors that provide for payments at amounts different from the established charges. These arrangement terms provide for subsequent settlement and cash flows that may occur well after the service is provided. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. Changes in the Company's expectation of the amount it will receive from the patient or third-party payors will be recorded in revenue unless there is a specific event that suggests the patient or third-party payor no longer has the ability and intent to pay the amount due and, therefore, the changes in its estimate of variable consideration better represent an impairment, or bad debt. These estimates are re-assessed each reporting period, and any amounts allocated to a satisfied performance obligation are recognized as revenue or a reduction of revenue in the period in which the transaction price changes. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company satisfies its performance obligation by providing quality of care services to its patients and residents on a daily basis until termination of the contract. The performance obligation is recognized on a time elapsed basis, by day, for which the services are provided. For these contracts, the Company has the right to consideration from the customer in an amount that directly corresponds with the value to the customer of the Company's performance to date. Therefore, the Company recognizes revenue based on the amount billable to the customer in accordance with the practical expedient in ASC 606-10-55-18. Additionally, because the Company applied ASC 606 using certain practical expedients, the Company elected not to disclose the aggregate amount of the transaction price for unsatisfied, or partially unsatisfied, performance obligations for all contracts with an original expected length of one year or less.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurs costs related to patient/resident contracts, such as legal and advertising expenses. The contract costs are expensed as incurred. They are not expected to be recovered and are not chargeable to the patient/resident regardless of whether the contract is executed.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information with respect to basic and diluted net income per common share is presented below in thousands, except per share:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(307</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">381</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(388</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,729</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations, net of income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(311</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">353</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(414</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,686</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share &#8211; basic</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share &#8211; basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.05</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.27</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per common share &#8211; diluted</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from continuing operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.01</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per common share &#8211; diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.05</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.26</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted Average Common Shares Outstanding:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,370</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,294</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,342</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,263</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,370</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,472</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,342</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,458</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of applying the modified retrospective method to adopt ASC 606, the following adjustments were made to our operating results:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Increase </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Decrease)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balances as if the previous accounting guidance was in effect</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Patient Revenues, net</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$141,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,789</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;text-decoration:underline;">(362</font><font style="font-family:inherit;font-size:9pt;">)</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,427</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(b)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$144,509</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Operating Expenses</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$111,440</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,789</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$115,229</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total Expenses</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$140,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,789</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$144,278</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Adjusts for the implicit price concession of bad debt expense.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Adjusts for the implementation of ASC 606.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Increase </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Decrease)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balances as if the previous accounting guidance was in effect</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Patient Revenues, net</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$282,367</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,252</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;text-decoration:underline;">(618</font><font style="font-family:inherit;font-size:9pt;">)</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,634</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(b)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$289,001</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Operating Expenses</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$223,718</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,252</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$230,970</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total Expenses</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$280,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,252</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$287,527</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Adjusts for the implicit price concession of bad debt expense.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Adjusts for the implementation of ASC 606.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of June 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">As Reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Increase </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Decrease)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balances as if the previous accounting guidance was in effect</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts Receivable</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$63,591</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(618)</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;text-decoration:underline;">16,050</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,432</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(b)</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$79,023</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accumulated Deficit</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$(15,673)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">618</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;text-decoration:underline;">(198)</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">420</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(a)</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">(c)</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$(15,253)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Adjusts for the implementation of ASC 606.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Adjusts for a direct reduction of accounts receivable that would have been reflected as allowance for doubtful accounts in the consolidated balance sheet prior to the adoption of ASC 606.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c) Reflects the tax adjustment for the ASC 606 adjustment of </font><font style="font-family:inherit;font-size:10pt;">$618</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The allocation of the purchase price to the net assets acquired is as follows:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:53.125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Park Place</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase Price</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on bargain purchase</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">925</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,675</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allocation:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Building</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,435</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">760</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Land Improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture, Fixtures and Equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">335</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,675</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information regarding stock options and SOSAR grants outstanding as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Range of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value-Grants</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Prices</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">$8.14 to $10.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">$2.37 to $6.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.56</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">206</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">206</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">206</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:65.8203125%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(79</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.27</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">171</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.81</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.9921875%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend Equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.91</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.28</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">SUBSEQUENT EVENTS</font></div><div style="line-height:120%;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 8, 2018 the Company entered into a membership interest purchase agreement with ALS Ontario Operating, Inc. to sell all of the issued and outstanding membership units of the Ontario Pointe facility. The transaction is expected to become effective in the third quarter of 2018.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 9, 2018 the Board of Directors of Diversicare Healthcare Services, Inc. announced the retirement of Kelly Gill as President, Chief Executive Officer and Board member of the Company, effective July 6, 2018. As a result of Mr. Gill's retirement, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$1,172</font><font style="font-family:inherit;font-size:10pt;"> in severance related expenses inclusive of </font><font style="font-family:inherit;font-size:10pt;">$259</font><font style="font-family:inherit;font-size:10pt;"> in additional stock based compensation expense in the second quarter of 2018. In accordance with Mr. Gill's employment agreement, the Company determined that the benefits to which Mr. Gill was entitled were probable of being paid. The Company also announced the appointment of James R. McKnight, Jr. as President and Chief Executive Officer of the Company.</font></div></div> EX-101.SCH 6 avca-20180630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2101100 - Disclosure - BUSINESS link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - BUSINESS (Details) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS - Schedule of Assets Acquired (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2406401 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Policies) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - EARNINGS PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - EARNINGS PER COMMON SHARE - Basic and Diluted Net Income (Loss) Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - EARNINGS PER COMMON SHARE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - EARNINGS PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - INTERIM CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 1002501 - Statement - INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - LONG-TERM DEBT AND INTEREST RATE SWAP link:presentationLink link:calculationLink link:definitionLink 2405401 - Disclosure - LONG-TERM DEBT AND INTEREST RATE SWAP (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - RECENT ACCOUNTING GUIDANCE link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - REVENUE RECOGNITION link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - REVENUE RECOGNITION - Adjustments to Operating Results (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - REVENUE RECOGNITION - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - REVENUE RECOGNITION (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Activity of Equity Compensation Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2407405 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Awards Outstanding and Exercisable (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock and Restricted Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 2410401 - Disclosure - SUBSEQUENT EVENTS SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 avca-20180630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 avca-20180630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 avca-20180630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Statement of Financial Position [Abstract] CURRENT ASSETS: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Receivables, less allowance for doubtful accounts of $14,235 at December 31, 2017 Accounts Receivable, Net, Current Other receivables Receivables, Net, Current Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Income tax refundable Income Taxes Receivable, Current Current assets of discontinued operations Disposal Group, Including Discontinued Operation, Assets, Current Total current assets Assets, Current PROPERTY AND EQUIPMENT, at cost Property, Plant and Equipment, Gross Less accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Property, Plant and Equipment, Net OTHER ASSETS: Assets, Noncurrent [Abstract] Deferred income taxes, net Deferred Income Tax Assets, Net Deferred lease and other costs, net Deferred Costs Acquired leasehold interest, net Acquired Leasehold Interest, Net Noncurrent Acquired leasehold interest, net. Assets held for sale Disposal Group, Including Discontinued Operation, Assets, Noncurrent Other noncurrent assets Other Assets, Noncurrent Total other assets Assets, Noncurrent, Other than Noncurrent Investments and Property, Plant and Equipment Total assets Assets CURRENT LIABILITIES: Liabilities, Current [Abstract] Current portion of long-term debt and capitalized lease obligations Long-term Debt and Capital Lease Obligations, Current Trade accounts payable Accounts Payable, Trade, Current Current liabilities of discontinued operations Disposal Group, Including Discontinued Operation, Liabilities, Current Accrued expenses: Accrued Liabilities, Current [Abstract] Payroll and employee benefits Employee-related Liabilities, Current Self-insurance reserves, current portion Self Insurance Reserve, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current NONCURRENT LIABILITIES: Liabilities, Noncurrent [Abstract] Long-term debt and capitalized lease obligations, less current portion and deferred financing costs, net Long-term Debt and Capital Lease Obligations Self-insurance reserves, less current portion Self Insurance Reserve, Noncurrent Other noncurrent liabilities Other Liabilities, Noncurrent Total noncurrent liabilities Liabilities, Noncurrent COMMITMENTS AND CONTINGENCIES Commitments and Contingencies SHAREHOLDERS’ EQUITY: Stockholders' Equity Attributable to Parent [Abstract] Common stock, authorized 20,000 shares, $.01 par value, 6,768 and 6,687 shares issued, and 6,536 and 6,455 shares outstanding, respectively Common Stock, Value, Issued Treasury stock at cost, 232 shares of common stock Treasury Stock, Value Paid-in capital Additional Paid in Capital, Common Stock Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Total shareholders’ equity Stockholders' Equity Attributable to Parent Total liabilities and shareholder's equity Liabilities and Equity Health Care Organizations [Abstract] COMMITMENTS AND CONTINGENCIES Malpractice Loss Contingency Disclosure [Text Block] Business Combinations [Abstract] Schedule of allocation for net assets acquired Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS Business Description and Basis of Presentation [Text Block] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Mortgage term loan Mortgage Term Loan [Member] Mortgage Term Loan [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Amended and restated credit agreement Amended and Restated Credit Agreement [Member] Amended and Restated Credit Agreement [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Mortgage loan Mortgages [Member] Name of Property [Axis] Name of Property [Axis] Name of Property [Domain] Name of Property [Domain] Trend Health and Rehab of Carthage, LLC (Trend Health) Trend Health and Rehab of Carthage, LLC (Trend Health) [Member] Trend Health and Rehab of Carthage, LLC (Trend Health) [Member] Investment, Name [Axis] Investment, Name [Axis] Investment, Name [Domain] Investment, Name [Domain] Unnamed pharmacy joint venture Unnamed Pharmacy Joint Venture [Member] Unnamed Pharmacy Joint Venture [Member] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Selma Nursing Centers Selma Nursing Centers [Member] Selma Nursing Centers [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Number of licensed nursing beds Number of Licensed Nursing Beds Number of licensed nursing beds. Purchase Price Business Combination, Consideration Transferred Increase to credit facility limit Line of Credit Facility, Terms, Maximum Increase in Capacity Line of Credit Facility, Terms, Maximum Increase in Capacity Business acquisition, acquisition expenses Business Acquisition, Transaction Costs Gain on bargain purchase Business Combination, Bargain Purchase, Gain Recognized, Amount Number of skilled nursing facilities classified as held for sale Number of Skilled Nursing Facilities, Held-For-Sale, Not Part Of Discontinued Operations Number of Skilled Nursing Facilities, Held-For-Sale, Not Part Of Discontinued Operations Cash termination payment Operating Leases, Rent Expense, Net Gain on sale of investment in unconsolidated affiliate Equity Method Investment, Realized Gain (Loss) on Disposal Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] NET INCOME (LOSS) Net Income (Loss) Attributable to Parent Discontinued operations Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Income (loss) from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Adjustments to reconcile income (loss) from continuing operations to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Provision for doubtful accounts Provision for Doubtful Accounts Deferred income tax provision (benefit) Deferred Income Tax Expense (Benefit) Provision for self-insured professional liability, net of cash payments Increase (Decrease) in Self Insurance Reserve Stock-based compensation Share-based Compensation Gain on sale of unconsolidated affiliate Provision for leases in excess of cash payments Provision For Leases In Excess Of Cash Payments Provision For Leases In Excess Of Cash Payments Deferred bonus Deferred Compensation, Bonus Deferred Compensation, Bonus Other Other Noncash Income (Expense) Changes in assets and liabilities affecting operating activities: Increase (Decrease) in Operating Capital [Abstract] Receivables, net Increase (Decrease) in Receivables Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Trade accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Net cash provided by continuing operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Discontinued operations Cash Provided by (Used in) Operating Activities, Discontinued Operations Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Deposit in escrow Payments to Acquire Businesses, Gross Proceeds from sale of unconsolidated affiliate Proceeds from Sale of Equity Method Investments Net cash used in continuing operations Net Cash Provided by (Used in) Investing Activities, Continuing Operations Discontinued operations Cash Provided by (Used in) Investing Activities, Discontinued Operations Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Repayment of debt obligations Repayments of Long-term Debt, Long-term Capital Lease Obligations, and Capital Securities Proceeds from issuance of debt Proceeds from Issuance of Long-term Debt and Capital Securities, Net Financing costs Payments of Financing Costs Issuance and redemption of employee equity awards Proceeds (Payments) for Issuance (Redemption) of Shares under Incentive and Share-based Compensation Plans, Including Stock Options Proceeds (Payments) for Issuance (Redemption) of Shares under Incentive and Share-based Compensation Plans, Including Stock Options Payment of common stock dividends Payments of Ordinary Dividends, Common Stock Payment for preferred stock restructuring Payments of Stock Issuance Costs Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations Discontinued operations Cash Provided by (Used in) Financing Activities, Discontinued Operations Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS Cash and Cash Equivalents, Period Increase (Decrease) CASH AND CASH EQUIVALENTS, beginning of period CASH AND CASH EQUIVALENTS, end of period SUPPLEMENTAL INFORMATION: Supplemental Cash Flow Information [Abstract] Cash payments of interest Interest Paid, Excluding Capitalized Interest, Operating Activities Cash payments of income taxes Income Taxes Paid, Net Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Acquisition of equipment through capital lease Capital Lease Obligations Incurred Earnings Per Share [Abstract] Per common share – basic and diluted Earnings Per Share, Basic and Diluted [Abstract] Net income (loss) Income Amounts Attributable to Parent, Disclosures [Abstract] Income (loss) from continuing operations Loss from discontinued operations, net of income taxes Net income (loss) Net Income (Loss) Available to Common Stockholders, Basic Per common share – basic Earnings Per Share, Basic [Abstract] Income from continuing operations (dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Loss from discontinued operations (dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Net income per common share – basic (dollars per share) Earnings Per Share, Basic Per common share – diluted Earnings Per Share, Diluted [Abstract] Income from continuing operations (dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Loss from discontinued operations (dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Net income per common share – diluted (dollars per share) Earnings Per Share, Diluted Weighted Average Common Shares Outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (shares) Weighted Average Number of Shares Outstanding, Basic Diluted (shares) Weighted Average Number of Shares Outstanding, Diluted BUSINESS Nature of Operations [Text Block] EARNINGS PER COMMON SHARE Earnings Per Share [Text Block] Basic and diluted net income (loss) per common share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Debt Disclosure [Abstract] LONG-TERM DEBT AND INTEREST RATE SWAP Long Term Debt And Derivative Instruments [Text Block] Long Term Debt And Derivative Instruments [Text Block] Document and Entity Information [Abstract] Document and entity information. Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Accounting Policies [Abstract] RECENT ACCOUNTING GUIDANCE New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Event [Table] Title of Individual [Axis] Title of Individual [Axis] Relationship to Entity [Domain] Relationship to Entity [Domain] Chief Executive Officer Chief Executive Officer [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Severance expenses Severance Costs Share-based compensation expense Allocated Share-based Compensation Expense Accounting Policies [Table] Accounting Policies [Table] Accounting Policies [Table] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Accounting Policies [Line Items] Accounting Policies [Line Items] [Line Items] for Accounting Policies [Table] Number of states in which entity operates Number of States in which Entity Operates Number of nursing centers Number Of Nursing Center Facilities Number Of Nursing Center Facilities Number of nursing center facilities owned Number Of Nursing Center Facilities Owned Number Of Nursing Center Facilities Owned Number of nursing center facilities leased Number Of Nursing Center Facilities Leased Number Of Nursing Center Facilities Leased Number of licensed nursing beds per center Number of Licensed Nursing Beds per Nursing Center Number of Licensed Nursing Beds per Nursing Center Number of licensed assisted and residential living beds Number of Licensed Assisted Living Beds Number of Licensed Assisted Living Beds Revenue from Contract with Customer [Abstract] Schedule of New Accounting Pronouncements and Changes in Accounting Principles Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Equity Award [Domain] Stock Options and Stock Appreciation Rights (SARs) Stock Options and Stock Appreciation Rights (SARs) [Member] Stock Options and Stock Appreciation Rights (SARs) [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding, beginning (shares) Share Based Compensation Arrangement By Share Based Payment Award, Awards Outstanding Number Share Based Compensation Arrangement By Share Based Payment Award, Awards Outstanding Number Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Gross Exercised (shares) Share-based Compensation Arrangement By Share Based Payment Award, Exercises In Period Share-based Compensation Arrangement By Share Based Payment Award, Exercises In Period Expired or cancelled (shares) Share Based Compensation Arrangement By Share Based Payment Award, Forfeitures And Expirations In Period Share Based Compensation Arrangement By Share Based Payment Award, Forfeitures And Expirations In Period Outstanding, ending (shares) Exercisable (shares) Share Based Compensation Arrangement By Share Based Payment Award, Exercisable Number Share Based Compensation Arrangement By Share Based Payment Award, Exercisable Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Outstanding, beginning (dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Weighted Average Exercise Price Granted (dollars per share) Share Based Compensation Arrangements By Share Based Payment Award Awards Grants In Period Weighted Average Exercise Price Share Based Compensation Arrangements By Share Based Payment Award Awards Grants In Period Weighted Average Exercise Price Exercised (dollars per share) Share Based Compensation Arrangements By Share Based Payment Award Awards Exercises In Period Weighted Average Exercise Price Share Based Compensation Arrangements By Share Based Payment Award Awards Exercises In Period Weighted Average Exercise Price Expired or cancelled (dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Awards Forfeitures And Expirations In Period Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Awards Forfeitures And Expirations In Period Weighted Average Exercise Price Outstanding, ending (dollars per share) Exercisable, weighted average exercise price (dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Awards Exercisable Weighted Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Awards Exercisable Weighted Average Exercise Price REVENUE RECOGNITION Revenue from Contract with Customer [Text Block] Gain on bargain purchase Assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Building Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Buildings Land Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land Land Improvements Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land Improvements Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land Improvements Furniture, Fixtures and Equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equipment Consolidation Consolidation, Policy [Policy Text Block] Basis of Accounting Basis of Accounting, Policy [Policy Text Block] Recent Accounting Guidance New Accounting Pronouncements, Policy [Policy Text Block] Revenue Recognition Revenue Recognition, Policy [Policy Text Block] Allowance for doubtful accounts receivable Allowance for Doubtful Accounts Receivable, Current Common stock, shares authorized (shares) Common Stock, Shares Authorized Common stock, par value (dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares issued (shares) Common Stock, Shares, Issued Common stock, shares outstanding (shares) Common Stock, Shares, Outstanding Treasury stock, shares (shares) Treasury Stock, Shares Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Number of equity method investments sold Number of Equity Method Investments Sold Number of Equity Method Investments Sold Line of Credit Facility [Table] Line of Credit Facility [Table] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Domain] Lease Arrangement, Type [Domain] Omega Healthcare Investors Inc Omega Healthcare Investors Inc [Member] Omega Healthcare Investors Inc [Member] Acquisition loan facility Mortgage Revolving Credit Facility [Member] Mortgage Revolving Credit Facility [Member] Credit agreement Line of Credit [Member] Amended revolver Revolving Credit Facility [Member] Letter of credit Letter of Credit [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] LIBOR London Interbank Offered Rate (LIBOR) [Member] Derivative Instrument Risk [Axis] Derivative Instrument [Axis] Derivative Contract Type [Domain] Derivative Contract [Domain] Interest rate swap Interest Rate Swap [Member] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Designated as hedging instrument Designated as Hedging Instrument [Member] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Loan acquisition costs Debt Issuance Costs, Gross Term of agreements Debt Instrument, Term Period of amortization Line of Credit Facility, Terms, Duration of Amortization Period for Principal and Interest Payments Line of Credit Facility, Terms, Duration of Amortization Period for Principal and Interest Payments Interest rate percentage Debt Instrument, Basis Spread on Variable Rate Debt interest rate at period end Debt Instrument, Interest Rate, Effective Percentage Notional amount of interest rate derivatives Derivative, Notional Amount Amended mortgage loan balance Loans Payable Number of owned nursing centers to secure Amended Mortgage Loan Debt Instrument, Collateral, Number Of Owned Nursing Centers Debt Instrument, Collateral, Number Of Owned Nursing Centers Fixed charge coverage ratio Debt Instrument, Covenant Terms, Quarterly Fixed Charge Ratio, Minimum Debt Instrument, Covenant Terms, Quarterly Fixed Charge Ratio, Minimum Borrowings outstanding Long-term Debt Annual fees for letters of credit issued under Revolver (as a percentage) Line of Credit Facility, Fee Percentage on Amount Outstanding Line of Credit Facility, Fee Percentage on Amount Outstanding Number of letters of credit Number of Letters of Credit Number of Letters of Credit Letters of credit security deposit for a lease Letters of Credit Outstanding, Amount Balance available for borrowing under revolving credit center Line of Credit Facility, Current Borrowing Capacity Annual fixed rate percentage Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate Net asset based on interest rate swap valuation model Derivative Asset Accumulated other comprehensive income (loss) Income tax benefit, interest rate swap Net Income Tax Benefit Net income tax benefit. Summarized activity of equity compensation plans Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Schedule of summarized activity of Restricted Share Units Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Schedule of summarized information regarding stock options and SOSAR grants outstanding Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Malpractice Insurance [Table] Schedule of Malpractice Insurance [Table] Trial Or Arbitration Schedule Timeframe [Axis] Trial Or Arbitration Schedule Timeframe [Axis] Trial Or Arbitration Schedule Timeframe [Axis] Scheduled For Trial Or Arbitration Over Next Twelve Months [Domain] Scheduled For Trial Or Arbitration Over Next Twelve Months [Domain] Scheduled For Trial Or Arbitration Over Next Twelve Months Scheduled for trial or arbitration over next 12 months Trial Or Arbitration Schedule Timeframe [Member] Trial Or Arbitration Schedule Timeframe [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] SHC Risk Carriers, Inc SHC Risk Carriers, Inc [Member] SHC Risk Carriers, Inc [Member] Insurance Type and Tier Identifier [Axis] Insurance Type and Tier Identifier [Axis] Type and Tier Identifier [Domain] Type and Tier Identifier [Domain] Professional malpractice liability insurance Professional Malpractice Liability Insurance [Member] Prefunded deductible policy Prefunded Deductible Policy [Member] Prefunded deductible policy. Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Unfavorable regulatory action Unfavorable Regulatory Action [Member] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Potential violations of false claims act Potential Violations of False Claims Act [Member] Potential Violations of False Claims Act [Member] Malpractice Insurance [Line Items] Malpractice Insurance [Line Items] Insurance policy coverage limits per claim Malpractice Insurance, Maximum Coverage Per Incident Malpractice insurance annual sublimit per center Malpractice Insurance, Annual Sublimit Per Center Malpractice Insurance, Annual Sublimit Per Center Aggregate policy limit Malpractice Insurance, Annual Coverage Limit Liability for reported and estimated future claims Malpractice Loss Contingency, Accrual, Undiscounted Number of professional liability lawsuits Number Of Professional Liability Lawsuits Number Of Professional Liability Lawsuits Cash expenditures for self-insured professional liability costs Malpractice Insurance Self Insured Costs Paid During Period Malpractice Insurance Self Insured Costs Paid During Period Estimated insurance recovery receivables Estimated Insurance Recoveries Number of facilities Loss Contingency, Number of Facilities Loss Contingency, Number of Facilities Number of civil investigative demands received Loss Contingency, New Claims Filed, Number Other Insurance Other Insurance Industry Disclosures [Abstract] Insurance policy coverage limits per claim Professional liability insurance, annual coverage limit per facility Malpractice Insurance Annual Coverage Limit Per Facility Malpractice Insurance Annual Coverage Limit Per Facility Liability for workers compensation claims Workers' Compensation Liability Workers compensation insurance, non current receivable for excess premiums paid Workers Compensation Receivable For Excess Premiums Paid Workers Compensation Receivable For Excess Premiums Paid Health insurance, maximum self-insured annual amount per individual Employee Health Insurance Maximum Payable Per Individual Annually Employee Health Insurance Maximum Payable Per Individual Annually Liability for reported claims and estimates for incurred but unreported claims Liability for Future Policy Benefits STOCK-BASED COMPENSATION Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Revenue, Initial Application Period Cumulative Effect Transition [Table] Revenue, Initial Application Period Cumulative Effect Transition [Table] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Difference Between Revenue Guidance In Effect before And After Topic 606, Adjustment For Implicit Price Concession Of Bad Debt Expense Difference Between Revenue Guidance In Effect before And After Topic 606, Adjustment For Implicit Price Concession Of Bad Debt Expense [Member] Difference Between Revenue Guidance In Effect before And After Topic 606, Adjustment For Implicit Price Concession Of Bad Debt Expense [Member] Difference Between Revenue Guidance In Effect before And After Topic 606, Adjustment For Implementation Difference Between Revenue Guidance In Effect before And After Topic 606, Adjustment For Implementation [Member] Difference Between Revenue Guidance In Effect before And After Topic 606, Adjustment For Implementation [Member] Difference Between Revenue Guidance In Effect before And After Topic 606, Allowance For Doubtful Accounts Difference Between Revenue Guidance In Effect before And After Topic 606, Allowance For Doubtful Accounts [Member] Difference Between Revenue Guidance In Effect before And After Topic 606, Allowance For Doubtful Accounts [Member] Difference Between Revenue Guidance In Effect before And After Topic 606, Tax Adjustment Difference Between Revenue Guidance In Effect before And After Topic 606, Tax Adjustment [Member] Difference Between Revenue Guidance In Effect before And After Topic 606, Tax Adjustment [Member] Difference between Revenue Guidance in Effect before and after Topic 606 Difference between Revenue Guidance in Effect before and after Topic 606 [Member] Calculated under Revenue Guidance in Effect before Topic 606 Calculated under Revenue Guidance in Effect before Topic 606 [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2014-09 Accounting Standards Update 2014-09 [Member] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Patient Revenues, net Revenue from Contract with Customer, Excluding Assessed Tax Operating Expenses Cost of Goods and Services Sold Total Expenses Costs and Expenses Accounts Receivable Accounts Receivable, Net Accumulated Deficit Exercise Price Range [Axis] Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] $8.14 to $10.80 Stock Options Exercise Price Range One [Member] Stock Options Exercise Price Range One [Member] $2.37 to $6.21 Stock Options Exercise Price Range Two [Member] Stock Options Exercise Price Range Two [Member] Range of exercise prices, minimum (dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Range of exercise prices, maximum (dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Weighted average exercise prices (dollars per share) Grants outstanding (shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Awards Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Awards Intrinsic value - grants outstanding Share-based Compensation Arrangement by Share-based Payment Award, Awards, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Awards, Outstanding, Intrinsic Value Grants exercisable (shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Awards Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Awards Intrinsic value - grants exercisable Share-based Compensation Arrangement by Share-based Payment Award, Awards, Exercisable, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Awards, Exercisable, Intrinsic Value Income Statement [Abstract] PATIENT REVENUES, net EXPENSES: Costs and Expenses [Abstract] Operating Lease and rent expense Professional liability Malpractice Loss Contingency, Premium Costs General and administrative General and Administrative Expense Total expenses OPERATING INCOME Operating Income (Loss) OTHER INCOME (EXPENSE): Nonoperating Income (Expense) [Abstract] Other income Other Nonoperating Income Interest expense, net Interest Expense Total other expense Nonoperating Income (Expense) INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest BENEFIT (PROVISION) FOR INCOME TAXES Income Tax Expense (Benefit) INCOME (LOSS) FROM CONTINUING OPERATIONS LOSS FROM DISCONTINUED OPERATIONS: Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent [Abstract] Operating loss, net of tax benefit NET INCOME (LOSS) PER COMMON SHARE: Per common share – basic Per common share – basic, Continuing operations (dollars per share) Per common share – basic, Discontinued operations (dollars per share) Per common share – diluted, Continuing operations (dollars per share) Per common share – diluted, Discontinued operations (dollars per share) COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK (dollars per share) Common Stock, Dividends, Per Share, Declared WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] 2008 Stock Purchase Plan Two Thousand And Eight Stock Purchase Plan [Member] Two Thousand And Eight Stock Purchase Plan [Member] 2010 Long Term Incentive Plan Two Thousand And Ten Long Term Incentive Plan [Member] Two Thousand And Ten Long Term Incentive Plan [Member] Restricted Stock Restricted Stock [Member] Vesting [Axis] Vesting [Axis] Vesting [Domain] Vesting [Domain] First anniversary of grant date Share-based Compensation Award, Tranche One [Member] Second anniversary of grant date Share-based Compensation Award, Tranche Two [Member] Third anniversary of grant date Share-based Compensation Award, Tranche Three [Member] Percentage of quoted market price offering rate Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Restriction period Stock Based Compensation Arrangement By Share Based Payment Award Restriction Period Stock Based Compensation Arrangement By Share Based Payment Award Restriction Period Shares authorized under the plan (shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Shares reserved for future issuance (shares) Common Stock, Capital Shares Reserved for Future Issuance Grant of restricted common stock (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Vesting percentage of awards Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Payment award, expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period SUBSEQUENT EVENTS Subsequent Events [Text Block] Tax expense (benefit), effect on operating loss Discontinued Operation, Tax Effect of Discontinued Operation Statement of Comprehensive Income [Abstract] NET INCOME (LOSS) OTHER COMPREHENSIVE INCOME: Other Comprehensive Income (Loss), Net of Tax [Abstract] Change in fair value of cash flow hedge, net of tax Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax Less: reclassification adjustment for amounts recognized in net income Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax Total other comprehensive income Other Comprehensive Income (Loss), Net of Tax COMPREHENSIVE INCOME (LOSS) Comprehensive Income (Loss), Net of Tax, Attributable to Parent BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS Business Combination Disclosure [Text Block] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Employee Stock Employee Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Outstanding, beginning (share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (shares) Dividend Equivalents (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease) Vested (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Cancelled (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Outstanding, ending (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Outstanding, beginning (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted-Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted-Average Grant Date Fair Value Granted (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Dividend Equivalents (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Dividend Equivalents, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Dividend Equivalents, Weighted Average Grant Date Fair Value Vested (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Cancelled (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Outstanding, ending (dollars per share) Antidilutive shares excluded from computation of diluted earnings per share (shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Medicaid Medicaid [Member] Medicaid [Member] Medicare Medicare [Member] Medicare [Member] Managed Care Managed Care [Member] Managed Care [Member] Private Pay and other Private Pay And Other [Member] Private Pay And Other [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Total revenues Revenue from Contract with Customer, Including Assessed Tax Total revenues, as a percent Revenue From Contract With Customer, Including Assessed Tax, Percentage Revenue From Contract With Customer, Including Assessed Tax, Percentage EX-101.PRE 10 avca-20180630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 medicaidrateperday.jpg begin 644 medicaidrateperday.jpg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end GRAPHIC 12 medicarerateperday.jpg begin 644 medicarerateperday.jpg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htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - shares
 6 Months Ended
Jun. 30, 2018
Jul. 30, 2018
Document and Entity Information [Abstract]    
Entity Registrant Name Diversicare Healthcare Services, Inc.  
Entity Central Index Key 0000919956  
Document Type 10-Q  
Document Period End Date Jun. 30, 2018  
Amendment Flag false  
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q2  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   6,536,158
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
INTERIM CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
CURRENT ASSETS:    
Cash and cash equivalents $ 3,811 $ 3,524
Receivables, less allowance for doubtful accounts of $14,235 at December 31, 2017 63,591 64,929
Other receivables 1,456 375
Prepaid expenses and other current assets 3,672 3,248
Income tax refundable 1,298 537
Current assets of discontinued operations 20 45
Total current assets 73,848 72,658
PROPERTY AND EQUIPMENT, at cost 135,485 147,549
Less accumulated depreciation and amortization (81,184) (78,345)
Property and equipment, net 54,301 69,204
OTHER ASSETS:    
Deferred income taxes, net 15,052 15,154
Deferred lease and other costs, net 114 137
Acquired leasehold interest, net 6,499 6,691
Assets held for sale 13,269 0
Other noncurrent assets 5,106 3,725
Total other assets 40,040 25,707
Total assets 168,189 167,569
CURRENT LIABILITIES:    
Current portion of long-term debt and capitalized lease obligations 12,760 13,065
Trade accounts payable 14,969 14,080
Current liabilities of discontinued operations 461 461
Accrued expenses:    
Payroll and employee benefits 20,059 20,013
Self-insurance reserves, current portion 9,044 8,792
Other current liabilities 7,284 7,856
Total current liabilities 64,577 64,267
NONCURRENT LIABILITIES:    
Long-term debt and capitalized lease obligations, less current portion and deferred financing costs, net 74,236 74,603
Self-insurance reserves, less current portion 17,393 13,458
Other noncurrent liabilities 5,826 8,779
Total noncurrent liabilities 97,455 96,840
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY:    
Common stock, authorized 20,000 shares, $.01 par value, 6,768 and 6,687 shares issued, and 6,536 and 6,455 shares outstanding, respectively 68 67
Treasury stock at cost, 232 shares of common stock (2,500) (2,500)
Paid-in capital 23,249 22,720
Accumulated deficit (15,673) (14,534)
Accumulated other comprehensive income 1,013 709
Total shareholders’ equity 6,157 6,462
Total liabilities and shareholder's equity $ 168,189 $ 167,569
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts receivable   $ 14,235
Common stock, shares authorized (shares) 20,000,000 20,000,000
Common stock, par value (dollars per share) $ 0.01 $ 0.01
Common stock, shares issued (shares) 6,768,000 6,687,000
Common stock, shares outstanding (shares) 6,536,000 6,455,000
Treasury stock, shares (shares) 232,000 232,000
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Income Statement [Abstract]        
PATIENT REVENUES, net $ 141,082 $ 142,550 $ 282,367 $ 284,050
EXPENSES:        
Operating 111,440 113,166 223,718 223,833
Lease and rent expense 13,725 13,763 27,438 27,506
Professional liability 3,182 2,724 5,957 5,394
General and administrative 9,295 8,221 17,434 17,194
Depreciation and amortization 2,847 2,620 5,728 5,107
Total expenses 140,489 140,494 280,275 279,034
OPERATING INCOME 593 2,056 2,092 5,016
OTHER INCOME (EXPENSE):        
Gain on sale of investment in unconsolidated affiliate 308 0 308 733
Other income 28 0 79 0
Interest expense, net (1,661) (1,541) (3,330) (3,024)
Total other expense (1,325) (1,541) (2,943) (2,291)
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES (732) 515 (851) 2,725
BENEFIT (PROVISION) FOR INCOME TAXES 425 (134) 463 (996)
INCOME (LOSS) FROM CONTINUING OPERATIONS (307) 381 (388) 1,729
LOSS FROM DISCONTINUED OPERATIONS:        
Operating loss, net of tax benefit (4) (28) (26) (43)
NET INCOME (LOSS) $ (311) $ 353 $ (414) $ 1,686
Per common share – basic        
Per common share – basic, Continuing operations (dollars per share) $ (0.05) $ 0.06 $ (0.06) $ 0.28
Per common share – basic, Discontinued operations (dollars per share) 0.00 0.00 0.00 (0.01)
Net income per common share – basic (dollars per share) (0.05) 0.06 (0.06) 0.27
Per common share – diluted        
Per common share – diluted, Continuing operations (dollars per share) (0.05) 0.06 (0.06) 0.27
Per common share – diluted, Discontinued operations (dollars per share) 0.00 0.00   (0.01)
Net income per common share – diluted (dollars per share) (0.05) 0.06 (0.06) 0.26
COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK (dollars per share) $ 0.055 $ 0.055 $ 0.110 $ 0.11
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:        
Basic (shares) 6,370 6,294 6,342 6,263
Diluted (shares) 6,370 6,472 6,342 6,458
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Income Statement [Abstract]        
Tax expense (benefit), effect on operating loss $ 0 $ 18 $ 11 $ 27
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Statement of Comprehensive Income [Abstract]        
NET INCOME (LOSS) $ (311) $ 353 $ (414) $ 1,686
OTHER COMPREHENSIVE INCOME:        
Change in fair value of cash flow hedge, net of tax 134 146 455 400
Less: reclassification adjustment for amounts recognized in net income (38) (116) (151) (233)
Total other comprehensive income 96 30 304 167
COMPREHENSIVE INCOME (LOSS) $ (215) $ 383 $ (110) $ 1,853
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:    
NET INCOME (LOSS) $ (414) $ 1,686
Discontinued operations (26) (43)
Income (loss) from continuing operations (388) 1,729
Adjustments to reconcile income (loss) from continuing operations to net cash provided by operating activities:    
Depreciation and amortization 5,728 5,107
Provision for doubtful accounts 0 4,187
Deferred income tax provision (benefit) (34) 403
Provision for self-insured professional liability, net of cash payments 1,722 (309)
Stock-based compensation 765 504
Gain on sale of unconsolidated affiliate (308) (733)
Provision for leases in excess of cash payments (916) (304)
Deferred bonus 0 600
Other 283 247
Changes in assets and liabilities affecting operating activities:    
Receivables, net 342 (7,313)
Prepaid expenses and other assets (2,651) 620
Trade accounts payable and accrued expenses 2,072 (2,647)
Net cash provided by continuing operations 6,615 2,091
Discontinued operations (632) (329)
Net cash provided by operating activities 5,983 1,762
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of property and equipment (3,896) (5,121)
Deposit in escrow 0 (8,673)
Proceeds from sale of unconsolidated affiliate 308 1,100
Net cash used in continuing operations (3,588) (12,694)
Discontinued operations 0 0
Net cash used in investing activities (3,588) (12,694)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Repayment of debt obligations (9,057) (14,166)
Proceeds from issuance of debt 8,203 26,074
Financing costs (137) (226)
Issuance and redemption of employee equity awards (78) (94)
Payment of common stock dividends (702) (692)
Payment for preferred stock restructuring (337) (327)
Net cash (used in) provided by financing activities (2,108) 10,569
Discontinued operations 0 0
Net cash (used in) provided by financing activities (2,108) 10,569
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 287 (363)
CASH AND CASH EQUIVALENTS, beginning of period 3,524 4,263
CASH AND CASH EQUIVALENTS, end of period 3,811 3,900
SUPPLEMENTAL INFORMATION:    
Cash payments of interest 2,920 2,563
Cash payments of income taxes 321 625
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]    
Acquisition of equipment through capital lease $ 0 $ 7
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
BUSINESS
 6 Months Ended
Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BUSINESS
BUSINESS
Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare” or the “Company”) provides long-term care services to nursing center patients in ten states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Mississippi, Missouri, Ohio, Tennessee, and Texas.
As of June 30, 2018, the Company’s continuing operations consist of 76 nursing centers with 8,456 licensed nursing beds. The Company owns 18 and leases 58 of its nursing centers. Our nursing centers range in size from 48 to 320 licensed nursing beds. The licensed nursing bed count does not include 497 licensed assisted and residential living beds.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS
 6 Months Ended
Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS
The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company had one equity method investee, which was sold during the fourth quarter of 2016. The sale resulted in a $1,366 gain in the fourth quarter of 2016. Subsequently, the Company recognized additional gains of $308 and $733 for the six-month periods ended June 30, 2018 and 2017, respectively, related to the liquidation of remaining assets affiliated with the partnership.
The interim consolidated financial statements for the three and six month periods ended June 30, 2018 and 2017, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at June 30, 2018, and the results of operations for the three and six month periods ended June 30, 2018 and 2017, and cash flows for the six month periods ended June 30, 2018 and 2017. The Company’s balance sheet information at December 31, 2017, was derived from its audited consolidated financial statements as of December 31, 2017.
Effective January 1, 2018, we adopted the requirements of Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606), as discussed in Notes 3 and 4 to the interim consolidated financial statements. All amounts and disclosures set forth in this Form 10-Q have been updated to comply with the new standard.
The results of operations for the periods ended June 30, 2018 and 2017 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
RECENT ACCOUNTING GUIDANCE
 6 Months Ended
Jun. 30, 2018
Accounting Policies [Abstract]  
RECENT ACCOUNTING GUIDANCE
RECENT ACCOUNTING GUIDANCE

Recent Accounting Standards Adopted by the Company
In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. Topic 606 is effective for annual and interim reporting periods beginning after December 15, 2017. The Company adopted the requirements of this standard effective January 1, 2018. The Company elected to apply the modified retrospective approach with the cumulative transition effect recognized in beginning retained earnings as of the date of adoption. The impact of the implementation to the consolidated financial statements for periods subsequent to adoption is not material. See Note 4, "Revenue Recognition" for a discussion regarding revenue recognition under the new standard.
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU was issued as part of the FASB Simplification Initiative and involves several aspects of accounting for share-based payment transactions, including the income tax consequences and classification on the statement of cash flows. We adopted this standard as of January 1, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230). The ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The ASU is effective for annual and interim periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018 using a retrospective approach. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires that the Statement of Cash Flows explain the changes during the period of cash and cash equivalents inclusive of amounts categorized as Restricted Cash. As a result, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) - Clarifying the Definition of a Business, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The adoption is effective for annual and interim periods beginning after December 15, 2017. The Company will evaluate future acquisitions under this guidance, which may result in future acquisitions being accounted for as asset acquisitions.
In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The amended standard specifies the modification accounting applicable to any entity which changes the terms or conditions of a share-based payment award. The new guidance is effective for all entities after December 15, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.
Accounting Standards Recently Issued But Not Yet Adopted by the Company
In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. Disclosures will be required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. We anticipate this standard will have a material impact on our consolidated financial position and results of operations. We have organized an implementation group of cross-functional departmental management to ensure the completeness of our lease information, analyze the appropriate classification of current leases under the new standard, and develop new processes to execute, approve and classify leases on an ongoing basis. We have also implemented software tools and processes to maintain lease information critical to applying the new standard. We are continuing to evaluate the extent of this anticipated impact on our consolidated financial position and results of operations and the quantitative and qualitative factors that will impact the Company as part of the adoption.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related notes.
In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which is intended to simplify and amend the application of hedge accounting to more clearly portray the economics of an entity’s risk management strategies in its financial statements. The new guidance will make more financial and nonfinancial hedging strategies eligible for hedge accounting and reduce complexity in fair value hedges of interest rate risk. The new guidance also changes how companies assess effectiveness and amends the presentation and disclosure requirements. The new guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally the entire change in the fair value of a hedging instrument will be required to be presented in the same income statement line as the hedged item. The new guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The new guidance is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those years. Early adoption is permitted in any interim period or fiscal year before the effective date. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures.
In February 2018, the FASB issued ASU No. 2018-02, Income Statement- Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows entities the option to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act from accumulated other comprehensive income (OCI) to retained earnings. The new guidance allows the option to apply the guidance retrospectively or in the period of adoption. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures.
In March 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 ("SAB No. 118"), which allowed SEC registrants to record provisional amounts in earnings for the year ended December 31, 2017 due to the complexities involved in accounting for the enactment of the Tax Cuts and Jobs Act. The Company recognized the estimated income tax effects of the Tax Cuts and Jobs Act in its 2017 Consolidated Financial Statements in accordance with SAB No. 118.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
REVENUE RECOGNITION
 6 Months Ended
Jun. 30, 2018
Revenue from Contract with Customer [Abstract]  
REVENUE RECOGNITION
REVENUE RECOGNITION
On January 1, 2018, the Company adopted ASC 606 using the modified retrospective method for all contracts as of the date of adoption. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC 605, Revenue Recognition (ASC 605), which is also referred to herein as "legacy GAAP". The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of the Company's services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. ASC 606 requires companies to exercise more judgment and recognize revenue in accordance with the standard's core principle by applying the following five steps:
Step 1: Identify the contract with a customer.
Step 2: Identify the performance obligations in the contract.
Step 3: Determine the transaction price.
Step 4: Allocate the transaction price to the performance obligations in the contract.
Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.
Performance obligations are promises made in a contract to transfer a distinct good or service to the customer. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company has concluded that the contracts with patients and residents represent a bundle of distinct services that are substantially the same, with the same pattern of transfer to the customer. Accordingly, the promise to provide quality care is accounted for as a single performance obligation.
The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding state. It was determined that the contracts are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans).
In order to determine the transaction price, the Company estimates the amount of variable consideration at the beginning of the contract using the expected value method. The estimates consider (i) payor type, (ii) historical payment trends, (iii) the maturity of the portfolio, and (iv) geographic payment trends throughout a class of similar payors. The Company typically enters into agreements with third-party payors that provide for payments at amounts different from the established charges. These arrangement terms provide for subsequent settlement and cash flows that may occur well after the service is provided. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. Changes in the Company's expectation of the amount it will receive from the patient or third-party payors will be recorded in revenue unless there is a specific event that suggests the patient or third-party payor no longer has the ability and intent to pay the amount due and, therefore, the changes in its estimate of variable consideration better represent an impairment, or bad debt. These estimates are re-assessed each reporting period, and any amounts allocated to a satisfied performance obligation are recognized as revenue or a reduction of revenue in the period in which the transaction price changes.
The Company satisfies its performance obligation by providing quality of care services to its patients and residents on a daily basis until termination of the contract. The performance obligation is recognized on a time elapsed basis, by day, for which the services are provided. For these contracts, the Company has the right to consideration from the customer in an amount that directly corresponds with the value to the customer of the Company's performance to date. Therefore, the Company recognizes revenue based on the amount billable to the customer in accordance with the practical expedient in ASC 606-10-55-18. Additionally, because the Company applied ASC 606 using certain practical expedients, the Company elected not to disclose the aggregate amount of the transaction price for unsatisfied, or partially unsatisfied, performance obligations for all contracts with an original expected length of one year or less.
The Company incurs costs related to patient/resident contracts, such as legal and advertising expenses. The contract costs are expensed as incurred. They are not expected to be recovered and are not chargeable to the patient/resident regardless of whether the contract is executed.

Financial Statement Impact of Adopting ASC 606

The Company adopted ASC 606 using the modified retrospective method. The cumulative effect of applying the new guidance to all contracts with customers as of January 1, 2018 was not material to the interim consolidated financial statements. As a result of applying the modified retrospective method to adopt ASC 606, the following adjustments were made to our operating results:

 
Three Months Ended June 30, 2018
 
As Reported
 
Increase
(Decrease)
 
Balances as if the previous accounting guidance was in effect
Patient Revenues, net
$141,082
 
3,789
(362)
3,427
(a)
(b)
$144,509
Operating Expenses
$111,440
 
3,789
(a)
$115,229
Total Expenses
$140,489
 
3,789
(a)
$144,278

(a) Adjusts for the implicit price concession of bad debt expense.
(b) Adjusts for the implementation of ASC 606.

 
Six Months Ended June 30, 2018
 
As Reported
 
Increase
(Decrease)
 
Balances as if the previous accounting guidance was in effect
Patient Revenues, net
$282,367
 
7,252
(618)
6,634
(a)
(b)
$289,001
Operating Expenses
$223,718
 
7,252
(a)
$230,970
Total Expenses
$280,275
 
7,252
(a)
$287,527

(a) Adjusts for the implicit price concession of bad debt expense.
(b) Adjusts for the implementation of ASC 606.

 
As of June 30, 2018
 
As Reported
 
Increase
(Decrease)
 
Balances as if the previous accounting guidance was in effect
Accounts Receivable
$63,591
 
(618)
16,050
15,432
(a)
(b)
$79,023
Accumulated Deficit
$(15,673)
 
618
(198)
420
(a)
(c)

$(15,253)

(a) Adjusts for the implementation of ASC 606.
(b) Adjusts for a direct reduction of accounts receivable that would have been reflected as allowance for doubtful accounts in the consolidated balance sheet prior to the adoption of ASC 606.
(c) Reflects the tax adjustment for the ASC 606 adjustment of $618.

Disaggregation of Revenue
The following table summarizes revenue from contracts with customers by payor source for the periods presented (dollar amounts in thousands):

 
Three Months Ended June 30,
 
2018
 
2018
 
2017(1)
 
As reported
 
As Adjusted to Legacy GAAP
 
As reported
Medicaid
$
65,603

46.5
%
 
$
75,216

52.0
%
 
$
73,510

51.6
%
Medicare
27,863

19.7
%
 
36,079

25.0
%
 
38,900

27.3
%
Managed Care
13,303

9.4
%
 
11,888

8.2
%
 
9,959

7.0
%
Private Pay and other
34,313

24.4
%
 
21,326

14.8
%
 
20,181

14.1
%
Total
$
141,082

100.0
%
 
$
144,509

100.0
%
 
$
142,550

100.0
%
 
Six Months Ended June 30,
 
2018
 
2018
 
2017(1)
 
As reported
 
As Adjusted to Legacy GAAP
 
As reported
Medicaid
$
129,489

45.9
%
 
$
148,431

51.4
%
 
$
146,383

51.5
%
Medicare
57,614

20.4
%
 
74,217

25.7
%
 
76,911

27.1
%
Managed Care
27,515

9.7
%
 
23,980

8.3
%
 
20,764

7.3
%
Private Pay and other
67,749

24.0
%
 
42,373

14.6
%
 
39,992

14.1
%
Total
$
282,367

100.0
%
 
$
289,001

100.0
%
 
$
284,050

100.0
%

(1) As noted above, prior period amounts have not been adjusted under the application of the modified retrospective method.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
LONG-TERM DEBT AND INTEREST RATE SWAP
 6 Months Ended
Jun. 30, 2018
Debt Disclosure [Abstract]  
LONG-TERM DEBT AND INTEREST RATE SWAP
LONG-TERM DEBT AND INTEREST RATE SWAP
The Company has agreements with a syndicate of banks for a mortgage term loan ("Original Mortgage Loan") and the Company’s revolving credit agreement ("Original Revolver"). On February 26, 2016, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated April 30, 2013. The Credit Agreement increased the Company's borrowing capacity to $100,000 allocated between a $72,500 Mortgage Loan ("Amended Mortgage Loan") and a $27,500 Revolver ("Amended Revolver"). The Amended Mortgage Loan consists of a $60,000 term loan facility and a $12,500 acquisition loan facility. Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of $2,162 and are being amortized over the five-year term of the agreements.
Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original principal balance of $72,500 with a five-year maturity through February 26, 2021, and a $27,500 Amended Revolver through February 26, 2021. The Amended Mortgage Loan has a term of five years, with principal and interest payable monthly based on a 25-year amortization. Interest on the term and acquisition loan facilities is based on LIBOR plus 4.0% and 4.75%, respectively. A portion of the Amended Mortgage Loan is effectively fixed at 5.79% pursuant to an interest rate swap with an initial notional amount of $30,000. The Amended Mortgage Loan balance was $72,630 as of June 30, 2018, consisting of $63,630 on the term loan facility with an interest rate of 6.00% and $9,000 on the acquisition loan facility with an interest rate of 6.8%. The Amended Mortgage Loan is secured by eighteen owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized and cross-defaulted. The Company’s Amended Revolver has an interest rate of LIBOR plus 4.0% and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions.
Effective October 3, 2016, the Company entered into the Second Amendment ("Second Revolver Amendment") to amend the Amended Revolver. The Second Revolver Amendment increased the Amended Revolver capacity from the $27,500 in the Amended Revolver to $52,250; provided that the maximum revolving facility be reduced to $42,250 on August 1, 2017. Subsequently, on June 30, 2017, the Company executed a Fourth Amendment (the "Fourth Revolver Amendment") to amend the Amended Revolver, which modifies the capacity of the revolver to remain at $52,250.
On December 29, 2016, the Company executed a Third Amendment ("Third Revolver Amendment") to amend the Amended Revolver. The Third Amendment modified the terms of the Amended Mortgage Loan Agreement by increasing the Company’s letter of credit sublimit from $10,000 to $15,000.
Effective June 30, 2017, the Company entered into a Second Amendment ("Second Term Amendment") to amend the Amended Mortgage Loan. The Second Term Amendment amended the terms of the Amended Mortgage Loan Agreement by increasing the Company's term loan facility by $7,500.
Effective February 27, 2018, the Company executed a Fifth Amendment to the Amended Revolver and a Third Amendment to the Amended Mortgage Loan. Under the terms of the Amendments, the minimum fixed charge coverage ratio shall not be less than 1.01 to 1.00 as of March 31, 2018 and for each quarter thereafter.
As of June 30, 2018, the Company had $15,000 borrowings outstanding under the Amended Revolver compared to $16,000 outstanding as of December 31, 2017. The outstanding borrowings on the revolver were used primarily to compensate for accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through the change in ownership process with Centers for Medicare & Medicaid Services (“CMS”). Annual fees for letters of credit issued under the Amended Revolver are 3.0% of the amount outstanding. The Company has eleven letters of credit with a total value of $13,714 outstanding as of June 30, 2018. Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of $36,891 the balance available for borrowing under the Amended Revolver was $8,177 at June 30, 2018.
The Company’s debt agreements contain various financial covenants, the most restrictive of which relates to debt service coverage ratios. The Company is in compliance with all such covenants at June 30, 2018.
Interest Rate Swap Transaction
As part of the debt agreements entered into in April 2013, the Company entered into an interest rate swap agreement with a member of the bank syndicate as the counterparty. The Company designated its interest rate swap as a cash flow hedge and the earnings component of the hedge, net of taxes, is reflected as a component of other comprehensive income (loss). In conjunction with the February 26, 2016 amendment to the Credit Agreement, the Company amended the terms of its interest rate swap. The interest rate swap agreement has the same effective date and maturity date as the Amended Mortgage Loan, and has an amortizing notional amount that was $28,135 as of June 30, 2018. The interest rate swap agreement requires the Company to make fixed rate payments to the bank calculated on the applicable notional amount at an annual fixed rate of 5.79% while the bank is obligated to make payments to the Company based on LIBOR on the same notional amount.
The Company assesses the effectiveness of its interest rate swap on a quarterly basis, and at June 30, 2018, the Company determined that the interest rate swap was highly effective. The interest rate swap valuation model indicated a net asset of $606 at June 30, 2018. The fair value of the interest rate swap is included in “other noncurrent assets” on the Company’s interim consolidated balance sheet. The asset related to the change in the interest rate swap included in accumulated other comprehensive income at June 30, 2018 is $412 net of the income tax provision of $194. As the Company’s interest rate swap is not traded on a market exchange, the fair value is determined using a valuation based on a discounted cash flow analysis. This analysis reflects the contractual terms of the interest rate swap agreement and uses observable market-based inputs, including estimated future LIBOR interest rates. The interest rate swap valuation is classified in Level 2 of the fair value hierarchy, in accordance with the FASB guidance set forth in ASC 820, Fair Value Measurement.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
COMMITMENTS AND CONTINGENCIES
 6 Months Ended
Jun. 30, 2018
Health Care Organizations [Abstract]  
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES
Professional Liability and Other Liability Insurance
The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. All of the Company's nursing centers in Florida, and Tennessee are now covered under the captive insurance policies along with many of the nursing centers in Alabama, Kentucky, and Texas. The insurance coverage provided for these centers under the SHC policy provides coverage limits of at least $500 per medical incident with a sublimit per center of $1,000 and total annual aggregate policy limits of $5,000. All other centers within the Company's portfolio are covered through various commercial insurance policies which provide similar coverage limits per medical incident, per location, and on an aggregate basis for covered centers. The deductibles for these policies are covered through the insurance subsidiary.
Reserve for Estimated Self-Insured Professional Liability Claims
Because the Company’s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company’s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of $24,229 as of June 30, 2018. This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period.
The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of this reserve. Since May 2012, Merlinos & Associates, Inc. (“Merlinos”) has assisted management in the preparation of the appropriate accrual for incurred but not reported general and professional liability claims based on data furnished as of May 31 and November 30 of each year. Merlinos primarily utilizes historical data regarding the frequency and cost of the Company's past claims over a multi-year period, industry data and information regarding the number of occupied beds to develop its estimates of the Company's ultimate professional liability cost for current periods.
On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company’s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator’s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company’s evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period.
As of June 30, 2018, the Company is engaged in 79 professional liability lawsuits. Eleven lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company’s cash expenditures for self-insured professional liability costs from continuing operations were $2,775 and $4,338 for the six months ended June 30, 2018 and 2017, respectively.
The Company follows the FASB ASU, "Presentation of Insurance Claims and Related Insurance Recoveries," that clarifies that a health care entity should not net insurance recoveries against a related professional liability claim and that the amount of the claim liability should be determined without consideration of insurance recoveries. Accordingly, the estimated insurance recovery receivables are included within "Other Current Assets" and "Other Noncurrent Assets" on the Consolidated Balance Sheet. As of June 30, 2018 there are estimated insurance recovery receivables of $3,080.
Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company’s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company’s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company’s reported earnings and financial position for the period in which the change in accrual is made.
Civil Investigative Demand ("CID")
In July 2013, the Company learned that the United States Attorney for the Middle District of Tennessee ("DOJ") had commenced a civil investigation of potential violations of the False Claims Act ("FCA").
In October 2014, the Company learned that the investigation was started by the filing under seal of a false claims action against the two centers that were subject of the original civil investigative demand ("CID"). In connection with this matter, between July 2013 and early February 2016, the Company received three civil investigative demands (a form of subpoena) for documents. The Company has responded to those demands and also provided voluntarily additional information requested by the DOJ. The DOJ has also taken testimony from current and former employees of the Company. In May 2018, the Company learned that a second FCA complaint had been filed in late 2016 relating to the Company’s practices and policies for rehabilitation therapy at some of its facilities. The government’s investigation relates to the Company’s practices and policies for rehabilitation and other services at all of its facilities, for preadmission evaluation forms ("PAEs") required by TennCare and for Pre-Admission Screening and Resident Reviews ("PASRRs") required by the Medicare program.
In June 2016, the Company received an authorized investigative demand (a form of subpoena) for documents in connection with a criminal investigation by the DOJ related to our practices with respect to PAEs and PASRRs, and the Company has provided documents responsive to this subpoena and continues to provide additional information as requested. The Company cannot predict the outcome of these investigations or the related lawsuits, and the outcome could have a materially adverse effect on the Company, including the imposition of treble damages, criminal charges, fines, penalties and/or a corporate integrity agreement. Additionally, the uncertainty regarding the outcome of this investigation makes it more difficult for the Company to pursue strategic possibilities, longer term initiatives or to make significant financial commitments outside of the normal course of its business. The Company is committed to provide caring and professional services to its patients and residents in compliance with applicable laws and regulations.
Other Insurance
With respect to workers’ compensation insurance, substantially all of the Company’s employees became covered under either a prefunded deductible policy or state-sponsored programs. The Company has been and remains a non-subscriber to the Texas workers’ compensation system and is, therefore, completely self-insured for employee injuries with respect to its Texas operations. From June 30, 2003 until June 30, 2007, the Company’s workers’ compensation insurance programs provided coverage for claims incurred with premium adjustments depending on incurred losses. For the period from July 1, 2007 until June 30, 2008, the Company is completely insured for workers' compensation exposure. From the period from July 1, 2008 through June 30, 2018, the Company is covered by a prefunded deductible policy. Under this policy, the Company is self-insured for the first $500 per claim, subject to an aggregate maximum of $3,000. The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers’ compensation claims is $593 at June 30, 2018. The Company has a non-current receivable for workers’ compensation policies covering previous years of $1,030 as of June 30, 2018. The non-current receivable is a function of payments paid to the Company’s insurance carrier in excess of the estimated level of claims expected to be incurred.
As of June 30, 2018, the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to $200 per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims is $1,615 at June 30, 2018. The differences between actual settlements and reserves are included in expense in the period finalized.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
STOCK-BASED COMPENSATION
 6 Months Ended
Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
STOCK-BASED COMPENSATION
STOCK-BASED COMPENSATION

Overview of Plans
In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (“Stock Purchase Plan”). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers. The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (“RSU's”) at 85% of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally two years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period. In June 2016, our shareholders approved an amendment to the Stock Purchase Plan to increase the number of shares of our common stock authorized under the Plan from 150 shares to 350 shares. No grants can be made under the Stock Purchase Plan after April 25, 2028.
In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (“2010 Plan”), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. In June 2017, our shareholders approved an amendment to the Long-Term Incentive Plan to increase the number of shares of our common stock authorized under the Plan from 380 shares to 680 shares. No grants can be made under the 2010 Plan after May 31, 2027.
Equity Grants and Valuations
During the six months ended June 30, 2018 and 2017, the Compensation Committee of the Board of Directors approved grants totaling approximately 90 and 88 shares of restricted common stock to certain employees and members of the Board of Directors, respectively. The fair value of restricted shares is determined as the quoted market price of the underlying common shares at the date of the grant. The restricted shares typically vest 33% on the first, second and third anniversaries of the grant date. Generally, unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. Upon vesting, all restrictions are removed.
Prior to 2017, the Compensation Committee of the Board of Directors also approved grants of Stock Only Stock Appreciation Rights (“SOSARs”) and Stock Options at the market price of the Company's common stock on the grant date. The SOSARs and Options vest 33% on the first, second and third anniversaries of the grant date, and expire 10 years from the grant date.
In computing the fair value estimates using the Black-Scholes-Merton valuation method, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.
Summarized activity of the equity compensation plans is presented below:
 
 
 
Weighted
 
Options/
 
Average
 
SOSARs
 
Exercise Price
Outstanding, December 31, 2017
211

 
$
6.64

Granted
30

 
8.14

Exercised
—

 
—

Expired or cancelled
(15
)
 
10.81

Outstanding, June 30, 2018
226

 
$
6.56

 
 
 
 
Exercisable, June 30, 2018
206

 
$
6.41


 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Shares
 
Fair Value
Outstanding, December 31, 2017
164

 
$
9.95

Granted
90

 
8.14

Dividend Equivalents
3

 
7.15

Vested
(79
)
 
10.27

Cancelled
(7
)
 
9.62

Outstanding, June 30, 2018
171

 
$
8.81


Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:
 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Share Units
 
Fair Value
Outstanding, December 31, 2017
44

 
$
9.59

Granted
16

 
8.14

Dividend Equivalents
1

 
7.14

Vested
(17
)
 
8.91

Outstanding, June 30, 2018
44

 
$
9.28



The SOSARs and Options were valued and recorded in the same manner, and, other than amounts that may be settled pursuant to employment agreements with certain members of management, will be settled with issuance of new stock for the difference between the market price on the date of exercise and the exercise price. The Company estimated the total recognized and unrecognized compensation related to SOSARs and stock options using the Black-Scholes-Merton equity grant valuation model.

In computing the fair value estimates using the Black-Scholes-Merton valuation model, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock.

The following table summarizes information regarding stock options and SOSAR grants outstanding as of June 30, 2018:
 
 
Weighted
 
 
 
 
 
 
 
 
 
 
Average
 
 
 
Intrinsic
 
 
 
Intrinsic
Range of
 
Exercise
 
Grants
 
Value-Grants
 
Grants
 
Value-Grants
Exercise Prices
 
Prices
 
Outstanding
 
Outstanding
 
Exercisable
 
Exercisable
$8.14 to $10.80
 
$
9.32

 
60

 
$
—

 
40

 
$
—

$2.37 to $6.21
 
$
5.56

 
166

 
$
206

 
166

 
$
206

 
 
 
 
226

 
 
 
206

 
 

Stock-based compensation expense is non-cash and is included as a component of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. The Company recorded total stock-based compensation expense of $765 and $504 in the six month periods ended June 30, 2018 and 2017, respectively.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
EARNINGS PER COMMON SHARE
 6 Months Ended
Jun. 30, 2018
Earnings Per Share [Abstract]  
EARNINGS PER COMMON SHARE
EARNINGS PER COMMON SHARE
Information with respect to basic and diluted net income per common share is presented below in thousands, except per share:
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2018
 
2017
 
2018
 
2017
Net income (loss)
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
(307
)
 
$
381

 
$
(388
)
 
$
1,729

Loss from discontinued operations, net of income taxes
(4
)
 
(28
)
 
(26
)
 
(43
)
Net income (loss)
$
(311
)
 
$
353

 
$
(414
)
 
$
1,686

 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2018
 
2017
 
2018
 
2017
Net income (loss) per common share:
 
 
 
 
 
 
 
Per common share – basic
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
(0.05
)
 
$
0.06

 
$
(0.06
)
 
$
0.28

Loss from discontinued operations
—

 
—

 
—

 
(0.01
)
Net income (loss) per common share – basic
$
(0.05
)
 
$
0.06

 
$
(0.06
)
 
$
0.27

Per common share – diluted
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
(0.05
)
 
$
0.06

 
$
(0.06
)
 
$
0.27

Loss from discontinued operations
—

 
—

 
—

 
(0.01
)
Net income (loss) per common share – diluted
$
(0.05
)
 
$
0.06

 
$
(0.06
)
 
$
0.26

Weighted Average Common Shares Outstanding:
 
 
 
 
 
 
 
Basic
6,370

 
6,294

 
6,342

 
6,263

Diluted
6,370

 
6,472

 
6,342

 
6,458


The effects of 226 and 46 SOSARs and options outstanding were excluded from the computation of diluted earnings per common share in the six months ended June 30, 2018 and 2017, respectively, because these securities would have been anti-dilutive.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS
 6 Months Ended
Jun. 30, 2018
Business Combinations [Abstract]  
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS
2017 Acquisition
During the year ended December 31, 2017, the Company expanded its operations to acquire a center that complements its current portfolio. On June 8, 2017, the Company entered into an Asset Purchase Agreement (the "Purchase Agreement") with Park Place Nursing and Rehabilitation Center, LLC, Dunn Nursing Home, Inc., Wood Properties of Selma LLC, and Homewood of Selma, LLC to acquire a 103-bed skilled nursing center in Selma, Alabama, for an aggregate purchase price of $8,750. In connection with the funding of the acquisition, on June 30, 2017, the Company amended the terms of its Second Amended and Restated Term Loan Agreement to increase the facility by $7,500, which is described in Note 5 to the interim consolidated financial statements herein. The acquisition transaction closed on July 1, 2017. In accordance with ASC 805, this transaction was accounted for as a business combination, which resulted in the expensing of $140 of acquisition costs and a $925 recorded gain on bargain purchase for the Company for the year ended December 31, 2017. The operating results of the acquired center have been included in the Company's consolidated statement of operations since the acquisition date. Supplemental pro forma information regarding the acquisition is not material to the consolidated financial statements. The allocation of the purchase price to the net assets acquired is as follows:
 
 
Park Place
Purchase Price
 
$
8,750

Gain on bargain purchase
 
925

 
 
$
9,675

 
 
 
Allocation:
 
 
Building
 
$
8,435

Land
 
760

Land Improvements
 
145

Furniture, Fixtures and Equipment
 
335

 
 
$
9,675


2018 Assets Held for Sale
During the first quarter of 2018, three of the Company's skilled nursing facilities met the accounting criteria to be classified as held for sale, but did not meet the accounting criteria to be reported as discontinued operations. The Company is selling the property and equipment affiliated with these centers. The recorded values of these centers' assets are $13,269. The centers' assets are classified as held for sale in the accompanying interim consolidated balance sheets.
2017 Lease Termination
On September 30, 2017, the Company entered into an Agreement with Trend Health and Rehab of Carthage, LLC ("Trend Health") to terminate the lease and the Company's right of possession of the center in Carthage, Mississippi. In consideration of the early termination of the lease, Trend Health provided the Company with a $250 cash termination payment which is included in lease termination receipts in the accompanying interim consolidated statements of operations for the year ended December 31, 2017. For accounting purposes, this transaction was not reported as a discontinued operation as this disposal did not represent a strategic shift that has (or will have) a major effect on the Company's operations and financial results.
2016 Sale of Investment in Unconsolidated Affiliate
On October 28, 2016, the Company and its partners entered into an asset purchase agreement to sell the pharmacy joint venture. The sale resulted in a $1,366 gain in the fourth quarter of 2016. Subsequently, the Company recognized additional gains of $308 and $733 for the six-month periods ended June 30, 2018 and 2017, respectively, related to the liquidation of remaining assets affiliated with the partnership.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
SUBSEQUENT EVENTS
 6 Months Ended
Jun. 30, 2018
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS

On July 8, 2018 the Company entered into a membership interest purchase agreement with ALS Ontario Operating, Inc. to sell all of the issued and outstanding membership units of the Ontario Pointe facility. The transaction is expected to become effective in the third quarter of 2018.

On July 9, 2018 the Board of Directors of Diversicare Healthcare Services, Inc. announced the retirement of Kelly Gill as President, Chief Executive Officer and Board member of the Company, effective July 6, 2018. As a result of Mr. Gill's retirement, the Company recorded $1,172 in severance related expenses inclusive of $259 in additional stock based compensation expense in the second quarter of 2018. In accordance with Mr. Gill's employment agreement, the Company determined that the benefits to which Mr. Gill was entitled were probable of being paid. The Company also announced the appointment of James R. McKnight, Jr. as President and Chief Executive Officer of the Company.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Policies)
 6 Months Ended
Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Consolidation
The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation.
Basis of Accounting
The interim consolidated financial statements for the three and six month periods ended June 30, 2018 and 2017, included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at June 30, 2018, and the results of operations for the three and six month periods ended June 30, 2018 and 2017, and cash flows for the six month periods ended June 30, 2018 and 2017. The Company’s balance sheet information at December 31, 2017, was derived from its audited consolidated financial statements as of December 31, 2017.
Effective January 1, 2018, we adopted the requirements of Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606), as discussed in Notes 3 and 4 to the interim consolidated financial statements. All amounts and disclosures set forth in this Form 10-Q have been updated to comply with the new standard.
The results of operations for the periods ended June 30, 2018 and 2017 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017.
Recent Accounting Guidance
Recent Accounting Standards Adopted by the Company
In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. Topic 606 is effective for annual and interim reporting periods beginning after December 15, 2017. The Company adopted the requirements of this standard effective January 1, 2018. The Company elected to apply the modified retrospective approach with the cumulative transition effect recognized in beginning retained earnings as of the date of adoption. The impact of the implementation to the consolidated financial statements for periods subsequent to adoption is not material. See Note 4, "Revenue Recognition" for a discussion regarding revenue recognition under the new standard.
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU was issued as part of the FASB Simplification Initiative and involves several aspects of accounting for share-based payment transactions, including the income tax consequences and classification on the statement of cash flows. We adopted this standard as of January 1, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230). The ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The ASU is effective for annual and interim periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018 using a retrospective approach. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires that the Statement of Cash Flows explain the changes during the period of cash and cash equivalents inclusive of amounts categorized as Restricted Cash. As a result, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018. The adoption did not have a material impact on our financial position, results of operations or cash flows.
In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) - Clarifying the Definition of a Business, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The adoption is effective for annual and interim periods beginning after December 15, 2017. The Company will evaluate future acquisitions under this guidance, which may result in future acquisitions being accounted for as asset acquisitions.
In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The amended standard specifies the modification accounting applicable to any entity which changes the terms or conditions of a share-based payment award. The new guidance is effective for all entities after December 15, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows.
Accounting Standards Recently Issued But Not Yet Adopted by the Company
In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. Disclosures will be required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. We anticipate this standard will have a material impact on our consolidated financial position and results of operations. We have organized an implementation group of cross-functional departmental management to ensure the completeness of our lease information, analyze the appropriate classification of current leases under the new standard, and develop new processes to execute, approve and classify leases on an ongoing basis. We have also implemented software tools and processes to maintain lease information critical to applying the new standard. We are continuing to evaluate the extent of this anticipated impact on our consolidated financial position and results of operations and the quantitative and qualitative factors that will impact the Company as part of the adoption.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related notes.
In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which is intended to simplify and amend the application of hedge accounting to more clearly portray the economics of an entity’s risk management strategies in its financial statements. The new guidance will make more financial and nonfinancial hedging strategies eligible for hedge accounting and reduce complexity in fair value hedges of interest rate risk. The new guidance also changes how companies assess effectiveness and amends the presentation and disclosure requirements. The new guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally the entire change in the fair value of a hedging instrument will be required to be presented in the same income statement line as the hedged item. The new guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The new guidance is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those years. Early adoption is permitted in any interim period or fiscal year before the effective date. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures.
In February 2018, the FASB issued ASU No. 2018-02, Income Statement- Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows entities the option to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act from accumulated other comprehensive income (OCI) to retained earnings. The new guidance allows the option to apply the guidance retrospectively or in the period of adoption. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures.
In March 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 ("SAB No. 118"), which allowed SEC registrants to record provisional amounts in earnings for the year ended December 31, 2017 due to the complexities involved in accounting for the enactment of the Tax Cuts and Jobs Act. The Company recognized the estimated income tax effects of the Tax Cuts and Jobs Act in its 2017 Consolidated Financial Statements in accordance with SAB No. 118.
Revenue Recognition
On January 1, 2018, the Company adopted ASC 606 using the modified retrospective method for all contracts as of the date of adoption. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC 605, Revenue Recognition (ASC 605), which is also referred to herein as "legacy GAAP". The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of the Company's services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. ASC 606 requires companies to exercise more judgment and recognize revenue in accordance with the standard's core principle by applying the following five steps:
Step 1: Identify the contract with a customer.
Step 2: Identify the performance obligations in the contract.
Step 3: Determine the transaction price.
Step 4: Allocate the transaction price to the performance obligations in the contract.
Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.
Performance obligations are promises made in a contract to transfer a distinct good or service to the customer. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company has concluded that the contracts with patients and residents represent a bundle of distinct services that are substantially the same, with the same pattern of transfer to the customer. Accordingly, the promise to provide quality care is accounted for as a single performance obligation.
The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding state. It was determined that the contracts are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans).
In order to determine the transaction price, the Company estimates the amount of variable consideration at the beginning of the contract using the expected value method. The estimates consider (i) payor type, (ii) historical payment trends, (iii) the maturity of the portfolio, and (iv) geographic payment trends throughout a class of similar payors. The Company typically enters into agreements with third-party payors that provide for payments at amounts different from the established charges. These arrangement terms provide for subsequent settlement and cash flows that may occur well after the service is provided. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. Changes in the Company's expectation of the amount it will receive from the patient or third-party payors will be recorded in revenue unless there is a specific event that suggests the patient or third-party payor no longer has the ability and intent to pay the amount due and, therefore, the changes in its estimate of variable consideration better represent an impairment, or bad debt. These estimates are re-assessed each reporting period, and any amounts allocated to a satisfied performance obligation are recognized as revenue or a reduction of revenue in the period in which the transaction price changes.
The Company satisfies its performance obligation by providing quality of care services to its patients and residents on a daily basis until termination of the contract. The performance obligation is recognized on a time elapsed basis, by day, for which the services are provided. For these contracts, the Company has the right to consideration from the customer in an amount that directly corresponds with the value to the customer of the Company's performance to date. Therefore, the Company recognizes revenue based on the amount billable to the customer in accordance with the practical expedient in ASC 606-10-55-18. Additionally, because the Company applied ASC 606 using certain practical expedients, the Company elected not to disclose the aggregate amount of the transaction price for unsatisfied, or partially unsatisfied, performance obligations for all contracts with an original expected length of one year or less.
The Company incurs costs related to patient/resident contracts, such as legal and advertising expenses. The contract costs are expensed as incurred. They are not expected to be recovered and are not chargeable to the patient/resident regardless of whether the contract is executed.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
REVENUE RECOGNITION (Tables)
 6 Months Ended
Jun. 30, 2018
Revenue from Contract with Customer [Abstract]  
Schedule of New Accounting Pronouncements and Changes in Accounting Principles
As a result of applying the modified retrospective method to adopt ASC 606, the following adjustments were made to our operating results:

 
Three Months Ended June 30, 2018
 
As Reported
 
Increase
(Decrease)
 
Balances as if the previous accounting guidance was in effect
Patient Revenues, net
$141,082
 
3,789
(362)
3,427
(a)
(b)
$144,509
Operating Expenses
$111,440
 
3,789
(a)
$115,229
Total Expenses
$140,489
 
3,789
(a)
$144,278

(a) Adjusts for the implicit price concession of bad debt expense.
(b) Adjusts for the implementation of ASC 606.

 
Six Months Ended June 30, 2018
 
As Reported
 
Increase
(Decrease)
 
Balances as if the previous accounting guidance was in effect
Patient Revenues, net
$282,367
 
7,252
(618)
6,634
(a)
(b)
$289,001
Operating Expenses
$223,718
 
7,252
(a)
$230,970
Total Expenses
$280,275
 
7,252
(a)
$287,527

(a) Adjusts for the implicit price concession of bad debt expense.
(b) Adjusts for the implementation of ASC 606.

 
As of June 30, 2018
 
As Reported
 
Increase
(Decrease)
 
Balances as if the previous accounting guidance was in effect
Accounts Receivable
$63,591
 
(618)
16,050
15,432
(a)
(b)
$79,023
Accumulated Deficit
$(15,673)
 
618
(198)
420
(a)
(c)

$(15,253)

(a) Adjusts for the implementation of ASC 606.
(b) Adjusts for a direct reduction of accounts receivable that would have been reflected as allowance for doubtful accounts in the consolidated balance sheet prior to the adoption of ASC 606.
(c) Reflects the tax adjustment for the ASC 606 adjustment of $618.
Disaggregation of Revenue
The following table summarizes revenue from contracts with customers by payor source for the periods presented (dollar amounts in thousands):

 
Three Months Ended June 30,
 
2018
 
2018
 
2017(1)
 
As reported
 
As Adjusted to Legacy GAAP
 
As reported
Medicaid
$
65,603

46.5
%
 
$
75,216

52.0
%
 
$
73,510

51.6
%
Medicare
27,863

19.7
%
 
36,079

25.0
%
 
38,900

27.3
%
Managed Care
13,303

9.4
%
 
11,888

8.2
%
 
9,959

7.0
%
Private Pay and other
34,313

24.4
%
 
21,326

14.8
%
 
20,181

14.1
%
Total
$
141,082

100.0
%
 
$
144,509

100.0
%
 
$
142,550

100.0
%
 
Six Months Ended June 30,
 
2018
 
2018
 
2017(1)
 
As reported
 
As Adjusted to Legacy GAAP
 
As reported
Medicaid
$
129,489

45.9
%
 
$
148,431

51.4
%
 
$
146,383

51.5
%
Medicare
57,614

20.4
%
 
74,217

25.7
%
 
76,911

27.1
%
Managed Care
27,515

9.7
%
 
23,980

8.3
%
 
20,764

7.3
%
Private Pay and other
67,749

24.0
%
 
42,373

14.6
%
 
39,992

14.1
%
Total
$
282,367

100.0
%
 
$
289,001

100.0
%
 
$
284,050

100.0
%

(1) As noted above, prior period amounts have not been adjusted under the application of the modified retrospective method.
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
STOCK-BASED COMPENSATION (Tables)
 6 Months Ended
Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Summarized activity of equity compensation plans
Summarized activity of the equity compensation plans is presented below:
 
 
 
Weighted
 
Options/
 
Average
 
SOSARs
 
Exercise Price
Outstanding, December 31, 2017
211

 
$
6.64

Granted
30

 
8.14

Exercised
—

 
—

Expired or cancelled
(15
)
 
10.81

Outstanding, June 30, 2018
226

 
$
6.56

 
 
 
 
Exercisable, June 30, 2018
206

 
$
6.41
Schedule of summarized activity of Restricted Share Units
 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Shares
 
Fair Value
Outstanding, December 31, 2017
164

 
$
9.95

Granted
90

 
8.14

Dividend Equivalents
3

 
7.15

Vested
(79
)
 
10.27

Cancelled
(7
)
 
9.62

Outstanding, June 30, 2018
171

 
$
8.81


Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows:
 
 
 
Weighted
 
 
 
Average
 
Restricted
 
Grant Date
 
Share Units
 
Fair Value
Outstanding, December 31, 2017
44

 
$
9.59

Granted
16

 
8.14

Dividend Equivalents
1

 
7.14

Vested
(17
)
 
8.91

Outstanding, June 30, 2018
44

 
$
9.28
Schedule of summarized information regarding stock options and SOSAR grants outstanding
The following table summarizes information regarding stock options and SOSAR grants outstanding as of June 30, 2018:
 
 
Weighted
 
 
 
 
 
 
 
 
 
 
Average
 
 
 
Intrinsic
 
 
 
Intrinsic
Range of
 
Exercise
 
Grants
 
Value-Grants
 
Grants
 
Value-Grants
Exercise Prices
 
Prices
 
Outstanding
 
Outstanding
 
Exercisable
 
Exercisable
$8.14 to $10.80
 
$
9.32

 
60

 
$
—

 
40

 
$
—

$2.37 to $6.21
 
$
5.56

 
166

 
$
206

 
166

 
$
206

 
 
 
 
226

 
 
 
206

 
 
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
EARNINGS PER COMMON SHARE (Tables)
 6 Months Ended
Jun. 30, 2018
Earnings Per Share [Abstract]  
Basic and diluted net income (loss) per common share
Information with respect to basic and diluted net income per common share is presented below in thousands, except per share:
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2018
 
2017
 
2018
 
2017
Net income (loss)
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
(307
)
 
$
381

 
$
(388
)
 
$
1,729

Loss from discontinued operations, net of income taxes
(4
)
 
(28
)
 
(26
)
 
(43
)
Net income (loss)
$
(311
)
 
$
353

 
$
(414
)
 
$
1,686

 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2018
 
2017
 
2018
 
2017
Net income (loss) per common share:
 
 
 
 
 
 
 
Per common share – basic
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
(0.05
)
 
$
0.06

 
$
(0.06
)
 
$
0.28

Loss from discontinued operations
—

 
—

 
—

 
(0.01
)
Net income (loss) per common share – basic
$
(0.05
)
 
$
0.06

 
$
(0.06
)
 
$
0.27

Per common share – diluted
 
 
 
 
 
 
 
Income (loss) from continuing operations
$
(0.05
)
 
$
0.06

 
$
(0.06
)
 
$
0.27

Loss from discontinued operations
—

 
—

 
—

 
(0.01
)
Net income (loss) per common share – diluted
$
(0.05
)
 
$
0.06

 
$
(0.06
)
 
$
0.26

Weighted Average Common Shares Outstanding:
 
 
 
 
 
 
 
Basic
6,370

 
6,294

 
6,342

 
6,263

Diluted
6,370

 
6,472

 
6,342

 
6,458
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS (Tables)
 6 Months Ended
Jun. 30, 2018
Business Combinations [Abstract]  
Schedule of allocation for net assets acquired
The allocation of the purchase price to the net assets acquired is as follows:
 
 
Park Place
Purchase Price
 
$
8,750

Gain on bargain purchase
 
925

 
 
$
9,675

 
 
 
Allocation:
 
 
Building
 
$
8,435

Land
 
760

Land Improvements
 
145

Furniture, Fixtures and Equipment
 
335

 
 
$
9,675
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
BUSINESS (Details)
Jun. 30, 2018
state
center
bed
Accounting Policies [Line Items]  
Number of states in which entity operates | state 10
Number of nursing centers | center 76
Number of licensed nursing beds 8,456
Number of nursing center facilities owned | center 18
Number of nursing center facilities leased | center 58
Number of licensed assisted and residential living beds 497
Minimum  
Accounting Policies [Line Items]  
Number of licensed nursing beds per center 48
Maximum  
Accounting Policies [Line Items]  
Number of licensed nursing beds per center 320
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Details)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Dec. 31, 2016
USD ($)
investment
Jun. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Schedule of Equity Method Investments [Line Items]          
Number of equity method investments sold | investment     1    
Gain on sale of investment in unconsolidated affiliate $ 308 $ 0   $ 308 $ 733
Unnamed pharmacy joint venture          
Schedule of Equity Method Investments [Line Items]          
Gain on sale of investment in unconsolidated affiliate     $ 1,366 $ 308 $ 733
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
REVENUE RECOGNITION - Adjustments to Operating Results (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]          
Patient Revenues, net $ 141,082 $ 142,550 $ 282,367 $ 284,050  
Operating Expenses 111,440 113,166 223,718 223,833  
Total Expenses 140,489 $ 140,494 280,275 $ 279,034  
Accounts Receivable 63,591   63,591    
Accumulated Deficit (15,673)   (15,673)   $ (14,534)
Difference Between Revenue Guidance In Effect before And After Topic 606, Adjustment For Implicit Price Concession Of Bad Debt Expense | Accounting Standards Update 2014-09          
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]          
Patient Revenues, net 3,789   7,252    
Difference Between Revenue Guidance In Effect before And After Topic 606, Adjustment For Implementation | Accounting Standards Update 2014-09          
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]          
Patient Revenues, net (362)   (618)    
Accounts Receivable (618)   (618)    
Accumulated Deficit 618   618    
Difference Between Revenue Guidance In Effect before And After Topic 606, Allowance For Doubtful Accounts | Accounting Standards Update 2014-09          
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]          
Accounts Receivable 16,050   16,050    
Difference Between Revenue Guidance In Effect before And After Topic 606, Tax Adjustment | Accounting Standards Update 2014-09          
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]          
Accumulated Deficit (198)   (198)    
Difference between Revenue Guidance in Effect before and after Topic 606 | Accounting Standards Update 2014-09          
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]          
Patient Revenues, net 3,427   6,634    
Operating Expenses 3,789   7,252    
Total Expenses 3,789   7,252    
Accounts Receivable 15,432   15,432    
Accumulated Deficit 420   420    
Calculated under Revenue Guidance in Effect before Topic 606          
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]          
Patient Revenues, net 144,509   289,001    
Operating Expenses 115,229   230,970    
Total Expenses 144,278   287,527    
Accounts Receivable 79,023   79,023    
Accumulated Deficit $ (15,253)   $ (15,253)    
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
REVENUE RECOGNITION - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Disaggregation of Revenue [Line Items]        
Total revenues $ 141,082   $ 282,367  
Total revenues, as a percent 100.00%   100.00%  
Medicaid        
Disaggregation of Revenue [Line Items]        
Total revenues $ 65,603   $ 129,489  
Total revenues, as a percent 46.50%   45.90%  
Medicare        
Disaggregation of Revenue [Line Items]        
Total revenues $ 27,863   $ 57,614  
Total revenues, as a percent 19.70%   20.40%  
Managed Care        
Disaggregation of Revenue [Line Items]        
Total revenues $ 13,303   $ 27,515  
Total revenues, as a percent 9.40%   9.70%  
Private Pay and other        
Disaggregation of Revenue [Line Items]        
Total revenues $ 34,313   $ 67,749  
Total revenues, as a percent 24.40%   24.00%  
Calculated under Revenue Guidance in Effect before Topic 606        
Disaggregation of Revenue [Line Items]        
Total revenues $ 144,509 $ 142,550 $ 289,001 $ 284,050
Total revenues, as a percent 100.00% 100.00% 100.00% 100.00%
Calculated under Revenue Guidance in Effect before Topic 606 | Medicaid        
Disaggregation of Revenue [Line Items]        
Total revenues $ 75,216 $ 73,510 $ 148,431 $ 146,383
Total revenues, as a percent 52.00% 51.60% 51.40% 51.50%
Calculated under Revenue Guidance in Effect before Topic 606 | Medicare        
Disaggregation of Revenue [Line Items]        
Total revenues $ 36,079 $ 38,900 $ 74,217 $ 76,911
Total revenues, as a percent 25.00% 27.30% 25.70% 27.10%
Calculated under Revenue Guidance in Effect before Topic 606 | Managed Care        
Disaggregation of Revenue [Line Items]        
Total revenues $ 11,888 $ 9,959 $ 23,980 $ 20,764
Total revenues, as a percent 8.20% 7.00% 8.30% 7.30%
Calculated under Revenue Guidance in Effect before Topic 606 | Private Pay and other        
Disaggregation of Revenue [Line Items]        
Total revenues $ 21,326 $ 20,181 $ 42,373 $ 39,992
Total revenues, as a percent 14.80% 14.10% 14.60% 14.10%
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
LONG-TERM DEBT AND INTEREST RATE SWAP (Details)
 3 Months Ended
Feb. 26, 2016
USD ($)
center
Mar. 31, 2018
Jun. 30, 2018
USD ($)
letter_of_credit
Dec. 31, 2017
USD ($)
Aug. 01, 2017
USD ($)
Jun. 30, 2017
USD ($)
Dec. 29, 2016
USD ($)
Dec. 28, 2016
USD ($)
Oct. 03, 2016
USD ($)
Line of Credit Facility [Line Items]                  
Accumulated other comprehensive income (loss)     $ 1,013,000 $ 709,000          
Interest rate swap                  
Line of Credit Facility [Line Items]                  
Notional amount of interest rate derivatives     $ 28,135,000            
Annual fixed rate percentage     5.79%            
Net asset based on interest rate swap valuation model     $ 606,000            
Accumulated other comprehensive income (loss)     412,000            
Income tax benefit, interest rate swap     $ (194,000)            
Amended and restated credit agreement                  
Line of Credit Facility [Line Items]                  
Loan acquisition costs $ 2,162,000                
Number of letters of credit | letter_of_credit     11            
Credit agreement | Amended and restated credit agreement                  
Line of Credit Facility [Line Items]                  
Borrowing capacity $ 100,000,000                
Term of agreements 5 years                
Mortgage loan | Amended and restated credit agreement                  
Line of Credit Facility [Line Items]                  
Borrowing capacity $ 72,500,000                
Term of agreements 5 years                
Period of amortization 25 years                
Amended mortgage loan balance     $ 72,630,000            
Number of owned nursing centers to secure Amended Mortgage Loan | center 18                
Mortgage loan | Amended and restated credit agreement | Interest rate swap                  
Line of Credit Facility [Line Items]                  
Debt interest rate at period end 5.79%                
Amended revolver | Amended and restated credit agreement                  
Line of Credit Facility [Line Items]                  
Borrowing capacity $ 27,500,000   36,891,000   $ 42,250,000 $ 52,250,000     $ 52,250,000
Fixed charge coverage ratio   1.01              
Borrowings outstanding     15,000,000 $ 16,000,000          
Balance available for borrowing under revolving credit center     $ 8,177,000            
Amended revolver | Amended and restated credit agreement | LIBOR                  
Line of Credit Facility [Line Items]                  
Interest rate percentage 4.00%                
Letter of credit | Amended and restated credit agreement                  
Line of Credit Facility [Line Items]                  
Borrowing capacity             $ 15,000,000 $ 10,000,000  
Annual fees for letters of credit issued under Revolver (as a percentage) 3.00%                
Mortgage term loan | Mortgage loan | Amended and restated credit agreement                  
Line of Credit Facility [Line Items]                  
Borrowing capacity $ 60,000,000                
Debt interest rate at period end     6.00%            
Amended mortgage loan balance     $ 63,630,000            
Mortgage term loan | Mortgage loan | Amended and restated credit agreement | Interest rate swap | Designated as hedging instrument                  
Line of Credit Facility [Line Items]                  
Notional amount of interest rate derivatives $ 30,000,000                
Mortgage term loan | Mortgage loan | Amended and restated credit agreement | LIBOR                  
Line of Credit Facility [Line Items]                  
Interest rate percentage 4.00%                
Acquisition loan facility | Mortgage loan | Amended and restated credit agreement                  
Line of Credit Facility [Line Items]                  
Borrowing capacity $ 12,500,000                
Debt interest rate at period end     6.80%            
Amended mortgage loan balance     $ 9,000,000            
Acquisition loan facility | Mortgage loan | Amended and restated credit agreement | LIBOR                  
Line of Credit Facility [Line Items]                  
Interest rate percentage 4.75%                
Omega Healthcare Investors Inc | Amended revolver | Amended and restated credit agreement                  
Line of Credit Facility [Line Items]                  
Letters of credit security deposit for a lease     $ 13,714,000            
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
COMMITMENTS AND CONTINGENCIES (Details)
 6 Months Ended 32 Months Ended
Jun. 30, 2018
USD ($)
lawsuit
Jun. 30, 2017
USD ($)
Feb. 29, 2016
civil_investigative_demand
Oct. 31, 2014
facility
Malpractice Insurance [Line Items]        
Number of professional liability lawsuits | lawsuit 79      
Cash expenditures for self-insured professional liability costs $ 2,775,000 $ 4,338,000    
Estimated insurance recovery receivables 3,080,000      
Other Insurance        
Liability for workers compensation claims 593,000      
Workers compensation insurance, non current receivable for excess premiums paid 1,030,000      
Unfavorable regulatory action | Potential violations of false claims act        
Malpractice Insurance [Line Items]        
Number of facilities | facility       2
Number of civil investigative demands received | civil_investigative_demand     3  
Professional malpractice liability insurance        
Malpractice Insurance [Line Items]        
Liability for reported and estimated future claims 24,229,000      
Prefunded deductible policy        
Malpractice Insurance [Line Items]        
Insurance policy coverage limits per claim 500,000      
Other Insurance        
Insurance policy coverage limits per claim 500,000      
Professional liability insurance, annual coverage limit per facility 3,000,000      
Health insurance, maximum self-insured annual amount per individual 200,000      
Liability for reported claims and estimates for incurred but unreported claims 1,615,000      
SHC Risk Carriers, Inc | Professional malpractice liability insurance        
Malpractice Insurance [Line Items]        
Insurance policy coverage limits per claim 500,000      
Malpractice insurance annual sublimit per center 1,000,000      
Aggregate policy limit 5,000,000      
Other Insurance        
Insurance policy coverage limits per claim $ 500,000      
Scheduled for trial or arbitration over next 12 months        
Malpractice Insurance [Line Items]        
Number of professional liability lawsuits | lawsuit 11      
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
May 31, 2017
Jun. 30, 2016
May 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Share-based compensation expense $ 765 $ 504      
Restricted Stock          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Grant of restricted common stock (shares) 90,000 88,000      
Restricted Stock | First anniversary of grant date          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting percentage of awards 33.00%        
Restricted Stock | Second anniversary of grant date          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting percentage of awards 33.00%        
Restricted Stock | Third anniversary of grant date          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting percentage of awards 33.00%        
Stock Options and Stock Appreciation Rights (SARs)          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Payment award, expiration period 10 years        
Stock Options and Stock Appreciation Rights (SARs) | First anniversary of grant date          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting percentage of awards 33.00%        
Stock Options and Stock Appreciation Rights (SARs) | Second anniversary of grant date          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting percentage of awards 33.00%        
Stock Options and Stock Appreciation Rights (SARs) | Third anniversary of grant date          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting percentage of awards 33.00%        
2008 Stock Purchase Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Percentage of quoted market price offering rate 85.00%        
Restriction period 2 years        
Shares authorized under the plan (shares)       350,000 150,000
2010 Long Term Incentive Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Shares reserved for future issuance (shares)   680,000 380,000    
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
STOCK-BASED COMPENSATION - Schedule of Activity of Equity Compensation Plans (Details) - Stock Options and Stock Appreciation Rights (SARs)
shares in Thousands
 6 Months Ended
Jun. 30, 2018
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]  
Outstanding, beginning (shares) | shares 211
Granted (shares) | shares 30
Exercised (shares) | shares 0
Expired or cancelled (shares) | shares (15)
Outstanding, ending (shares) | shares 226
Exercisable (shares) | shares 206
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]  
Outstanding, beginning (dollars per share) | $ / shares $ 6.64
Granted (dollars per share) | $ / shares 8.14
Exercised (dollars per share) | $ / shares 0.00
Expired or cancelled (dollars per share) | $ / shares 10.81
Outstanding, ending (dollars per share) | $ / shares 6.56
Exercisable, weighted average exercise price (dollars per share) | $ / shares $ 6.41
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
STOCK-BASED COMPENSATION - Schedule of Restricted Stock and Restricted Stock Units Activity (Details)
shares in Thousands
 6 Months Ended
Jun. 30, 2018
$ / shares
shares
Restricted Stock Units (RSUs)  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Outstanding, beginning (share) | shares 164
Granted (shares) | shares 90
Dividend Equivalents (shares) | shares 3
Vested (shares) | shares (79)
Cancelled (shares) | shares (7)
Outstanding, ending (shares) | shares 171
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Outstanding, beginning (dollars per share) | $ / shares $ 9.95
Granted (dollars per share) | $ / shares 8.14
Dividend Equivalents (dollars per share) | $ / shares 7.15
Vested (dollars per share) | $ / shares 10.27
Cancelled (dollars per share) | $ / shares 9.62
Outstanding, ending (dollars per share) | $ / shares $ 8.81
Employee Stock  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Outstanding, beginning (share) | shares 44
Granted (shares) | shares 16
Dividend Equivalents (shares) | shares 1
Vested (shares) | shares (17)
Outstanding, ending (shares) | shares 44
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Outstanding, beginning (dollars per share) | $ / shares $ 9.59
Granted (dollars per share) | $ / shares 8.14
Dividend Equivalents (dollars per share) | $ / shares 7.14
Vested (dollars per share) | $ / shares 8.91
Outstanding, ending (dollars per share) | $ / shares $ 9.28
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
STOCK-BASED COMPENSATION - Schedule of Awards Outstanding and Exercisable (Details) - Stock Options and Stock Appreciation Rights (SARs) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 6 Months Ended
Jun. 30, 2018
Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Weighted average exercise prices (dollars per share) $ 6.56 $ 6.64
Grants outstanding (shares) 226  
Grants exercisable (shares) 206  
$8.14 to $10.80    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Range of exercise prices, minimum (dollars per share) $ 8.14  
Range of exercise prices, maximum (dollars per share) 10.80  
Weighted average exercise prices (dollars per share) $ 9.32  
Grants outstanding (shares) 60  
Intrinsic value - grants outstanding $ 0  
Grants exercisable (shares) 40  
Intrinsic value - grants exercisable $ 0  
$2.37 to $6.21    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Range of exercise prices, minimum (dollars per share) $ 2.37  
Range of exercise prices, maximum (dollars per share) 6.21  
Weighted average exercise prices (dollars per share) $ 5.56  
Grants outstanding (shares) 166  
Intrinsic value - grants outstanding $ 206  
Grants exercisable (shares) 166  
Intrinsic value - grants exercisable $ 206  
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
EARNINGS PER COMMON SHARE - Basic and Diluted Net Income (Loss) Per Common Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Net income (loss)        
Income (loss) from continuing operations $ (307) $ 381 $ (388) $ 1,729
Loss from discontinued operations, net of income taxes (4) (28) (26) (43)
Net income (loss) $ (311) $ 353 $ (414) $ 1,686
Per common share – basic        
Income from continuing operations (dollars per share) $ (0.05) $ 0.06 $ (0.06) $ 0.28
Loss from discontinued operations (dollars per share) 0.00 0.00 0.00 (0.01)
Net income per common share – basic (dollars per share) (0.05) 0.06 (0.06) 0.27
Per common share – diluted        
Income from continuing operations (dollars per share) (0.05) 0.06 (0.06) 0.27
Loss from discontinued operations (dollars per share) 0.00 0.00   (0.01)
Net income per common share – diluted (dollars per share) $ (0.05) $ 0.06 $ (0.06) $ 0.26
Weighted Average Common Shares Outstanding:        
Basic (shares) 6,370 6,294 6,342 6,263
Diluted (shares) 6,370 6,472 6,342 6,458
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
EARNINGS PER COMMON SHARE - Narrative (Details) - shares
shares in Thousands
 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Earnings Per Share [Abstract]    
Antidilutive shares excluded from computation of diluted earnings per share (shares) 226 46
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS - Narrative (Details)
 3 Months Ended 6 Months Ended 12 Months Ended
Jul. 01, 2017
USD ($)
bed
Jun. 30, 2018
USD ($)
bed
Mar. 31, 2018
facility
Jun. 30, 2017
USD ($)
Dec. 31, 2016
USD ($)
Jun. 30, 2018
USD ($)
bed
Jun. 30, 2017
USD ($)
Dec. 31, 2017
USD ($)
Business Acquisition [Line Items]                
Number of licensed nursing beds | bed   8,456       8,456    
Number of skilled nursing facilities classified as held for sale | facility     3          
Assets held for sale   $ 13,269,000       $ 13,269,000   $ 0
Cash termination payment   13,725,000   $ 13,763,000   27,438,000 $ 27,506,000  
Gain on sale of investment in unconsolidated affiliate   $ 308,000   0   308,000 733,000  
Selma Nursing Centers                
Business Acquisition [Line Items]                
Number of licensed nursing beds | bed 103              
Purchase Price $ 8,750,000              
Business acquisition, acquisition expenses               140,000
Gain on bargain purchase $ 925,000             925,000
Unnamed pharmacy joint venture                
Business Acquisition [Line Items]                
Gain on sale of investment in unconsolidated affiliate         $ 1,366,000 $ 308,000 733,000  
Trend Health and Rehab of Carthage, LLC (Trend Health)                
Business Acquisition [Line Items]                
Cash termination payment               $ 250,000
Mortgage term loan | Amended and restated credit agreement | Mortgage loan | Selma Nursing Centers                
Business Acquisition [Line Items]                
Increase to credit facility limit       $ 7,500,000     $ 7,500,000  
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.10.0.1
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS - Schedule of Assets Acquired (Details) - Selma Nursing Centers - USD ($)
$ in Thousands
 12 Months Ended
Jul. 01, 2017
Dec. 31, 2017
Business Acquisition [Line Items]    
Purchase Price $ 8,750  
Gain on bargain purchase 925 $ 925
Assets acquired 9,675  
Building 8,435  
Land 760  
Land Improvements 145  
Furniture, Fixtures and Equipment $ 335  
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1
SUBSEQUENT EVENTS SUBSEQUENT EVENTS (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2018
Jun. 30, 2017
Subsequent Event [Line Items]      
Share-based compensation expense   $ 765 $ 504
Chief Executive Officer      
Subsequent Event [Line Items]      
Severance expenses $ 1,172    
Share-based compensation expense $ 259    
EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 51 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 52 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 54 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 123 225 1 false 45 0 false 12 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.advocatinc.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - INTERIM CONSOLIDATED BALANCE SHEETS Sheet http://www.advocatinc.com/role/InterimConsolidatedBalanceSheets INTERIM CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1001501 - Statement - INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.advocatinc.com/role/InterimConsolidatedBalanceSheetsParenthetical INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.advocatinc.com/role/InterimConsolidatedStatementsOfOperations INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1002501 - Statement - INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Sheet http://www.advocatinc.com/role/InterimConsolidatedStatementsOfOperationsParenthetical INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Statements 5 false false R6.htm 1003000 - Statement - INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Sheet http://www.advocatinc.com/role/InterimConsolidatedStatementsOfComprehensiveIncome INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statements 6 false false R7.htm 1004000 - Statement - INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.advocatinc.com/role/InterimConsolidatedStatementsOfCashFlows INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 2101100 - Disclosure - BUSINESS Sheet http://www.advocatinc.com/role/Business BUSINESS Notes 8 false false R9.htm 2102100 - Disclosure - CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS Sheet http://www.advocatinc.com/role/ConsolidationAndBasisOfPresentationOfFinancialStatements CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS Notes 9 false false R10.htm 2103100 - Disclosure - RECENT ACCOUNTING GUIDANCE Sheet http://www.advocatinc.com/role/RecentAccountingGuidance RECENT ACCOUNTING GUIDANCE Notes 10 false false R11.htm 2104100 - Disclosure - REVENUE RECOGNITION Sheet http://www.advocatinc.com/role/RevenueRecognition REVENUE RECOGNITION Notes 11 false false R12.htm 2105100 - Disclosure - LONG-TERM DEBT AND INTEREST RATE SWAP Sheet http://www.advocatinc.com/role/LongTermDebtAndInterestRateSwap LONG-TERM DEBT AND INTEREST RATE SWAP Notes 12 false false R13.htm 2106100 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.advocatinc.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 13 false false R14.htm 2107100 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.advocatinc.com/role/StockBasedCompensation STOCK-BASED COMPENSATION Notes 14 false false R15.htm 2108100 - Disclosure - EARNINGS PER COMMON SHARE Sheet http://www.advocatinc.com/role/EarningsPerCommonShare EARNINGS PER COMMON SHARE Notes 15 false false R16.htm 2109100 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS Sheet http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactions BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS Notes 16 false false R17.htm 2110100 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.advocatinc.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 17 false false R18.htm 2202201 - Disclosure - CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Policies) Sheet http://www.advocatinc.com/role/ConsolidationAndBasisOfPresentationOfFinancialStatementsPolicies CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Policies) Policies 18 false false R19.htm 2304301 - Disclosure - REVENUE RECOGNITION (Tables) Sheet http://www.advocatinc.com/role/RevenueRecognitionTables REVENUE RECOGNITION (Tables) Tables http://www.advocatinc.com/role/RevenueRecognition 19 false false R20.htm 2307301 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.advocatinc.com/role/StockBasedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://www.advocatinc.com/role/StockBasedCompensation 20 false false R21.htm 2308301 - Disclosure - EARNINGS PER COMMON SHARE (Tables) Sheet http://www.advocatinc.com/role/EarningsPerCommonShareTables EARNINGS PER COMMON SHARE (Tables) Tables http://www.advocatinc.com/role/EarningsPerCommonShare 21 false false R22.htm 2309301 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS (Tables) Sheet http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactionsTables BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS (Tables) Tables http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactions 22 false false R23.htm 2401401 - Disclosure - BUSINESS (Details) Sheet http://www.advocatinc.com/role/BusinessDetails BUSINESS (Details) Details http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactionsTables 23 false false R24.htm 2402402 - Disclosure - CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Details) Sheet http://www.advocatinc.com/role/ConsolidationAndBasisOfPresentationOfFinancialStatementsDetails CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Details) Details http://www.advocatinc.com/role/ConsolidationAndBasisOfPresentationOfFinancialStatementsPolicies 24 false false R25.htm 2404402 - Disclosure - REVENUE RECOGNITION - Adjustments to Operating Results (Details) Sheet http://www.advocatinc.com/role/RevenueRecognitionAdjustmentsToOperatingResultsDetails REVENUE RECOGNITION - Adjustments to Operating Results (Details) Details 25 false false R26.htm 2404403 - Disclosure - REVENUE RECOGNITION - Disaggregation of Revenue (Details) Sheet http://www.advocatinc.com/role/RevenueRecognitionDisaggregationOfRevenueDetails REVENUE RECOGNITION - Disaggregation of Revenue (Details) Details 26 false false R27.htm 2405401 - Disclosure - LONG-TERM DEBT AND INTEREST RATE SWAP (Details) Sheet http://www.advocatinc.com/role/LongTermDebtAndInterestRateSwapDetails LONG-TERM DEBT AND INTEREST RATE SWAP (Details) Details http://www.advocatinc.com/role/LongTermDebtAndInterestRateSwap 27 false false R28.htm 2406401 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.advocatinc.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.advocatinc.com/role/CommitmentsAndContingencies 28 false false R29.htm 2407402 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) Sheet http://www.advocatinc.com/role/StockBasedCompensationNarrativeDetails STOCK-BASED COMPENSATION - Narrative (Details) Details 29 false false R30.htm 2407403 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Activity of Equity Compensation Plans (Details) Sheet http://www.advocatinc.com/role/StockBasedCompensationScheduleOfActivityOfEquityCompensationPlansDetails STOCK-BASED COMPENSATION - Schedule of Activity of Equity Compensation Plans (Details) Details 30 false false R31.htm 2407404 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock and Restricted Stock Units Activity (Details) Sheet http://www.advocatinc.com/role/StockBasedCompensationScheduleOfRestrictedStockAndRestrictedStockUnitsActivityDetails STOCK-BASED COMPENSATION - Schedule of Restricted Stock and Restricted Stock Units Activity (Details) Details 31 false false R32.htm 2407405 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Awards Outstanding and Exercisable (Details) Sheet http://www.advocatinc.com/role/StockBasedCompensationScheduleOfAwardsOutstandingAndExercisableDetails STOCK-BASED COMPENSATION - Schedule of Awards Outstanding and Exercisable (Details) Details 32 false false R33.htm 2408402 - Disclosure - EARNINGS PER COMMON SHARE - Basic and Diluted Net Income (Loss) Per Common Share (Details) Sheet http://www.advocatinc.com/role/EarningsPerCommonShareBasicAndDilutedNetIncomeLossPerCommonShareDetails EARNINGS PER COMMON SHARE - Basic and Diluted Net Income (Loss) Per Common Share (Details) Details 33 false false R34.htm 2408403 - Disclosure - EARNINGS PER COMMON SHARE - Narrative (Details) Sheet http://www.advocatinc.com/role/EarningsPerCommonShareNarrativeDetails EARNINGS PER COMMON SHARE - Narrative (Details) Details 34 false false R35.htm 2409402 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS - Narrative (Details) Sheet http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactionsNarrativeDetails BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS - Narrative (Details) Details http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactionsTables 35 false false R36.htm 2409403 - Disclosure - BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS - Schedule of Assets Acquired (Details) Sheet http://www.advocatinc.com/role/BusinessDevelopmentsAndOtherSignificantTransactionsScheduleOfAssetsAcquiredDetails BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS - Schedule of Assets Acquired (Details) Details 36 false false R37.htm 2410401 - Disclosure - SUBSEQUENT EVENTS SUBSEQUENT EVENTS (Details) Sheet http://www.advocatinc.com/role/SubsequentEventsSubsequentEventsDetails SUBSEQUENT EVENTS SUBSEQUENT EVENTS (Details) Details 37 false false All Reports Book All Reports avca-20180630.xml avca-20180630.xsd avca-20180630_cal.xml avca-20180630_def.xml avca-20180630_lab.xml avca-20180630_pre.xml http://fasb.org/srt/2018-01-31 http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/invest/2013-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true ZIP 56 0000919956-18-000038-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000919956-18-000038-xbrl.zip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